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Abstract 
Toll-like receptors (TLRs) are in the front-line during the initiation of an innate 
immune response against invading pathogens. TLRs are type I transmembrane proteins 
that are expressed on the surface of immune system cells. They are evolutionarily 
conserved between insects and vertebrates. To date, 13 groups of mammalian TLRs 
have been identified, ten in humans and 13 in mice. They share a modular structure that 
consists of a leucine-rich repeat (LRR) ectodomain, a single transmembrane helix and a 
cytoplasmic Toll/interleukin-1 receptor (TIR) domain. Most TLRs have been shown to 
recognize pathogen-associated molecular patterns (PAMPs) from a wide range of 
invading agents and initiate intracellular signal transduction pathways to trigger 
expression of genes, the products of which can control innate immune responses. The 
TLR signaling pathways, however, must be under tight negative regulation to 
maintain immune balance because over-activation of immune responses in the body 
can cause autoimmune diseases. 
The TLR ectodomains are highly variable and are directly involved in ligand 
recognition. So far, crystal structures are missing for most TLR ectodomains because 
structure determination by X-ray diffraction or nuclear magnetic resonance (NMR) 
spectroscopy experiments remains time-consuming, and sometimes the crystallization 
of a protein can be very difficult. Computational modeling enables initial predictions of 
three-dimensional structures for the investigation of receptor-ligand interaction 
mechanisms. Computational methods are also helpful to develop new TLR agonists 
and antagonists that have therapeutic significance for diseases. 
In this dissertation, an LRR template assembly approach for homology modeling of 
TLR ligand-binding domains is discussed. To facilitate the modeling work, two 
databases, TollML and LRRML, have been established. With this LRR template 
assembly approach, the ligand-binding domains of human TLR5-10 and mouse 
TLR11-13 were modeled. Based on the models of human TLR7, 8 and 9, we 
predicted potential ligand-binding residues and possible configurations of the 
receptor-ligand complex using a combined procedure. In addition, we modeled the 
cytoplasmic TIR domains of TLR4 and 7, the TLR adaptor protein MyD88 (myeloid 
differentiation primary response protein 88) and the TLR inhibitor SIGIRR (Single 
immunoglobulin interleukin-1 receptor-related molecule) to investigate the structural 
mechanism of TLR negative regulation. 
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1. Introduction 
Toll-like receptors (TLRs) are a class of membrane-bound proteins that are widely 
expressed in insects, plants and animals. They recognize invading microbial pathogens 
and rapidly initiate intracellular signal transduction pathways to trigger expression of 
genes, whose products can control innate immune responses [1]. Therefore, TLRs have 
opened up a range of therapeutic possibilities, in particular for infectious diseases. 
Understanding the mechanisms of TLR-ligand interactions from a structural point of 
view will contribute to the development of new TLR agonists and antagonists that have 
therapeutic significance for diseases. 
TLRs share a modular structure that consists of a leucine-rich repeat (LRR) 
ectodomain, a single transmembrane helix and a cytoplasmic Toll/interleukin-1 
receptor (TIR) domain. The ectodomains are highly variable across different TLRs. 
They are directly involved in the recognition of a variety of pathogen-associated 
molecular patterns (PAMPs). By contrast, the intracellular TIR domain is conserved 
across all TLRs and shared by downstream signaling adaptor molecules. Until now, 
four crystal structures of TLR ectodomain-ligand complexes have been determined 
[2-5]. These structures demonstrate how the LRR-based platform is adapted to the 
ligand recognition. Compared with the very limited number of known structures of 
TLRs, the high-throughput genome sequencing projects, however, have led to the 
identification of more than 2,000 TLR sequences [6]. Thus, the structures of most TLRs 
are still unknown because structure determination by X-ray diffraction or nuclear 
magnetic resonance (NMR) spectroscopy experiments remains time-consuming, and 
crystallization of a protein complex can be very difficult. It is clear that the discrepancy 
between the rate at which novel protein sequences are discovered and the rate at which 
detailed structural information on proteins can be obtained from X-ray or NMR 
methods will persist for the foreseeable future. In this regard, protein structure 
prediction methods are powerful tools to bridge the gap between sequence 
determination and structure determination. Protein structure prediction refers to the 
effort of generating three-dimensional models from amino acid sequences using 
computer algorithms. Homology modeling is currently the most accurate protein 
structure prediction method. It can carry out rapid and large-scale structure predictions 
for TLRs based on those known TLR structures. The resulting models will be useful to 
infer structure-function relationships and to provide targets for mutagenesis 
experiments. A large amount of previous research showed the feasibility and reliability 
of homology modeling applied to structural studies of proteins [7-11]. 
In this thesis, we focus on model construction and analysis of TLR ligand-binding 
domains with computational methods. Due to different repeat numbers and distinct 
arrangements of LRRs contained in TLR ligand-binding domains, a standard 
homology modeling method failed to predict a proper model. We developed an LRR 
template assembly method for homology modeling of the ligand-binding domains of 
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human TLR5-10 and mouse TLR11-13, the crystal structures of which have not been 
determined. This approach is supported by two databases, TollML and LRRML. Then, 
we analyzed the models of human TLR7, 8 and 9, which respond to microbial nucleic 
acids, with a number of protein structure analysis programs to suggest potential 
ligand-binding residues and possible receptor dimer-ligand complex forms. These 
results provide determinate targets for further mutagenesis experiments. 
Over-activation of the nucleic acid recognition TLRs can lead to autoimmune diseases 
such as systemic lupus erythematosus [12-15]. Understanding the mechanisms of 
negative regulation of TLR signaling is highly important for the treatment of 
autoimmune diseases caused by TLRs. Previous studies showed that SIGIRR (Single 
immunoglobulin interleukin-1 receptor-related molecule) is an endogenous inhibitor of 
TLR signaling. Thus, we modeled the cytoplasmic TIR domains of TLR4 and 7, the 
TLR adaptor protein MyD88 (myeloid differentiation primary response protein 88) 
and SIGIRR. Through protein-protein docking studies, we suggested models of TIR 
complexes involved in the TLR inhibition. In vivo deletion experiments supported our 
hypothesis that SIGIRR may exert its inhibitory effect mainly via its BB-loop region. 
This dissertation starts with a brief overview (Chapter 1) of the thesis. In Chapters 2-5, 
the biological background of TLRs, basic theories of protein structure prediction and 
the research motivation are described. Chapter 6 details the relevant computational 
methods that were used in this study. Chapter 7 comprises the extended abstracts of 
six published scientific papers on important aspects of in silico structural 
investigations of TLRs: an LRR template assembly approach for homology modeling 
of TLR ligand-binding domains, models of ligand-binding domains of human/mouse 
TLR5-13, structural analyses of human TLR7/8/9 and models of inhibition 
mechanisms of TLR signaling pathways. Finally, Chapter 8 summarizes our findings 
and attempts to suggest future studies. 
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2. Toll-Like Receptors 
2.1 Immune System 
The immune system can be understood as a network of biological structures and 
processes that work together to defend the body against attack by foreign “invaders”. 
There are two major divisions of the human immune system, the innate immune system 
and the adaptive immune systems [16]. The innate immune system is the first-line host 
defense that provides an immediate but non-specific response against invading 
pathogens such as bacteria and viruses. The adaptive immune system is the second-line 
defense that mediates a delayed and specific response [17]. The innate immune 
recognition relies on a limited number of germline-encoded pattern recognition 
receptors (PRRs). These PRRs can recognize PAMPs which are unique to microbial 
pathogens [18]. Recognition of these PAMPs allows the immune system to distinguish 
infectious non-self from non-infectious self. The adaptive immune responses are 
essential for control of pathogens that escape elimination by the innate immune 
response and are important for the development of a long-term immunological memory 
[16, 19]. Because of its role in the immune memory, the adaptive immune system’s 
contribution to pathogen elimination and vaccine development has been widely studied 
[20-22]. 
The PRRs of the innate immune system serve an essential role not only in recognition 
of pathogens but also in directing the course and type of innate immune responses 
generated following exposure to foreign antigens. The best understood group of PRRs 
is the Toll-like receptor (TLR) family [23]. “Toll” originally refers to a cell surface 
receptor that governs the dorsal-ventral orientation in the early Drosophila 
melanogaster larvae [24]. Together with other antimicrobial peptides it was later found 
to play a crucial role in antifungal defense in adult Drosophila [25]. Sequencing of the 
Drosophila genome revealed nine proteins belonging to the Toll family [26]. Although 
a function in host defense has so far only been attributed to some of them, it is assumed 
that each is involved in the host defense against pathogens. In 1997, the first 
mammalian proteins that are structurally related to Drosophila Toll were identified by 
Medzhitov and co-workers. These receptors were designated as human TLR4 [27]. In 
turn, Beutler and co-workers used positional cloning to show that TLR4-deficient mice 
could not respond to lipopolysaccharides [28]. This result identified TLR4 as one of the 
key components of the receptor for lipopolysaccharides. The progress of genome 
sequencing projects has led so far to the identification of 13 groups of TLRs in 
mammalian genomes, ten (TLR1-10) in humans and 13 (TLR1-13) in mice and more 
than 20 in non-mammalian genomes [29]. 
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2.2 Structure of Toll-Like Receptors 
TLRs are type I integral membrane glycoproteins consisting of a ligand-binding 
ectodomain (500-800 amino acids) and a cytoplasmic signaling domain (TIR domain, 
ca. 150 amino acids) [30] (Figure 1). The ectodomain contains 17-26 tandem LRR 
motifs and resembles a solenoid bent into a horseshoe shape. At both ends, there are 
terminal LRRs (N/C-terminal LRR) that shield the hydrophobic core of the solenoid. 
All TLR ectodomains are decorated with several N-linked glycans, which are likely to 
influence receptor surface representation, trafficking and pattern recognition. For 
example, TLR2 and 4 require glycosylations for function [31]. The ectodomains are 
highly variable across different TLRs. They are directly involved in the recognition of a 
variety of PAMPs. In contrast to the ectodomain, the intracellular TIR domain is 
conserved across all TLRs and shared by downstream signaling adaptor molecules. It 
contains a central five-stranded parallel β-sheet that is surrounded by a total of five 
helices on both sides [32] (basic protein structure conceptions introduced in section 3.2). 
The ectodomain and the TIR domain are joined by a single transmembrane helix stretch 
(ca. 20 amino acids), which determines the subcellular localization of TLRs [33]. Upon 
receptor ligation, a TIR signaling complex is formed between the receptor and the 
adaptor TIR domains [34]. 
 
Figure 1: Structure of the TLR and LRR. 
LRRs are arrays of 20 to 30 amino acid long protein segments that are unusually rich in 
the hydrophobic amino acid leucine. An LRR motif can be divided into a highly 
conserved segment (HCS) and a variable segment (VS) (Figure 1). The HCS consists of 
an 11 or 12 residue long stretch with the consensus sequence LxxLxLxxN(Cx)xL. Here, 
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the letter L stands for Leu, Ile, Val or Phe; N stands for Asn, Thr, Ser or Cys; and x is 
any amino acid. The VS is quite diverse in length and consensus sequence. Accordingly, 
eight classes of LRRs have been proposed as follows [35, 36]: RI-like (RI), 
Cysteine-containing (CC), Bacterial (S), SDS22-like (SDS22), Plant-specific (PS), 
Typical (T), Treponema pallidum (Tp) and CD42b-like (CD42b). Of these, the T and S 
types have been observed in TLRs [37]. Protein domains with LRR architecture form 
curved or horseshoe-shaped solenoid structures where an LRR is a turn of the solenoid. 
The concave side of the LRR domain is defined by a parallel β-sheet with each LRR 
HCS contributing one strand. The strands are interwoven with a variety of structural 
elements on the convex side, which is constituted by the VSs of LRRs (Figure 1). 
 
Figure 2: Molecular tree of the vertebrate TLR1-13. Adapted from [38] with permission from the 
National Academy of Sciences, USA. 
TLR protein sequences are now available for a number of vertebrate species. Using 
these sequences, a complete molecular phylogenetic analysis of the known vertebrate 
TLRs against the complete sequences of Takifugu rubripes TLRs was performed, 
providing a comprehensive overview (Figure 2) [38]. Accordingly, mammalian TLRs 
can be divided into six major families. The TLR1 family consists of TLR1, 2, 6 and 10. 
This family contains fewer (20-21) LRRs than the other families. TLR3 constitutes the 
TLR3 family. It contains 25 LRRs. TLR4 constitutes the TLR4 family with 23 LRRs. 
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TLR5 constitutes the TLR5 family with 22 LRRs. The TLR7 family consists of TLR7, 8 
and 9 and contains 27 LRRs. A remarkable feature of the TLR7 family is the presence of 
a less structured region between LRR14 and 15 of the ectodomain. TLR11, 12 and 13 
are included into the TLR11 family, which contains 24-27 LRRs. 
2.3 Function of Toll-Like Receptors 
TLRs recognize broad classes of PAMPs and are emerging as a central player in 
initiating and directing immune responses to pathogens [1, 39]. Their ligands are 
lipoproteins or lipopeptides as recognized by TLR2 complexed with TLR1 or 6, viral 
double-stranded RNAs (dsRNAs) by TLR3, lipopolysaccharides by TLR4, bacterial 
flagellins by TLR5, single-stranded RNAs (ssRNAs) and synthetic imidazoquinolines 
by TLR7 or 8, microbial CpG DNAs by TLR9, and Toxoplasma gondii profilin by 
TLR11 [40]. So far, no ligands have been identified for TLR10, 12 and 13. Table 1 
illustrates ligands and localizations of all known mammalian TLRs. TLR3, 7, 8 and 9, 
all of which recognize nucleic acids, are not expressed on the cell surface like other 
TLRs but are exclusively expressed in endosomal compartments. In the case of 
bacterial infection, immune cells engulf bacteria by phagocytosis. The CpG DNA is 
then exposed after degradation of bacteria in endosomes or endolysosomes. In the case 
of viral infection, viruses invade cells by endocytosis, and the viral contents (nucleic 
acids) are exposed to the cytoplasm by fusion of the viral membrane and the endosomal 
membrane. Thus, the bacterial or viral nucleic acids may be recognized by these 
endosomal TLRs [41]. Because pathogen and host nucleic acids have very similar 
structures, these endosomal TLRs may face an extra challenge to induce antipathogen 
immune responses while avoiding the induction of autoimmune diseases by 
inappropriate recognition of self nucleic acids. Recent studies have revealed an 
over-activation of TLR3, 7, 8 and 9 in systemic lupus erythematosus and several other 
autoimmune diseases [12-15, 42]. 
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TLRs Ligands Ligand origins Localization 
TLR1-2 Triacyl-lipopeptides Bacteria Cell surface 
TLR2 Lipoproteins, lipopeptides Bacteria Cell surface 
TLR3 Double-stranded 
RNA, Poly(I-C) 
Viruses Endosome, 
lysosome 
TLR4 Lipopolysaccharides Gram-negative bacteria Cell surface 
TLR5 Flagellins Bacteria Cell surface 
TLR6-2 Diacyl-lipopeptides Mycoplasmas Cell surface 
TLR7, 8 Single-stranded RNA, 
imidazoquinolines 
Viruses, 
synthetic compounds 
Endosome, 
lysosome 
TLR9 Unmethylated CpG DNA Bacteria Endosome, 
lysosome 
TLR10 unknown unknown Cell surface 
TLR11 Profilin Apicomplexan 
parasites 
Cell surface 
TLR12, 13 unknown unknown unknown 
Table 1: Ligands and localizations of mammalian TLRs. 
After the recognition of PAMPs, the TLR intracellular TIR domain recruits adaptor 
molecules to activate the downstream signaling pathways. The signaling pathways 
culminate in the induction of antimicrobial factors such as interferons, tumor necrosis 
factors and interleukins through transcription factors NF-κB and IRFs (Figure 3). 
Except for TLR3, all TLRs utilize MyD88 as an adaptor protein to recruit downstream 
signaling molecules including the protein kinases IRAK4 (interleukin-1 receptor type 
I-associated protein kinases 4), IRAK1 and TRAF6 (tumor necrosis factor 
receptor-associated factor 6). TRAF6 functions together with a series of ubiquitins that 
lead to the activation of a protein kinase complex consisting of TAK1, TAB1 and TAB2. 
The activated TAK1 kinase results in the activation of the IκB kinase and subsequent 
nuclear translocation of NF-κB. Differently, the TIR domain of TLR3 binds to another 
adaptor protein TRIF (TIR domain-containing adapter inducing interferon-β), which 
binds directly to TRAF6 and RIP1 to activate NF-κB or alternatively, binds to TBK1 to 
activate IRF3 and IRF7. TLR4 can use both the MyD88-dependant and the 
MyD88-independant (TRIF-dependant) pathways to signal. The TLR signaling 
pathways, however, must be under tight negative regulation to maintain immune 
balance to prevent autoimmunity described above. The best-characterized TLR 
inhibitor is SIGIRR, which can directly interact with the TLR TIR domains and 
MyD88 TIR domains to reduce or terminate the activation of TLR signaling (detailed 
in chapter 5). 
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Figure 3: TLR signaling pathways. Adapted from [43] with permission from Elsevier, UK. 
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3. Protein Structure Prediction 
3.1 Overview 
Protein structure prediction refers to the effort of generating three-dimensional models 
from amino acid sequences using computer algorithms [44]. The importance of 
computational prediction of protein structures is increasing owing to the rapid growth 
in the number of sequenced genomes and the relatively slow growth in the number of 
experimentally determined protein structures by X-ray crystallography or NMR 
methods [45]. In many cases the predicted three-dimensional protein models are highly 
useful for experimentalists guiding the design of new experiments for further 
investigations of protein functions. This section describes important conceptions of 
protein structure and current algorithms of protein structure prediction and analysis. 
3.2 Four Levels of Protein Structure 
Proteins are polymers of amino acids also called polypeptides. Proteins are not linear 
molecules. Rather, they fold into intricate three-dimensional structures that are unique 
to one another. It is this three-dimensional structure that allows proteins to function. 
The protein structure can be broken down into the following four levels [46] (Figure 4): 
 
Figure 4: Four levels of protein structures. Figure taken from http://www.genome.gov/. 
 Primary structure refers to the “linear” sequence of amino acids. 
 Secondary structure is the “local” ordered structure brought about via hydrogen 
bonding mainly within the peptide backbone. The most common secondary 
structure elements in proteins are the α-helix and β-sheet. 
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 Tertiary structure is the “global” folding of a single polypeptide chain. A major 
driving force in determining the tertiary structure of globular proteins is the 
hydrophobic effect. The polypeptide chain folds such that the side chains of the 
non-polar amino acids are “hidden” within the structure, and the side chains of 
the polar residues are exposed on the outer surface. 
 Quaternary structure involves the association of two or more polypeptide chains 
into a multi-subunit structure. Not all proteins exhibit quaternary structure. 
Quaternary structures are stabilized mainly by non-covalent interactions: 
hydrogen bonding, van der Waals interactions and ionic bonding. 
3.3 Protein Structure Prediction 
The prediction of the three-dimensional structure of a protein indicates the prediction of 
a protein’s tertiary structure from its amino acid sequence. Protein structure prediction 
techniques fall into three categories [45]: 
1) Homology modeling 
Homology modeling, also called comparative modeling, exploits the fact that 
evolutionarily related proteins with similar sequences, as measured by sequence 
identity, have similar structures. The sequence identity is defined by the percentage 
of identical residues at each position based on an optimal sequence alignment. The 
sequence identity defines the branch length between two protein nodes in a 
phylogenetic tree (as demonstrated in Figure 2). The modeling procedure can be 
divided into a number of steps [47] (Figure 5). First, suitable template(s) (sequence 
identity ≥ 30%) related to the target sequence are selected from the Protein Data 
Bank (PDB) [48]. The PDB is the single worldwide repository for the processing 
and distribution of three-dimensional structural data of large molecules of proteins 
and nucleic acids. PDB accepts only experimentally derived structures. The Basic 
Local Alignment Search Tool (BLAST) of PDB can find sequence-similar protein 
structures for a query protein sequence. Second, an alignment of the target sequence 
to the template(s) is generated. A protein sequence alignment is an arrangement of 
two or more protein sequences that represents the evolutionary relationship among 
the sequences. Gaps are inserted between the residues so that identical or similar 
amino acids are aligned in successive columns. Third, coordinates of the 
three-dimensional model are built based on the alignment and template structures. 
This step can be divided into two main trends. One is to model the structure by 
copying the coordinates of the template in the aligned core regions. The variable 
regions are modeled by taking fragments with similar sequences from a database of 
previously observed loops. Then, the mutated side chains are replaced with 
rotamers that satisfy the stereochemical criteria, together with limited energy 
optimization. This algorithm is implemented by SWISS-MODEL [49]. The other 
possibility is to use the distance and torsion angles and interatomic distances from 
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the aligned regions of the template as modeling constraints, which permits the use 
of information from multiple, possibly conflicting, structures. This approach also 
requires the idealization of the geometry of the entire chain with constraints derived 
from a database of protein structures. MODELLER is a well-known program that 
implements this algorithm. [50]. Last, the previous steps are repeated according to 
the model evaluation to refine the model until acceptable results are obtained. 
Model evaluation tools and their working principles are detailed in section 6.2. 
 
Figure 5: Flowchart of homology modeling. Adapted from [51] with permission from Future 
Medicine Ltd, UK. 
2) Protein threading 
Protein threading, also called fold recognition, uses a database of known 
three-dimensional protein structures (templates) to match a query protein sequence. 
This is accomplished by the aid of a scoring function that assesses the fit of the 
query sequence to a given template structure. The scoring function is usually 
derived from the template database and includes pairwise atom contact and 
solvation terms, e.g., the Z-score function. The template with the best score is 
assumed to be the one adopted by the sequence. 
3) Ab initio modeling 
The “thermodynamic hypothesis” states that the amino acid sequence perfectly 
determines the native three-dimensional structure of a protein, and the native 
structure is the one for which the free energy achieves the global minimum [52]. 
This inspires ab initio methods in protein structure prediction. Ab initio methods 
make structure predictions without using any structural information of previously 
solved protein structure; instead, they are entirely based on the first principles of 
physics. All energetics involved in the folding process of a protein are calculated by 
energy functions, and the structure with the lowest free energy is found. 
Homology modeling is mainly used for detailed (e.g., all heavy-atoms) structure 
prediction when a query protein has a close homolog (sequence identity ≥ 30%) in the 
Protein Structure Prediction 
16 
PDB. If there is no homolog for the query protein, protein threading is used for template 
recognition and backbone structure prediction. If protein threading fails to detect a 
suitable template (i.e., no template with a Z-score better than a cutoff value), ab initio 
modeling should be selected. In this work, we focused mainly on the homology 
modeling approach. The TLR family comprises homologous TLR members as 
illustrated in Figure 2. The determined crystal structures of TLRs (see section 4.1) 
supplied useful sources of homologous templates for the TLRs with unknown 
structures. 
3.4 Molecular Docking 
Protein-protein interactions and protein-nucleic acid interactions are important for 
numerous biological processes. In general, the molecular interactions are driven by four 
kinds of forces [53]: electrostatic forces (caused by complementary charges), 
electrodynamic forces (van der Waals interactions), steric forces (caused by entropy) 
and solvent-related forces (hydrophobicity/hydrophilicity). Moreover, the interaction 
sites of the interacting molecules usually have a high shape complementarity [54]. Thus, 
the interaction sites of proteins can be theoretically predicted, given the 
three-dimensional structures or models of the interacting molecules. Molecular docking 
is a computational approach that models the quaternary structure of complexes formed 
by two or more interacting molecules as they would occur in a living organism. There 
are two categories of docking: protein-protein docking and protein-nucleic acid 
docking. In the protein-protein docking, if a small protein molecule (≤ 30 residues) is 
docked onto a relative large protein receptor or enzyme, it is called protein-ligand 
docking. The protein-ligand docking is widely used in the rational design of drugs. If 
the bond angles, bond lengths and torsion angles of the components are not modified at 
any stage of complex generation, it is called rigid-body docking. The rigid-body 
docking showed success in predicting interactions between rigid globular protomers in 
protein complexes [55]. When substantial conformational changes occur within the 
components during complex formation, the rigid-body docking is inadequate. In this 
case a flexible docking that permits conformational changes during complexing is 
needed. However, to enumerate all possible conformational changes is prohibitively 
time-consuming. The flexible docking therefore checks only a small subset of possible 
conformational changes. 
Docking itself produces a large number of plausible candidate interacting 
conformations. These candidates are evaluated and ranked by different scoring 
functions to identify structures that are most likely to occur in nature. A helpful way, if 
possible, to reduce the top-scoring false positive poses is to consider some restrictions 
from the known data, such as experimentally identified essential interacting residues, 
steric compatibility with other molecules or membranes, and residue conservation 
across species. A number of docking programs are described in section 6.3. 
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4. Structure Predictions of TLR Ligand-Binding 
Domains 
4.1 Overview 
Although experimental methods have provided high-resolution structures for only 
several TLR ligand-binding domains, computational prediction methods will provide 
valuable structural information for the majority of TLR sequences whose structures are 
not yet solved experimentally. In this section, we highlight the essentiality of structure 
prediction of TLRs and describe a template assembly strategy for homology modeling 
of a series of TLR ligand-binding domains. 
4.2 Crystal Structures of TLR Ligand-Binding Domains 
In 2005, Choe and co-workers and later Bell and co-workers first reported crystal 
structures of monomeric human TLR3 ligand-binding domains in atomic detail. They 
represent the first insight into the molecular basis of TLR recognition. The overall 
structure of TLR3 ligand-binding domain is that of a large horseshoe-shaped solenoid 
with an inner diameter of 42 Å, an outer diameter of 90 Å and a thickness of 35 Å [56] 
(Figure 6). The concave inner surface consists of a large parallel β-sheet with each 
β-strand roughly perpendicular to the solenoid axis and linked to the next strand by an 
irregular loop. The molecular surface of the TLR3 is abundantly and unevenly 
populated with N-linked carbohydrates. Notably, one face of the horseshoe is 
completely devoid of any glycosylation [57]. Later, the crystal structure of liganded 
TLR3 determined by Liu et al. (2008) proved that it is just the glycosylation-free face 
that binds to the dsRNA ligand. Until now, four crystal structures of human or mouse 
TLR-ligand complexes, TLR1-TLR2-lipopeptide (Pam3CSK4), TLR4-MD-2- 
lipopolysaccharides, TLR3-dsRNA and TLR6-TLR2-lipopeptide (Pam2CSK4) have 
been determined [2-5]. They provide experimental evidence for how these receptors 
bind to a remarkably large variety of ligands and how the agonists induce dimerization 
of the receptors. 
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Figure 6: Overview of TLR3 ligand-binding domain structure in carton representation (left) and in 
secondary structure surface representation (right). The N-linked glycans are shown as green 
ball-and-stick (right). 
In the TLR1-TLR2 complexes, the lipid chains of the triacyl-lipopeptide Pam3CSK4 
bridge both receptors; two of the three lipid chains are inserted into an internal pocket in 
TLR2, and the remaining amide-bound lipid chain is inserted into a narrower channel in 
TLR1 (Figure 7A). Different from the TLR1-TLR2 complex, the TLR6-TLR2 complex 
recognizes diacyl-lipopeptide Pam2CSK4 which lacks the amide-bound lipid chain. 
The only two lipid chains of Pam2CSK4 are inserted into a large internal pocket in 
TLR2 (Figure 7D). The molecular interface of TLR2-TLR6 is greatly increased 
compared with TLR2-TLR1, which compensates for the lack of interactions between 
the amide-bound lipid chain and TLR6. TLR3 has multiple intermolecular contacts that 
stabilize the complex (Figure 7B). The dsRNA interacts with both an N-terminal and a 
C-terminal site on the glycan-free surface of each TLR3 ligand-binding domain, which 
are on opposite sides of the dsRNA, with the C-termini in contact and the N-termini 
outstretched at opposing ends of the linear dsRNA molecule. In the TLR4-MD2- 
lipopolysaccharides complexes, the lipopolysaccharide interacts with a large 
hydrophobic pocket in MD-2 and directly bridges the two components of the multimer 
(Figure 7C). Five of the six lipid chains of lipopolysaccharides are buried deep inside 
the pocket and the remaining chain is exposed to the surface of MD-2, forming a 
hydrophobic interaction with the conserved phenylalanines of TLR4. 
All of these complexes reveal an M-shaped architecture. In these dimeric arrangements, 
the C-termini of the ectodomains of TLRs converge in the center, and such a 
convergence should bring the two intracellular TIR domains close together and so 
promote their dimerization. 
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Figure 7: Crystal structures of TLR ligand-binding domains complexed with ligands. 
4.3 An LRR Template Assembly Approach for Homology Modeling of 
TLR Ligand-Binding Domains 
As described in section 3.3, the quality of the homology models strongly depends on 
the sequence identity between the target and template. Below 30% identity, serious 
errors may occur [58]. Standard homology modeling approaches search full-length 
templates that cover the complete or the major parts of a target protein sequence from 
the PDB [48]. Nevertheless, a proper full-length template with a sufficiently high 
sequence identity to the ligand-binding domain of TLRs is often missing due to 
different repeat numbers and distinct arrangements of LRRs contained in TLRs. For 
Structure Predictions of TLR Ligand-Binding Domains 
20 
instance, the full-length sequence identities between the human TLR5 ligand-binding 
domain (structure unknown) and the structure-known TLRs, TLR1 (PDB code: 
2Z7X:B), TLR2 (2Z7X:A), TLR3 (2A0Z:A), TLR4(3FXI:A) and TLR6 (3A79:B), are 
18.4%, 18.0%, 23.9%, 23.5% and 20.9%, respectively. They are much lower than the 
cutoff value 30%. This limitation can be overcome by assembling multiple LRR 
templates. In this approach, the most similar (on the sequence level) single LRR with a 
known structure is searched for each LRR in the target sequence as a local template. 
Such an LRR template may be derived from TLR structures or from other protein 
structures. Thereby, a suitable template may be found even for an insertion-containing 
irregular LRR in the target. All local template sequences are then combined to generate 
a multiple sequence alignment for the complete target sequence. In this way, a 
high-quality model can be created, even if no adequate single template is available. 
 
Figure 8: Flowchart of the LRR template assembly approach. A target sequence of a TLR 
ligand-binding domain is partitioned into LRR segments by TollML or LRRFinder. Then LRRML 
provides an optimal individual LRR structural template for each target LRR segment and generates 
target-template alignments. Next, the templates and the sequence alignments are inputted into an 
automatic model construction program to obtain a three-dimensional model. 
To facilitate the multiple template assembly of LRR domains of TLRs, we have 
developed the LRRML database [59], which archives individual LRR structures 
manually identified from all known LRR protein structures (detailed in section 7.1). 
The suffix “ML” indicates that the database is supported by the extensible markup 
language (XML) technology (http://www.w3.org). In addition, we have developed 
TollML [6], a database of sequence motifs of TLRs. In TollML, all known sequences of 
TLR ectodomains were semi-automatically partitioned into LRR segments and are 
made available for query (detailed in section 7.2). For newly sequenced TLRs that are 
not yet archived in TollML, we have implemented an LRR prediction program named 
LRRFinder on the TollML webpage. It requires as input an LRR-containing amino acid 
sequence and returns the number and positions of LRRs in the input sequence. With the 
help of these two databases, LRR partitions of a TLR ectodomain can be directly 
obtained, and an optimal structure template for each LRR segment can be quickly found. 
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A schematic flowchart of the modeling procedure is shown in Figure 8. This LRR 
assembly method was successfully evaluated with the crystal structures of mouse TLR3 
and 6, and was superior to a standard full-length template-based method. 
4.4 Homology Models of TLR5-13 Ligand-Binding Domains 
As mentioned above, 13 groups of TLRs have been found in mammalian genomes, ten 
in humans (TLR1-10) and 13 in mice (TLR1-13). The crystal structures of 
human/mouse TLR1-4 and mouse TLR6 ligand-binding domains were determined 
during the last six years. To enable first insight into the structural basis of 
receptor-ligand interactions of the structure-unknown TLRs, we modeled the human 
TLR5-10 and mouse TLR11-13 ligand-binding domains with our LRR template 
assembly method (detailed in section 7.3). Before these models were constructed, we 
modeled mouse TLR3 as a test case. We assumed that the structure of the TLR3 
ligand-binding domain was unknown and excluded the LRRs of human and mouse 
TLR3 from the LRRML database before template selection. Our model was very well 
superimposed with the crystal structure of mouse TLR3, in particular at both of its 
ligand-binding sites. Moreover, we also compared our resulting model of human TLR6 
with the crystal structure of mouse TLR6. They showed a high structural agreement. 
These values indicated that the models predicted with our method are high quality and 
can be used to predict potential ligand-binding sites. 
TLR7, 8 and 9 are closely related and comprise a subfamily with a longer amino acid 
sequence than other TLRs. They are intracellularly localized and signal in response to 
non-self nucleic acids. They also contain an irregular segment, which is treated as an 
undefined region [36, 37, 60], following the LRR14. A recent study indicated that 
TLR7 and 9 exit the endoplasmic reticulum and travel to endolysosomes. The 
ectodomains of TLR7 and 9 are cleaved at the irregular segment upon arriving in the 
endolysosomes [61]. Only the rear parts (LRR15-26) are capable of binding ligand and 
recruiting MyD88 adaptor on activation. This cleavage process may also happen to 
TLR8 because of the high homology between TLR7/8/9 [61]. Based on this finding, we 
modeled the cleaved forms of TLR7/8/9 ectodomains and predicted potential 
ligand-binding residues and possible configurations of the receptor-ligand complex 
(detailed in section 3.1). 
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5. Models of SIGIRR Inhibiting the TLR4 and 7 
Signaling Pathways 
SIGIRR, also known as TIR8 (Toll/interleukin-1 receptor 8), is another TIR 
domain-containing transmembrane protein. Its TIR domain cannot activate NF-кB 
because it lacks two essential amino acids (Ser447 and Tyr536) [62]. Its small single 
extracellular immunoglobulin domain does not support ligand binding. SIGIRR rather 
acts as an endogenous inhibitor of MyD88-dependent TLR signaling because 
overexpression of SIGIRR in Jurkat or HepG2 cells substantially reduced  the 
lipopolysaccharide activation of NF-кB [63-65]. Although TLRs recognize a variety of 
structures derived from pathogens leading to subsequent initiation of the relevant 
immune responses, they are also crucial in the induction and perpetuation of certain 
autoimmune diseases. For example, TLR7, 8 and 9 overstimulation by self RNA and 
DNA is an important mechanism involved in promoting systemic lupus erythematosus 
and psoriasis [15, 66]. In this vein, SIGIRR might contribute to the control of 
TLR-mediated autoimmunity. Lech et al. (2008) reported that, compared with wild type 
mice, Sigirr-deficient mice develop excessive lymphoproliferation when introduced 
into the context of a lupus susceptibility gene [67]. However, SIGIRR’s inhibition 
mechanism remains unknown owing to a lack of structural information. 
We constructed models for intracellular TIR domains of TLR4, TLR7, MyD88 and 
SIGIRR using homology modeling. Because the TIR domain is a highly conserved 
protein module, the determined crystal structures of TIR domains of human TLR1, 2, 
10 and IL-1RAPL (interleukin-1 receptor accessory protein-like) [32, 68, 69] could 
serve as closely homologous full-length templates. Through protein-protein docking 
studies, we developed models of essential TIR complexes involved in the TLR4 and 7 
signaling and the SIGIRR inhibiting processes. We suggested that SIGIRR might exert 
its inhibitory effect by blocking the molecular interface of TLR4, TLR7 and the MyD88 
adaptor mainly via its BB-loop region (detailed in section 7.5). In vivo deletion 
experiments indicated that lack of the BB-loop completely abrogated SIGIRR’s 
inhibitory effect on TLR7 signaling, in accordance with our hypothesis. 
 
 
 
 
 
 
 
 
Structure Predictions of TLR Ligand-Binding Domains 
24 
 
 
 
 
 
 
 
 
Methods 
25 
6. Methods 
6.1 Protein Modeling 
This section lists important methods that were used for the three-dimensional protein 
model construction and refinement. 
MODELLER [70] is one of the most widely used computer programs for homology 
modeling of protein three-dimensional structures. In the simplest case, the input is an 
alignment of a sequence to be modeled with the sequence(s) of the template structure(s), 
and the atomic coordinates of the template(s). MODELLER then automatically 
calculates a model containing all non-hydrogen atoms. It implements homology 
modeling by satisfaction of spatial restraints, by which a set of geometrical criteria are 
used to create a probability density function for the location of each atom in the protein. 
ModLoop [71] is a web tool for automated modeling of loops in protein structures. The 
inputs are the atomic coordinates of a protein structure in PDB format and the 
specification of the starting and ending residues of one or more segments to be modeled, 
containing no more than 20 residues in total. The output is the coordinates of the 
non-hydrogen atoms in the modeled segments. The modeling relies on a protocol 
consisting of a conjugate gradient minimization and a molecular dynamics simulation. 
THREADER [72] is a protein fold recognition method, whereby a query sequence is 
fitted (threaded) directly onto the carbon backbone coordinates of non-redundant 
protein structures derived from the PDB. The degree of compatibility between the 
sequence and each proposed structure is evaluated through a set of empirical potentials 
derived from proteins of known structure. The specific aspect of this approach is that 
the matching of sequence to backbone coordinates is performed in full 
three-dimensional space, incorporating specific pair interactions explicitly. 
pGenTHREADER [73] is a sequence profile-based structural template recognition 
method for protein homology modeling. It calculates sequence profiles from an input 
sequence and generates profile-profile alignments of the input and template sequences. 
The algorithm of the alignments linearly combines secondary structure-specific 
gap-penalties, pair potentials and solvation potentials. The output is the PDB structures 
that serve as candidate templates ranked by target-template similarities. 
PSIPRED [74] is a protein secondary structure prediction method. It performs a 
PSI-BLAST search [75] for a query sequence and then feeds the resulting profiles of the 
query through two consecutive feed-forward neural networks (a machine learning 
algorithm) to predict secondary structure. 
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6.2 Model Evaluation 
All protein model quality assessment programs used in this study are listed below. 
PROCHECK [76] provides a check on the stereochemistry of a three-dimensional 
protein structure or model. Its outputs comprise a number of plots, such as the 
Ramachandran plot [77] and a comprehensive residue-by-residue listing. These provide 
an assessment of the overall quality of the structure compared with well-refined 
structures of the same resolution and also highlight regions that may need further 
investigation. 
ProQ [78] is a neural network-based method to predict the quality of a protein model. It 
extracts structural features from an input model, such as the frequency of atom-atom 
contacts, and measures them either by LGscore [79] (for long target proteins) or 
MaxSub [80] (for short proteins). 
ModFOLD [81] combines scores obtained from the ModSSEA method [82], the 
MODCHECK method and the two ProQ methods using a neural network. It can 
provide the following: (i) a single score and a P-value, which represents a quantitative 
measure of the confidence in a model related to the predicted quality of a single protein 
model; (ii) rankings for multiple models for the same protein target according to 
predicted model quality; and (iii) predictions of the local quality (per-residue errors) 
within multiple models. 
MetaMQAP [83] is an up-to-date protein model evaluation tool. It is a meta-predictor- 
based on a multivariate regression model, which uses scores from eight previously 
published model evaluation methods. MetaMQAP predicts the absolute deviation (in 
Ångströms) of individual Cα atoms between the model and the unknown true structure 
as well as global deviations (expressed as root mean square deviations). 
6.3 Docking 
As described in section 3.4, there are two categories of docking: protein-protein 
docking and protein-nucleic acid docking. In this study, two protein-protein docking 
methods and five protein-nucleic acid docking methods were used. 
6.3.1 Protein-Protein Docking 
GRAMM-X [84] uses the correlation technique Fast Fourier Transformation (FFT) for 
the global search of the best rigid-body conformations. During the FFT search, the 
protein surface representation is smoothed to account for possible conformational 
changes upon binding. The search results are further refined by optimization in 
continuous coordinates and rescoring with several knowledge-based potential terms. 
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ZDOCK [85] is also an FFT search-based rigid-body docking method. An important 
feature of ZDOCK is that it employs a powerful scoring function, which integrates 
pairwise shape complementarity, desolvation and electrostatics during the FFT search. 
6.3.2 Protein-Nucleic Acid Docking 
BindN [86] takes an amino acid sequence as input and predicts potential DNA or 
RNA-binding residues using a statistics-based machine-learning model, a support 
vector machine (SVM) [87]. This machine was trained by protein datasets with known 
DNA or RNA-binding residues selected from PDB. Three sequence features from the 
training proteins were considered: the side chain pKa-value, hydrophobicity index and 
molecular mass of an amino acid. 
DP-Bind [88] is a web server for predicting DNA-binding sites in a DNA-binding 
protein from its amino acid sequence. The web server implements three machine 
learning methods: SVM, kernel logistic regression (KLR) [87] and penalized logistic 
regression (PLR) [87]. An input can be either a sequence alone or an automatically 
generated profile of evolutionary conservation in the form of PSI-BLAST 
position-specific scoring matrix. The training data were taken from PDB. 
DBS-PRED [89] makes use of two features of a query protein sequence, the amino acid 
composition and the sequence neighborhood/solvent accessibility, to predict the 
DNA-binding residues. A neural network was trained to recognize the relationship 
between the protein features and the DNA-binding sites. The training data were taken 
from the PDB and Swiss-Prot [90]. 
DBSPSSM [91] is a neural network-based method to utilize evolutionary information 
of amino acid sequences in terms of their position-specific scoring matrixes for 
predictions of DNA-binding site. The training data were taken from the PDB. 
PreDs [92], different from the above methods, predicts DNA-binding sites from 
three-dimensional coordinates in PDB format instead of from an amino acid sequence. 
PreDs calculates the shapes (local and the global average curvatures) and the 
electrostatic potential of the molecular surface of the query protein. Then, the method 
judges whether each vertex on the molecular surface is likely to appear at a 
DNA-binding site or not, based on statistics derived from PDB structures of 
protein-DNA complexes. 
6.4 Model Visualization and Analysis 
Several model visualization programs with numerous built-in scripts were used in this 
study. They provide necessary help in displaying and analyzing protein structures and 
rendering figures. 
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VMD [93] is a molecular graphics program designed for the display and analysis of 
biopolymers such as proteins and nucleic acids. Molecules are displayed as one or more 
“representations”, in which each representation embodies a particular rendering 
method and coloring scheme for a selected subset of atoms. VMD contains a set of tools 
for interactive problem solving in structural biology. 
SPDBV [94] is a molecular graphics program that provides a user-friendly interface 
allowing to analyze several proteins simultaneously. A useful function of SPDBV is 
that the protein structures can be superimposed to deduce structural alignments and 
compare their active sites or any other relevant parts. Amino acid mutations, H-bonds, 
angles and distances between atoms can be obtained using the intuitive graphic and 
menu interface. 
SuperPose [95] is a web server for both pairwise and multiple protein structure 
superpositions using a modified quaternion eigenvalue approach. SuperPose generates 
sequence alignments, structure alignments, PDB coordinates, root mean square 
deviation statistics and difference distance plots and images of the superimposed 
molecules. 
PISA [96] is an interactive tool for the exploration of macromolecular (protein, 
DNA/RNA and ligand) interfaces, prediction of probable quaternary structures, 
database searches of structurally similar interfaces and assemblies and searches on 
various assembly and PDB entry parameters. 
Additionally, Jalview [97] was used to view and edit multiple sequence alignments. It 
allows the identification of functional residues by comparison of subgroups of 
sequences arranged on a cluster tree. A number of color schemes were predefined to 
color alignments or groups. 
 
 
Results 
29 
7. Results (Extended Abstracts of Manuscripts) 
7.1 Paper 1: LRRML: A Conformational Database and An XML 
Description of Leucine-Rich Repeats (LRRs) 
(Manuscript see Appendix at page 45) 
Leucine-rich repeats (LRRs) are present in more than 6,000 proteins. They play an 
important role in protein-ligand interactions. To date, more than 100 crystal structures 
of LRR proteins have been determined. This knowledge has increased our ability to use 
the crystal structures as templates to model the TLR ligand-binding domains and other 
LRR proteins with unknown structures. Because the individual three-dimensional LRR 
structures are not directly available from the established databases and there are only a 
few detailed annotations for them, a conformational LRR database useful for homology 
modeling of LRR proteins is desirable. We developed LRRML, a conformational 
database and an extensible markup language (XML) description of LRRs. The release 
1.4 contains 1,475 individual LRR structures, which were identified from 130 PDB 
protein structures. All LRR entries are provided with three groups of manual 
annotations: first, classification into eight LRR types; second, partition into a highly 
conserved segment (HCS) and a variable segment (VS); and third, labeling of insertion 
segments longer than three amino acids according to LRR consensus sequences. In 
addition, an XML document type definition (DTD) was specified to exchange and store 
the LRRs. A construction pipeline is shown in Figure 9. 
 
Figure 9: Construction pipeline of the LRRML database. 
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Through a similarity search against LRRML, the most similar individual LRR 
structural template can be found for each LRR segment contained in a query protein 
sequence. A target-template alignment will also be generated. This is a key step 
towards homology modeling of TLR ligand-binding domains using the LRR template 
assembly approach. To demonstrate the capabilities of the database, we modeled the 
mouse Toll-like receptor 3 ectodomain as a test case by combining multiple LRR 
templates obtained from LRRML. A comparison of the model with the crystal structure 
(PDB code: 3CIG) showed a very good structural agreement. In conclusion, LRRML 
provides a source for homology modeling and structural analysis of LRR proteins. This 
database is available at http://lrrml.lrz.de/. 
7.2 Paper 2: TollML: A Database of Toll-like Receptor Structural 
Motifs 
(Manuscript see Appendix at page 55) 
Systematic and accurate motif partitions, in particular the leucine-rich repeats (LRRs) 
partitions, of Toll-like receptors (TLRs) are fundamental to modeling the 
three-dimensional structures of TLRs. Such partitions are not available in any current 
protein databases. In this regard, we developed the TollML database. 
TLRs have become the focus of a tremendous research interest because of their crucial 
role in the innate immune system. A central repository for the growing amount of 
relevant TLR sequence information has been created. Nevertheless, structural motifs of 
most TLR protein sequences, such as leucine-rich repeats (LRRs), are poorly annotated 
in the established databases. A database that organizes the structural motifs of TLRs can 
be useful for developing pattern recognition programs and structural modeling of TLRs. 
We describe TollML, a database that integrates all of the TLR sequencing data from the 
NCBI protein database. Entries were first divided into TLR families (TLR1-23) and 
then semi-automatically subdivided into three levels of structural motif categories: (1) 
signal peptide (SP), ectodomain (ECD), transmembrane domain (TD) and Toll/IL-1 
receptor (TIR) domain of each TLR; (2) LRRs of each ECD; (3) highly conserved 
segment (HCS), variable segment (VS) and insertions of each LRR. These categories 
can be quickly searched using an easy-to-use web interface and dynamically displayed 
by graphics. Additionally, all entries have hyperlinks to various sources including 
NCBI, Swiss-Prot, PDB, LRRML and PubMed in order to supply broad external 
information for users. The release 3.1 contains 2,572 TLR entries divided into 23 
families. A total of 46,720 LRR motifs were recognized from these TLR entries. The 
database is available at http://tollml.lrz.de/. 
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7.3 Paper 3: A Leucine-Rich Repeat Assembly Approach for 
Homology Modeling of Human TLR5-10 and Mouse TLR11-13 
Ectodomains 
(Manuscript see Appendix at page 63) 
Crystal structures are currently missing for most Toll-like receptor (TLR) 
ligand-binding ectodomains. Thus, their ligand recognition mechanisms are poorly 
understood. Computational approaches enable rapid large-scale predictions of their 
three-dimensional structures. The TLR ectodomains are composed of varying numbers 
and types of leucine-rich repeats (LRRs). Although the determined crystal structures of 
TLR ectodomains can provide structural templates for homology modeling of other 
TLR ectodomains, the quality of the predicted models that are generated from these 
full-length templates can be limited due to low sequence identity (< 30%) between the 
target and template. 
To obtain better templates for modeling, we have developed an LRR template assembly 
approach. Individual LRR templates that are locally optimal for the target sequence are 
assembled into multiple templates. Two test cases underlined the feasibility and 
reliability of the method. First, two models of mouse TLR3 were constructed using a 
standard full-length template method (model 1, Figure 10a) and our LRR template 
assembly method (model 2, Figure 10b). Model 2 was very well superimposed with the 
crystal structure (PDB code: 3CIG, Figure 10c) at both of its ligand-binding regions. 
The backbone root mean square deviations (RMSDs) were 1.96 Å and 1.90 Å, 
respectively. By contrast, model 1 showed serious structural disorder spanning from 
LRR6 through LRR10. Second, another two models of human TLR6 were constructed 
using a standard full-length template method (model 3, Figure 10d) and our LRR 
template assembly method (model 4, Figure 10e). Both models well matched the crystal 
structure of mouse TLR6 (3A79, residue ID 33-474, Figure 10f), with backbone 
RMSDs of 1.89 Å and 1.94 Å, respectively. In the first test case, there was no proper 
full-length template for the target protein. Therefore, the standard method failed to 
produce a realistic model. In the second test case, the structure of human TLR1 (2Z7X) 
provided an excellent full-length template for TLR6 because TLR1 and TLR6 possess 
the same number of LRRs and have a high sequence identity (63.3%). Under these very 
good conditions, both, the standard and our approaches, provided high-quality models. 
These comparison results proved that our method reveals its particular strength in 
situations where no adequate full-length templates are available. 
With this method we constructed ectodomain models of human TLR5, TLR6, TLR7, 
TLR8, TLR9 and TLR10, and mouse TLR11, TLR12 and TLR13 that can be used as 
first passes for a computational simulation of ligand-docking or to design mutation 
experiments. As an application example, we performed molecular electrostatics 
calculations of the mouse TLR11 model with a parasite profilin ligand. The results 
show that the entire surface of the profilin of Plasmodium falciparum (PDB code: 2JKF) 
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is predominantly negatively charged, whereas TLR11 exhibits several positively 
charged patches. Furthermore, protein-protein docking studies using GRAMM-X show 
that profilin and the positive patches on TLR11 possess compatible sizes and 
electrostatic complementarity. 
 
Figure 10: Homology models and crystal structures of TLR3 and six ectodomains. (a) The mouse 
TLR3 model based on the standard method. The framed region exhibits serious disorder. (b) The 
mouse TLR3 model based on the LRR template assembly method. (c) The crystal structure of 
mouse TLR3 (PDB code: 3CIG). (d) The human TLR6 model based on the standard method. (e) 
The human TLR6 model based on the LRR template assembly method. (f) The crystal structure of 
mouse TLR6 (3A79). 
This template assembly approach can be extended to modeling of other repetitive 
proteins. 
7.4 Paper 4: Homology Modeling of Human Toll-Like Receptors 
TLR7, 8 and 9 Ligand-Binding Domains 
(Manuscript see Appendix at page 82) 
Nucleic acid-sensing Toll-like receptors (TLRs), TLR3, 7, 8 and 9, recognize different 
types of microbial nucleic acids after they are transferred in the cell. Understanding 
their ligand-binding mechanisms is crucial for development of agonists and 
antagonists with therapeutic potential for infectious diseases. So far, there are no 
crystallographic structures for TLR7/8/9. To enable first predictions of the 
receptor-ligand interaction sites, we developed three-dimensional models for the 
ligand-binding domains of human TLR7/8/9 based on homology modeling. The 
predicted results can guide experimentalists to design new site-directed mutation 
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experiments to unravel the ligand-binding mechanisms of these receptors. 
 
Figure 11: Important residues in ligand-binding regions of TLR7/8/9. Blue: essential residues as 
reported in the literature; pink: residues close the blue ones (within two LRRs) but excluded from 
the potential ligand-binding residues through the four investigating processes; green: suggested 
potential ligand-binding residues (residue name and number are labeled). 
To achieve a high sequence similarity between targets and templates, structural 
segments from all known TLR ectodomain structures (human TLR1/2/3/4 and mouse 
TLR3/4) were used as candidate templates for the modeling. Based on our models, we 
identified potential ligand-binding residues for TLR7/8/9 using combined procedures. 
Only the surface residues that fulfilled the four qualifications as follows were regarded 
as potential ligand-binding residues: (1) highly conserved across mammalian species; 
(2) non-negatively charged; (3) spatially close (within two LRRs) to the experimentally 
determined ligand-binding residues (Asp543 in TLR8; Asp535 and Tyr537 in TLR9); 
and (4) positively predicted by at least two protein-nucleic acid docking programs. 
Figure 11 illustrates names and locations of these residues. We suggest further 
investigations of these residues through mutation experiments. Moreover, we propose 
three potential receptor-ligand 2:1 complexing mechanisms based on the resulting 
models together with considerations of the potential ligand-binding residues. 
7.5 Paper 5: Inhibition of the Toll-Like Receptors TLR4 and 7 
Signaling Pathways by SIGIRR: A Computational Approach 
(Manuscript see Appendix at page 91) 
Understanding the mechanisms of negative regulation of Toll-like receptor (TLR) 
signaling will help to develop novel therapies to treat autoimmunity. TLRs belong to 
the Toll-like receptor/interleukin-1 receptor (TLR/IL-1R) superfamily, which is defined 
by a common cytoplasmic Toll/interleukin-1 receptor (TIR) domain. TLRs recognize 
pathogen-associated molecular patterns and initiate an intracellular kinase cascade to 
trigger an immediate defensive response. SIGIRR (single immunoglobulin 
interleukin-1 receptor-related molecule), another member of the TLR/IL-1R 
superfamily, acts as a negative regulator of MyD88-dependent TLR signaling. It 
attenuates the recruitment of MyD88 adaptors to the receptors with its intracellular TIR 
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domain. Thus, SIGIRR is a highly important molecule for the therapy of autoimmune 
diseases caused by TLRs. Currently, the structural mechanism of interactions between 
SIGIRR, TLRs and adaptor molecules is unclear. To develop a working hypothesis for 
this interaction, we constructed three-dimensional models for the TIR domains of 
TLR4, TLR7, MyD88 and SIGIRR based on computational modeling. Through a 
protein-protein docking analysis, we developed models of essential complexes 
involved in the TLR4 and 7 signaling and the SIGIRR inhibiting processes. We suggest 
that SIGIRR may exert its inhibitory effect by blocking the molecular interface of 
TLR4, TLR7 and the MyD88 adaptor mainly via its BB-loop region. 
7.6 Paper 6: Lack of SIGIRR/TIR8 Aggravates Hydrocarbon 
Oil-Induced Systemic Lupus 
(Manuscript see Appendix at page 100) 
Multiple genetic factors contribute to the clinical variability of spontaneous systemic 
lupus erythematosus but their role in drug-induced systemic lupus erythematosus 
remains largely unknown. Hydrocarbon oil-induced systemic lupus erythematosus 
depends on mesothelial cell apoptosis and Toll-like receptor (TLR)-7-mediated 
induction of type interferons. Hence, we hypothesized SIGIRR/TIR8, an endogenous 
TLR inhibitor, prevents oil-induced systemic lupus erythematosus. Sigirr-deficient 
dendritic cells expressed higher TLR7 mRNA levels and TLR7 activation resulted in 
increased IL-12 production in vitro. In vivo, lack of SIGIRR increased surface CD40 
expression on spleen CD11c+ dendritic cells and MX-1, TNF, IL-12, BAFF, and BCL-2 
mRNA expression six months after pristane injection. Spleen cell counts of CD4-/CD8- 
autoreactive T cells and B220+ B cells were also increased in Sigirr-/- mice. Serum 
autoantibody analysis revealed that Sigirr-deficiency specifically enhanced the 
production of rheumatoid factor (from four months of age) and anti-snRNP IgG (from 
five months of age) while anti-Smith IgG or anti-dsDNA IgG were independent of the 
Sigirr genotype. This effect was sufficient to significantly aggravate lupus nephritis in 
Sigirr-deficient mice. Structure model prediction identified the BB-loop of SIGIRR’s 
intracellular TIR domain to interact with TLR7 and MyD88. BB-loop deletion was 
sufficient to completely abrogate SIGIRR’s inhibitory effect on TLR7 signaling. Thus, 
SIGIRR/TIR8 protects from hydrocarbon oil-induced lupus via suppressing the 
TLR7-mediated activation of dendritic cells most likely via its intracellular BB-loop. 
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8. Conclusions 
This thesis focuses on three-dimensional structure prediction of TLR ligand-binding 
domains. In the view of the periodic arrangement of LRRs that comprise the TLR 
ligand-binding domains, an LRR template assembly approach was developed for 
homology modeling of these domains. The approach was implemented through two 
protein structure databases, TollML and LRRML. In TollML, all known TLR protein 
sequences (release 3.1: 2,572 entries) were semi-automatically partitioned into 
individual LRR sequences and are made available for query. On the other hand, 
LRRML archives individual LRR structures (release 0.7: 1,475 entries) manually 
identified from all known crystal structures of LRR proteins, with a similarity search 
function. The databases are available at http://tollml.lrz.de/ and http://lrrml.lrz.de/, 
respectively. Thus, the most similar (on the sequence level) LRR with a known 
structure can be found as a local template for each LRR contained in the target protein 
sequence. All local template sequences are then combined to generate a multiple 
sequence alignment for the complete target sequence. Finally, the templates 
(three-dimensional coordinates) and the sequence alignments are inputted into an 
automatic model construction program to obtain a three-dimensional model. To 
validate the template assembly approach, we constructed the models of TLR3 and 6 and 
superimposed them with the corresponding crystal structures. The high similarities 
(RMSDs < 2 Å) between the models and crystal structures underlined the feasibility 
and reliability of this method. Furthermore, the comparison of our method with a 
standard full-length template modeling method (pGenTHREADER) showed that our 
method is significantly superior in situations where no adequate full-length templates 
are available. 
With the LRR template assembly method, a series of models of full-length TLR 
ligand-binding domains (human TLR5-10 and mouse TLR11-13) and the cleaved 
TLR7/8/9 ligand-binding domains were constructed. Model evaluation results 
indicated the high quality of all resulting models. The molecular surface electrostatics 
investigation and docking study of the mouse TLR11 model with a parasite profilin 
ligand demonstrated the usability of these models. Then, we identified potential 
ligand-binding residues for the cleaved TLR7/8/9 by combining results from four steps 
of investigations. The potential ligand-binding residues constitute a continuous 
ligand-binding region, which possesses a compatible size with the ssRNA or CpG DNA 
ligand and is located on the insertion-containing surface of the TLR horseshoe. The 
models together with the predicted ligand-binding regions could be used to derive a 
working hypothesis for the conformation of the receptor-ligand complex. Three models 
of the receptor-ligand 2:1 complexes were proposed, where the two receptor monomers 
sandwich the ligand at different positions. Thus, the minimum ligand size required by 
the three models is also different. 
Inappropriate ligand recognition of TLRs can lead to autoimmune disorders. For this 
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reason, SIGIRR, as a negative regulator of TLRs, is highly important for the therapy of 
autoimmune diseases caused by TLRs. Our studies on the structural interactions 
between SIGIRR, TLR4, TLR7 and the TLR adaptor protein MyD88 showed that 
SIGIRR might block the molecular interface of TLR4, TLR7 and MyD88 mainly via 
the BB-loop of its intracellular TIR domain. 
Still, the process of going from protein sequences to structures and to functions is far 
from being automated. Bioinformatic predictions become particularly helpful in an 
environment where the computational methods can be used in concert with 
experimental techniques for protein structure and function determination. Here, the 
predictions exercise their strengths by creating groundwork for subsequent experiments 
that follow up these predicted data. 
 
 
 
References 
37 
References 
1. Takeda K, Akira S: Toll-like receptors in innate immunity. Int Immunol 2005, 
17(1):1-14. 
2. Jin MS, Kim SE, Heo JY, Lee ME, Kim HM, Paik SG, Lee H, Lee JO: Crystal 
structure of the TLR1-TLR2 heterodimer induced by binding of a 
tri-acylated lipopeptide. Cell 2007, 130(6):1071-1082. 
3. Park BS, Song DH, Kim HM, Choi BS, Lee H, Lee JO: The structural basis of 
lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature 2009, 
458(7242):1191-1195. 
4. Liu L, Botos I, Wang Y, Leonard JN, Shiloach J, Segal DM, Davies DR: 
Structural basis of toll-like receptor 3 signaling with double-stranded RNA. 
Science 2008, 320(5874):379-381. 
5. Kang JY, Nan X, Jin MS, Youn SJ, Ryu YH, Mah S, Han SH, Lee H, Paik SG, 
Lee JO: Recognition of lipopeptide patterns by Toll-like receptor 2-Toll-like 
receptor 6 heterodimer. Immunity 2009, 31(6):873-884. 
6. Gong J, Wei T, Zhang N, Jamitzky F, Heckl WM, Rossle SC, Stark RW: 
TollML: a database of toll-like receptor structural motifs. J Mol Model 
2010, 16(7):1283-1289. 
7. Tuccinardi T, Ortore G, Rossello A, Supuran CT, Martinelli A: Homology 
modeling and receptor-based 3D-QSAR study of carbonic anhydrase IX. J 
Chem Inf Model 2007, 47(6):2253-2262. 
8. Singh N, Avery MA, McCurdy CR: Toward Mycobacterium tuberculosis 
DXR inhibitor design: homology modeling and molecular dynamics 
simulations. J Comput Aided Mol Des 2007, 21(9):511-522. 
9. Hazai E, Bikadi Z: Homology modeling of breast cancer resistance protein 
(ABCG2). J Struct Biol 2008, 162(1):63-74. 
10. Bisson WH, Koch DC, O'Donnell EF, Khalil SM, Kerkvliet NI, Tanguay RL, 
Abagyan R, Kolluri SK: Modeling of the aryl hydrocarbon receptor (AhR) 
ligand binding domain and its utility in virtual ligand screening to predict 
new AhR ligands. J Med Chem 2009, 52(18):5635-5641. 
11. Wu B, Zhang Y, Kong J, Zhang X, Cheng S: In silico predication of nuclear 
hormone receptors for organic pollutants by homology modeling and 
molecular docking. Toxicol Lett 2009, 191(1):69-73. 
12. Savarese E, Chae OW, Trowitzsch S, Weber G, Kastner B, Akira S, Wagner H, 
Schmid RM, Bauer S, Krug A: U1 small nuclear ribonucleoprotein immune 
complexes induce type I interferon in plasmacytoid dendritic cells through 
TLR7. Blood 2006, 107(8):3229-3234. 
13. Means TK, Latz E, Hayashi F, Murali MR, Golenbock DT, Luster AD: Human 
lupus autoantibody-DNA complexes activate DCs through cooperation of 
CD32 and TLR9. J Clin Invest 2005, 115(2):407-417. 
14. Vollmer J, Tluk S, Schmitz C, Hamm S, Jurk M, Forsbach A, Akira S, Kelly 
KM, Reeves WH, Bauer S et al: Immune stimulation mediated by 
autoantigen binding sites within small nuclear RNAs involves Toll-like 
receptors 7 and 8. J Exp Med 2005, 202(11):1575-1585. 
15. Barrat FJ, Meeker T, Gregorio J, Chan JH, Uematsu S, Akira S, Chang B, 
Duramad O, Coffman RL: Nucleic acids of mammalian origin can act as 
endogenous ligands for Toll-like receptors and may promote systemic 
References 
38 
lupus erythematosus. J Exp Med 2005, 202(8):1131-1139. 
16. Janeway CA, Jr.: How the immune system works to protect the host from 
infection: a personal view. Proc Natl Acad Sci U S A 2001, 98(13):7461-7468. 
17. Janeway CA, Jr., Medzhitov R: Innate immune recognition. Annu Rev 
Immunol 2002, 20:197-216. 
18. Kawai T, Akira S: Toll-like receptor and RIG-I-like receptor signaling. Ann 
N Y Acad Sci 2008, 1143:1-20. 
19. Schwartz RS: Advances in Immunology -- A New Series of Review Articles. 
N Engl J Med 2000, 343(1):61-62. 
20. Hopkins PA, Sriskandan S: Mammalian Toll-like receptors: to immunity 
and beyond. Clin Exp Immunol 2005, 140(3):395-407. 
21. Ahmed R, Gray D: Immunological memory and protective immunity: 
understanding their relation. Science 1996, 272(5258):54-60. 
22. Medzhitov R, Janeway CA, Jr.: Innate immunity: impact on the adaptive 
immune response. Curr Opin Immunol 1997, 9(1):4-9. 
23. Jurk M, Kritzler A, Debelak H, Vollmer J, Krieg AM, Uhlmann E: 
Structure-activity relationship studies on the immune stimulatory effects 
of base-modified CpG toll-like receptor 9 agonists. ChemMedChem 2006, 
1(9):1007-1014. 
24. Stein D, Roth S, Vogelsang E, Nusslein-Volhard C: The polarity of the 
dorsoventral axis in the Drosophila embryo is defined by an extracellular 
signal. Cell 1991, 65(5):725-735. 
25. Lemaitre B, Nicolas E, Michaut L, Reichhart JM, Hoffmann JA: The 
dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the 
potent antifungal response in Drosophila adults. Cell 1996, 86(6):973-983. 
26. Tauszig S, Jouanguy E, Hoffmann JA, Imler JL: Toll-related receptors and the 
control of antimicrobial peptide expression in Drosophila. Proc Natl Acad 
Sci U S A 2000, 97(19):10520-10525. 
27. Medzhitov R, Preston-Hurlburt P, Janeway CA, Jr.: A human homologue of 
the Drosophila Toll protein signals activation of adaptive immunity. Nature 
1997, 388(6640):394-397. 
28. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, Birdwell D, Alejos 
E, Silva M, Galanos C et al: Defective LPS signaling in C3H/HeJ and 
C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998, 
282(5396):2085-2088. 
29. Kumar H, Kawai T, Akira S: Pathogen recognition in the innate immune 
response. Biochem J 2009, 420(1):1-16. 
30. Brodsky I, Medzhitov R: Two modes of ligand recognition by TLRs. Cell 
2007, 130(6):979-981. 
31. Weber AN, Morse MA, Gay NJ: Four N-linked glycosylation sites in human 
toll-like receptor 2 cooperate to direct efficient biosynthesis and secretion. 
J Biol Chem 2004, 279(33):34589-34594. 
32. Xu Y, Tao X, Shen B, Horng T, Medzhitov R, Manley JL, Tong L: Structural 
basis for signal transduction by the Toll/interleukin-1 receptor domains. 
Nature 2000, 408(6808):111-115. 
33. Barton GM, Kagan JC, Medzhitov R: Intracellular localization of Toll-like 
receptor 9 prevents recognition of self DNA but facilitates access to viral 
DNA. Nat Immunol 2006, 7(1):49-56. 
References 
39 
34. O'Neill LA, Bowie AG: The family of five: TIR-domain-containing 
adaptors in Toll-like receptor signalling. Nat Rev Immunol 2007, 
7(5):353-364. 
35. Kajava AV: Structural diversity of leucine-rich repeat proteins. J Mol Biol 
1998, 277(3):519-527. 
36. Bell JK, Mullen GE, Leifer CA, Mazzoni A, Davies DR, Segal DM: 
Leucine-rich repeats and pathogen recognition in Toll-like receptors. 
Trends Immunol 2003, 24(10):528-533. 
37. Matsushima N, Tanaka T, Enkhbayar P, Mikami T, Taga M, Yamada K, Kuroki 
Y: Comparative sequence analysis of leucine-rich repeats (LRRs) within 
vertebrate toll-like receptors. BMC Genomics 2007, 8:124. 
38. Roach JC, Glusman G, Rowen L, Kaur A, Purcell MK, Smith KD, Hood LE, 
Aderem A: The evolution of vertebrate Toll-like receptors. Proc Natl Acad 
Sci U S A 2005, 102(27):9577-9582. 
39. Takeda K, Kaisho T, Akira S: Toll-like receptors. Annu Rev Immunol 2003, 
21:335-376. 
40. Gay NJ, Gangloff M: Structure and function of Toll receptors and their 
ligands. Annu Rev Biochem 2007, 76:141-165. 
41. Werling D, Piercy J, Coffey TJ: Expression of TOLL-like receptors (TLR) by 
bovine antigen-presenting cells-potential role in pathogen discrimination? 
Vet Immunol Immunopathol 2006, 112(1-2):2-11. 
42. Lang KS, Georgiev P, Recher M, Navarini AA, Bergthaler A, Heikenwalder M, 
Harris NL, Junt T, Odermatt B, Clavien PA et al: Immunoprivileged status of 
the liver is controlled by Toll-like receptor 3 signaling. J Clin Invest 2006, 
116(9):2456-2463. 
43. Takeda K, Akira S: TLR signaling pathways. Semin Immunol 2004, 16(1):3-9. 
44. Zhang Y: I-TASSER server for protein 3D structure prediction. BMC 
Bioinformatics 2008, 9:40. 
45. Zaki MJ, Bystroff C: Protein Structure Prediction, 2 edn: Humana Press; 
2008. 
46. Petsko GA, Ringe D: Protein Structure and Function: New Science Pres; 
2004. 
47. Ginalski K: Comparative modeling for protein structure prediction. Curr 
Opin Struct Biol 2006, 16(2):172-177. 
48. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, 
Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res 2000, 
28(1):235-242. 
49. Arnold K, Bordoli L, Kopp J, Schwede T: The SWISS-MODEL workspace: a 
web-based environment for protein structure homology modelling. 
Bioinformatics 2006, 22(2):195-201. 
50. Fiser A, Do RK, Sali A: Modeling of loops in protein structures. Protein Sci 
2000, 9(9):1753-1773. 
51. Kopp J, Schwede T: Automated protein structure homology modeling: a 
progress report. Pharmacogenomics 2004, 5(4):405-416. 
52. Anfinsen CB: Principles that govern the folding of protein chains. Science 
1973, 181(96):223-230. 
53. Cserhati T, Szogyi M: Role of hydrophobic and hydrophilic forces in 
References 
40 
peptide-protein interaction: new advances. Peptides 1995, 16(1):165-173. 
54. Zhang Q, Sanner M, Olson AJ: Shape complementarity of protein-protein 
complexes at multiple resolutions. Proteins 2009, 75(2):453-467. 
55. Cheng TM, Blundell TL, Fernandez-Recio J: Structural assembly of 
two-domain proteins by rigid-body docking. BMC Bioinformatics 2008, 
9:441. 
56. Bell JK, Botos I, Hall PR, Askins J, Shiloach J, Segal DM, Davies DR: The 
molecular structure of the Toll-like receptor 3 ligand-binding domain. Proc 
Natl Acad Sci U S A 2005, 102(31):10976-10980. 
57. Choe J, Kelker MS, Wilson IA: Crystal structure of human toll-like receptor 
3 (TLR3) ectodomain. Science 2005, 309(5734):581-585. 
58. Baker D, Sali A: Protein structure prediction and structural genomics. 
Science 2001, 294(5540):93-96. 
59. Wei T, Gong J, Jamitzky F, Heckl WM, Stark RW, Roessle SC: LRRML: a 
conformational database and an XML description of leucine-rich repeats 
(LRRs). BMC Struct Biol 2008, 8(1):47. 
60. Gibbard RJ, Morley PJ, Gay NJ: Conserved features in the extracellular 
domain of human toll-like receptor 8 are essential for pH-dependent 
signaling. J Biol Chem 2006, 281(37):27503-27511. 
61. Ewald SE, Lee BL, Lau L, Wickliffe KE, Shi GP, Chapman HA, Barton GM: 
The ectodomain of Toll-like receptor 9 is cleaved to generate a functional 
receptor. Nature 2008, 456(7222):658-662. 
62. Thomassen E, Renshaw BR, Sims JE: Identification and characterization of 
SIGIRR, a molecule representing a novel subtype of the IL-1R superfamily. 
Cytokine 1999, 11(6):389-399. 
63. Wald D, Qin J, Zhao Z, Qian Y, Naramura M, Tian L, Towne J, Sims JE, Stark 
GR, Li X: SIGIRR, a negative regulator of Toll-like receptor-interleukin 1 
receptor signaling. Nat Immunol 2003, 4(9):920-927. 
64. Polentarutti N, Rol GP, Muzio M, Bosisio D, Camnasio M, Riva F, Zoja C, 
Benigni A, Tomasoni S, Vecchi A et al: Unique pattern of expression and 
inhibition of IL-1 signaling by the IL-1 receptor family member 
TIR8/SIGIRR. Eur Cytokine Netw 2003, 14(4):211-218. 
65. Qin J, Qian Y, Yao J, Grace C, Li X: SIGIRR inhibits interleukin-1 receptor- 
and toll-like receptor 4-mediated signaling through different mechanisms. 
J Biol Chem 2005, 280(26):25233-25241. 
66. Gilliet M, Conrad C, Geiges M, Cozzio A, Thurlimann W, Burg G, Nestle FO, 
Dummer R: Psoriasis triggered by toll-like receptor 7 agonist imiquimod in 
the presence of dermal plasmacytoid dendritic cell precursors. Arch 
Dermatol 2004, 140(12):1490-1495. 
67. Lech M, Kulkarni OP, Pfeiffer S, Savarese E, Krug A, Garlanda C, Mantovani A, 
Anders HJ: Tir8/Sigirr prevents murine lupus by suppressing the 
immunostimulatory effects of lupus autoantigens. J Exp Med 2008, 
205(8):1879-1888. 
68. Nyman T, Stenmark P, Flodin S, Johansson I, Hammarstrom M, Nordlund P: 
The crystal structure of the human toll-like receptor 10 cytoplasmic 
domain reveals a putative signaling dimer. J Biol Chem 2008, 
283(18):11861-11865. 
69. Khan JA, Brint EK, O'Neill LA, Tong L: Crystal structure of the 
Toll/interleukin-1 receptor domain of human IL-1RAPL. J Biol Chem 2004, 
References 
41 
279(30):31664-31670. 
70. Eswar N, Webb B, Marti-Renom MA, Madhusudhan MS, Eramian D, Shen MY, 
Pieper U, Sali A: Comparative protein structure modeling using 
MODELLER. Curr Protoc Protein Sci 2007, Chapter 2:Unit 2 9. 
71. Fiser A, Sali A: ModLoop: automated modeling of loops in protein 
structures. Bioinformatics 2003, 19(18):2500-2501. 
72. Jones DT, Taylor WR, Thornton JM: A new approach to protein fold 
recognition. Nature 1992, 358(6381):86-89. 
73. Lobley A, Sadowski MI, Jones DT: pGenTHREADER and 
pDomTHREADER: new methods for improved protein fold recognition 
and superfamily discrimination. Bioinformatics 2009, 25(14):1761-1767. 
74. Bryson K, McGuffin LJ, Marsden RL, Ward JJ, Sodhi JS, Jones DT: Protein 
structure prediction servers at University College London. Nucleic Acids 
Res 2005, 33(Web Server issue):W36-38. 
75. Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ: 
Gapped BLAST and PSI-BLAST: a new generation of protein database 
search programs. Nucleic Acids Res 1997, 25(17):3389-3402. 
76. Laskowski RA, MacArthur MW, Moss DS, Thornton JM: PROCHECK: a 
program to check the stereochemical quality of protein structures. J Appl 
Cryst 1993, 26:283-291. 
77. Ramachandran GN, Ramakrishnan C, Sasisekharan V: Stereochemistry of 
polypeptide chain configurations. J Mol Biol 1963, 7:95-99. 
78. Wallner B, Elofsson A: Can correct protein models be identified? Protein Sci 
2003, 12(5):1073-1086. 
79. Cristobal S, Zemla A, Fischer D, Rychlewski L, Elofsson A: A study of quality 
measures for protein threading models. BMC Bioinformatics 2001, 2:5. 
80. Siew N, Elofsson A, Rychlewski L, Fischer D: MaxSub: an automated 
measure for the assessment of protein structure prediction quality. 
Bioinformatics 2000, 16(9):776-785. 
81. McGuffin LJ: The ModFOLD server for the quality assessment of protein 
structural models. Bioinformatics 2008, 24(4):586-587. 
82. McGuffin LJ: Benchmarking consensus model quality assessment for 
protein fold recognition. BMC Bioinformatics 2007, 8:345. 
83. Pawlowski M, Gajda MJ, Matlak R, Bujnicki JM: MetaMQAP: a meta-server 
for the quality assessment of protein models. BMC Bioinformatics 2008, 
9:403. 
84. Tovchigrechko A, Vakser IA: GRAMM-X public web server for 
protein-protein docking. Nucleic Acids Res 2006, 34(Web Server 
issue):W310-314. 
85. Chen R, Li L, Weng Z: ZDOCK: an initial-stage protein-docking algorithm. 
Proteins 2003, 52(1):80-87. 
86. Wang L, Brown SJ: BindN: a web-based tool for efficient prediction of DNA 
and RNA binding sites in amino acid sequences. Nucleic Acids Res 2006, 
34(Web Server issue):W243-248. 
87. Vapnik CA: Statistical Learning Theory: John Wiley and Sons; 1998. 
88. Hwang S, Gou Z, Kuznetsov IB: DP-Bind: a web server for sequence-based 
prediction of DNA-binding residues in DNA-binding proteins. 
References 
42 
Bioinformatics 2007, 23(5):634-636. 
89. Ahmad S, Gromiha MM, Sarai A: Analysis and prediction of DNA-binding 
proteins and their binding residues based on composition, sequence and 
structural information. Bioinformatics 2004, 20(4):477-486. 
90. Boeckmann B, Bairoch A, Apweiler R, Blatter MC, Estreicher A, Gasteiger E, 
Martin MJ, Michoud K, O'Donovan C, Phan I et al: The SWISS-PROT 
protein knowledgebase and its supplement TrEMBL in 2003. Nucleic Acids 
Res 2003, 31(1):365-370. 
91. Ahmad S, Sarai A: PSSM-based prediction of DNA binding sites in proteins. 
BMC Bioinformatics 2005, 6:33. 
92. Tsuchiya Y, Kinoshita K, Nakamura H: PreDs: a server for predicting 
dsDNA-binding site on protein molecular surfaces. Bioinformatics 2005, 
21(8):1721-1723. 
93. Humphrey W, Dalke A, Schulten K: VMD: visual molecular dynamics. J Mol 
Graph 1996, 14(1):33-38, 27-38. 
94. Guex N, Peitsch MC: SWISS-MODEL and the Swiss-PdbViewer: an 
environment for comparative protein modeling. Electrophoresis 1997, 
18(15):2714-2723. 
95. Maiti R, Van Domselaar GH, Zhang H, Wishart DS: SuperPose: a simple 
server for sophisticated structural superposition. Nucleic Acids Res 2004, 
32(Web Server issue):W590-594. 
96. Krissinel E, Henrick K: Inference of macromolecular assemblies from 
crystalline state. J Mol Biol 2007, 372(3):774-797. 
97. Waterhouse AM, Procter JB, Martin DM, Clamp M, Barton GJ: Jalview 
Version 2--a multiple sequence alignment editor and analysis workbench. 
Bioinformatics 2009, 25(9):1189-1191. 
 
 
 
 
 
Acknowledgements 
43 
Acknowledgements 
This dissertation was written at the Department of Earth and Environmental Sciences 
and the Center for NanoScience (CeNS) of the LMU Munich. It was supported by 
Graduiertenkolleg 1202 of the Deutsche Forschungsgemeinschaft (DFG) and the DFG 
excellence cluster Nanosystems Initiative Munich (NIM). 
First of all, I would like to thank Prof. Dr. Wolfgang M. Heckl for providing me the 
opportunity and lab space in his group for this research work. I am deeply indebted to 
my mentor Prof. Dr. Robert W. Stark, whose support, stimulating suggestions and 
encouragement helped me throughout all stages of this work. His permanent support 
enabled me to prepare conduct, analyze and conclude the work presented here. I 
especially thank Dr. Ferdinand Jamitzky (Leibniz-Rechenzentrum der Bayerischen 
Akademie der Wissenschaften) and Dr. Shaila C. Roessle who introduced the research 
subject to me and significantly increased my scientific knowledge on protein structure 
predictions. 
I would like to thank Prof. Dr. Hans J. Anders (Medizinische Poliklinik Innenstadt, 
Klinikum der LMU) for not only being an excellent co-mentor but also for giving me 
helpful discussions about the combination of experimental and computational methods. 
My thanks also go to Dr. Maciej Lech (Medizinische Poliklinik Innenstadt, Klinikum 
der LMU) for the providing the in vivo mutagenesis results. Further I would like to 
thank Prof. Dr. Stefan Endres (Abteilung für Klinische Pharmakologie, Klinikum der 
LMU) for all the constructive discussion and help in solving scientific and personal 
problems. 
I appreciated the assistance of undergraduate student Ning Zhang (Institut für 
Informatik der LMU), who conducted the preliminary work on the TLR dataset 
processing and testing within the scope of her diploma thesis. 
Last but not least, I would like to particularly thank Jing Gong, my co-author as well as 
my wife, for constructive and productive team-work. Her work focused on database 
programming and protein-protein interaction (docking) analyses. I am profoundly 
grateful to her for all her help and support inside and outside the lab. 
Finally, I would like to thank all whose direct and indirect support helped me to 
complete my thesis on time. 
 
 
 
 
 
Acknowledgements 
44 
 
 
 
 
 
 
Appendix 
45 
Appendix 
Paper 1 
 
 
 
 
 
 
 
 
 
LRRML: a conformational database and an XML description of leucine-rich repeats 
(LRRs) 
BMC Struct. Biol., 2008, 8:47 
Tiandi Wei, Jing Gong, Ferdinand Jamitzky, Wolfgang M. Heckl, Robert W. Stark and 
Shaila C. Rössle 
 
BMC Structural Biology
Database
LRRML: a conformational database and an XML description of
leucine-rich repeats (LRRs)
Tiandi Wei†1, Jing Gong*†1, Ferdinand Jamitzky1,2, Wolfgang M Heckl1,3,
Robert W Stark1 and Shaila C Rössle1
Address: 1Department of Earth and Environmental Sciences, Ludwig-Maximilians-Universität München, Theresienstr, 41, 80333 Munich,
Germany, 2Leibniz Supercomputing Centre, 85748 Garching, Germany and 3Deutsches Museum, 80538 Munich, Germany
E-mail: Tiandi Wei - tiandi@informatik.uni-muenchen.de; Jing Gong* - gongj@informatik.uni-muenchen.de;
Ferdinand Jamitzky - jamitzky@lrz.de; Wolfgang M Heckl - heckl@lmu.de; Robert W Stark - stark@lrz.uni-muenchen.de;
Shaila C Rössle - shaila.roessle@lrz.uni-muenchen.de;
*Corresponding author †Equal contributors
Published: 05 November 2008 Received: 5 June 2008
BMC Structural Biology 2008, 8:47 doi: 10.1186/1472-6807-8-47 Accepted: 5 November 2008
This article is available from: http://www.biomedcentral.com/1472-6807/8/47
© 2008 Wei et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0),
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Background: Leucine-rich repeats (LRRs) are present in more than 6000 proteins. They are found in
organisms ranging from viruses to eukaryotes and play an important role in protein-ligand interactions.
To date, more than one hundred crystal structures of LRR containing proteins have been determined.
This knowledge has increased our ability to use the crystal structures as templates to model LRR
proteins with unknown structures. Since the individual three-dimensional LRR structures are not
directly available from the established databases and since there are only a few detailed annotations for
them, a conformational LRR database useful for homology modeling of LRR proteins is desirable.
Description: We developed LRRML, a conformational database and an extensible markup
language (XML) description of LRRs. The release 0.2 contains 1261 individual LRR structures,
which were identified from 112 PDB structures and annotated manually. An XML structure was
defined to exchange and store the LRRs. LRRML provides a source for homology modeling and
structural analysis of LRR proteins. In order to demonstrate the capabilities of the database we
modeled the mouse Toll-like receptor 3 (TLR3) by multiple templates homology modeling and
compared the result with the crystal structure.
Conclusion: LRRML is an information source for investigators involved in both theoretical and
applied research on LRR proteins. It is available at http://zeus.krist.geo.uni-muenchen.de/~lrrml.
Background
Leucine-rich repeats (LRRs) are arrays of 20 to 30 amino
acid long protein segments that are unusually rich in the
hydrophobic amino acid leucine. They are present in
more than 6000 proteins in different organisms ranging
from viruses to eukaryotes [1]. The structure of the
LRRs and their arrangement in repetitive stretches
of variable length generate a versatile and highly
evolvable framework for the binding of manifold
proteins and non-protein ligands [2]. The crystal
structure of the ribonuclease inhibitor (RI) yielded the
first insight into the three-dimensional molecular basis
of LRRs [3]. It has a horseshoe shaped solenoid structure
with parallel b-sheet lining the inner circumference and
a-helices flanking its outer circumference. To date, there
are over one hundred crystal structures available.
All known LRR domains adopt an arc or horseshoe
shape [1].
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The LRR sequences can be divided into a highly conserved
segment (HCS) and a variable segment (VS). The highly
conserved segment consists of an 11 or 12 residue stretch
with the consensus sequence LxxLxLxxN(Cx)xL. Here, the
letter L stands for Leu, Ile, Val or Phe forming the
hydrophobic core, N stands for Asn, Thr, Ser or Cys, and x
is any amino acid. The variable segment is quite diverse in
length and consensus sequence, accordingly eight classes
of LRRs have been proposed [4, 5]: 'RI-like (RI)', 'Cysteine-
containing (CC)', 'Bacterial (S)', 'SDS22-like (SDS22)',
'Plant-specific (PS)', 'Typical (T)', 'Treponema pallidum
(Tp)' and 'CD42b-like (CD42b)'.
The discrepancy between the numbers of structure-known
LRR proteins and the structure-unknown ones triggered
studies focusing on the homologymodeling of LRR proteins
[6-8]. Homology modeling is a computational method,
which is widely used to identify structural features defining
molecular interactions [8-10]. The modeling results are an
important input for the design of biochemical experiments.
The first step of homology modeling is the selection of a
structure-known protein, which serves as a template for the
unknown target structure. In practice, however, it is difficult
to find a complete template which has a high enough
sequence identity to the target repetitive protein (single
template modeling), due to different repeat numbers and
varying arrangements. This limitation can be overcome by
combining multiple templates. First, the most similar
structure-known LRRs are found for each LRR in the target
sequence as a local template. Second, all local templates are
combined to generate the multiple sequence alignments for
the entire target sequence. Thus, it is possible to construct a
start model for further investigation, even if no adequate
single template is available. Such an approach, however,
requires a comprehensive database of LRRs to extract
adequate template candidates. So far, the individual three-
dimensional LRR structures are not directly available from
the established databases and there are only a few detailed
annotations for them. Additional information such as
sequence insertions and types is missing. In order to
consolidate this information and to provide a source for
homologymodeling and structural analysis of LRR proteins,
we developed LRRML, a database and an extensible markup
language (XML) description of LRR structures.
Construction and content
Structure-known LRR proteins were extracted from the
Protein Data Bank (PDB) [11] release Sept 10, 2008. In
order to ensure that all LRR proteins were found, we
combined three groups of search results. First, 'leucine rich
repeat', 'leucine rich repeats', 'leucine-rich repeat', 'leucine-
rich repeats', 'lrr' and 'lrrs' were used as keywords in the PDB
quick search; second, 'SCOP classification -> Alpha and beta
proteins (a/b) -> Leucine-rich repeat' was used as options in
PDB advanced search; third, 'CATH classification -> Alpha
Beta -> Alpha-Beta Horseshoe -> Leucine-rich repeat' was
used as options in PDB advanced search. Because of the
irregularity (mutations and insertions in the sequence) of
LRRs reliable identifications of LRRs contained in the LRR
proteins could only be performed manually. We inspected
the three-dimensional structures of the LRR proteins using
molecular viewers and identified each LRR based on two
criteria:
1. A LRR begins at the beginning of the highly conserved
segment (HCS) and ends at the end of the variable segment
(VS) (just before the HCS of the next LRR).
2. TheHCS of a LRRmust pose a typical conformation, i.e. a
short b-sheet begins at about position 3 and a hydrophobic
core is formed by the four L residues at position 1, 4, 6,
and 11.
The LRRs were then manually classified according to the
consensus sequences [4, 5]. In addition to the eight
canonical LRR classes listed in the background section we
included a new class 'other' for the N-/C-terminal LRRs and
some hyper-irregular LRRs. Table 1 illustrates the consensus
sequences of the eight canonical LRR classes.
During the LRR identification and classification all sequence
insertions longer than 3 residueswere annotated. About one
tenth of entries have insertions longer than 3 residues while
few entries have deletions, which suggests that the evolution
of LRRs may prefer insertion to deletion.
The LRRML release 0.2 contains 1261 LRR entries from
112 PDB structures. Among them 548 LRRs are distinct on
sequence level, indicating that different molecules can
share identical LRRs. By superimposition, we found that
they also have highly similar structures. This fact enhances
the confidence in modeling LRR proteins using multiple
LRR templates. A histogram of entry length distribution
Table 1: Consensus sequences of the eight canonical LRR classes
[4, 5].
Classes HCS VS
Typical type (T) LxxLxLxxNxL xxLxxxxLxxLxx
Bacterial type (S) LxxLxLxxNxL xxLPx(x)LPxx
Ribonuclease inhibitor-like
type (RI)
LxxLxLxxNxL xxxxxxxLxxxLxxxxx
SDS22-like type (SDS22) LxxLxLxxNxL xxLxxLxxLxx
Cysteine-containing type (CC) LxxLxLxxCxxL TDxxxxxLxxxCxx
Plant-specific type (PS) LxxLxLxxNxL xxxLPxxLGxLxx
Treponema pallidum type (Tp) LxxLxLPxxLxx LxxxAFxxCxx
CD42b type (CD42b) LxxLxLxxNxL xxLPxxxxxxxxx
L: Leu, Ile, Val, Phe; N: Asn, Thr, Ser, Cys; P: Pro; T: Thr; D: Asp; G: Gly;
A: Ala; F: Phe; C: Cys; x: random residues.
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(Figure 1) shows that the LRR lengths are concentrated in
the interval from 20 to 29, which covers the characteristic
lengths of consensus sequences of the eight canonical
LRR classes. Some entries have a sequence longer than 30,
because they contain large insertions. Table 2 presents the
distribution of LRR entries and PDB entries over the nine
classes respectively. The classification results are consis-
tent with a previous report which showed that LRRs from
different classes never occur simultaneously in the same
protein and have most probably evolved independently
[4]. Exceptions to this rule are the T and S types which
often exist in the same protein forming the super motif
'STT' [12]. It is assumed that both evolved from a
common precursor [1].
Currently, there are several protein databases containing
information on LRRs, such as Pfam [13], InterPro [14],
SMART [15] and Swiss-Prot [16]. These databases predict
the LRR numbers and boundaries for their LRR protein
entries by various computational methods, no matter
whether the entries have known three-dimensional
structures or not, thereby 'false negative' occurs frequently.
Table 3 lists the numbers of structure-known LRR proteins
and their LRRs covered by these databases. As more
detailed examples, LRR numbers of LRR proteins from
different classes reported by the established databases are
compared in Table 4. Additionally, the individual three-
dimensional LRR structures are not directly available from
these databases. In order to combine the information
required for homology modeling and structural analysis,
LRRML is provided with three prominent characteristics:
1. Each database entry is an individual three-dimen-
sional LRR structure, which was identified with high
accuracy.
2. Extensive annotations, such as systematic classifica-
tion, secondary structures, HCS/VS partitions and
sequence insertion, are provided.
3. LRRs were extracted from all structure-known LRR
protein structures from PDB.
Figure 1
LRR entry length distribution. The most common entry lengths vary from 20 to 29. Each LRR class has a characteristic
length distribution. Some entries have a sequence length larger than 29 due to insertions.
Table 2: Numbers of LRR and PDB entries (release 0.2) in the nine LRR classes.
T S RI SDS22 CC PS Tp CD42b Other Total
LRR structures 272 72 151 372 184 10 0 0 200 1261
LRR entries 169 40 59 114 28 10 0 0 128 548
PDB entries 32 13 50 16 1 0 0 - 112
Up to present, no crystal structures for LRR proteins of Tp/CD42b types are determined. Different from other LRR types, the S type and T type LRRs
evolved from a common precursor [1] and thus can exist in the same PDB entry simultaneously.
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XML description
The extensible markup language (XML) was standardized
in the 90s and is well established as a format for
hierarchical data. It can be queried and parsed more
easily by application programs. Therefore, more and
more biological databases use the XML as data saving
format and database management system (DBMS)
[17-19]. LRRML was designed by using eXist [20], an
XML DBMS, and using XPath/XQuery [21] for processing
queries and web forms. We developed a LRR markup
language (LRRML) for exchanging and storing LRR
structures. It consists of four blocks of information:
1. The sequence information (XML tag <l:Sequence>):
amino acid sequence and sequence length.
2. The classification information (XML tag <l:Type>):
class name and consensus sequences.
3. The sequence partitions (XML tag <l:Regions>): amino
acid sequence, position, length and insertion of HCS
and VS.
4. The corresponding PDB sources (XML tag
<l:Sources>): ID, chain, LRR number and classification
of the source PDB entries; serial number, position,
DSSP [22] secondary structure and three-dimensional
coordinates of the current LRR in these source PDB
entries.
An example describing the LRR3 from PDB entry 2O6S is
shown in Figure 2. The document type definition (DTD)
file of LRRML is provided asAdditional file 1.
Utility
Web application
The entire database can be browsed by LRR IDs or by
PDB IDs. When browsing, the entries appear in a
summary table containing at first ID, type and sequence.
Clicking on an ID opens an XML Stylesheet (XSLT) [21]
converted HTML web page that presents the entry in
detail. The original XML file and the coordinates file in
PDB format can also be downloaded. The XSLT file used
is provided as Additional file 2. Aside from the textual
view, a LRR structure can be visualized by the online
molecular viewer Jmol [23]. After loading, users can
change the view settings flexibly by themselves. LRRML
is provided with various search functions, including PDB
ID search which returns all LRRs contained in this PDB
structure, class search which returns all LRRs of this class,
or length search which returns all LRRs with this
sequence length. To simplify the homology modeling,
the similarity search was implemented. It returns the
structures of the most similar LRRs for a structure-
unknown LRR. The target LRR sequence can be searched
against the entire database, a certain LRR class or LRRs
with a certain length. At first, a global pair wise sequence
alignment with sequence identity will be generated for
the target LRR and each of the LRRs in the user selected
set. Then, the most similar LRRs will be returned as
template candidates, ranked by sequence identity.
The DBMS provides a REST-style application programming
interface (API) through HTTP, which supports GET and
POST requests. A unique resource identifier (URI) 'http://
zeus.krist.geo.uni-muenchen.de:8081/exist/rest/...' is trea-
ted by the server as path to a database collection. Also,
request parameters can help select any required elements.
Table 3: Coverage of LRR proteins with PDB structures of
different databases.
Databases Numbers of LRR proteins
with PDB structures
Numbers of identified
LRRs
InterPro 62 325
Swiss-Prot 98 997
Pfam 48 173
SMART 84 547
LRRML 112 1261
The results were obtained on October 13, 2008.
Table 4: Comparison of LRR numbers of different LRR proteins by different databases.
PDB codes Protein functions LRR classes InterPro Swiss-Prot Pfam SMART LRRML
2A0Z Immune System T 18 22 7 20 25
1G9U Toxin S 7 15 1 0 15
2FT3 Structural Protein T+S 8 8 5 9 12
1K5D Signaling Protein RI 2 8 0 0 11
1GWB Glycoprotein SDS22 6 6 4 7 8
2P1M Signaling Protein CC 2 16 0 6 18
1OGQ Inhibitor PS 7 10 2 0 10
All listed LRR numbers include N-/C-terminal LRRs. To date, only the LRRML database contains the complete set of LRRs of all LRR proteins with
known structures. The results were obtained on October 13, 2008.
BMC Structural Biology 2008, 8:47 http://www.biomedcentral.com/1472-6807/8/47
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Figure 2
The LRRML description of a LRR structure. This entry is a 24 residue long typical LRR. The first 11 residues compose
its HCS and the last 13 residues compose its VS (no insertions). It is contained only in the chain A of PDB structure
2O6S (a protein involved in the immune system). It is the third one of the 7 LRRs of 2O6S, from position 77 to 100.
Its secondary structure was extracted from DSSP and its three-dimensional coordinate file is available though the hyperlink on
the corresponding web page.
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Figure 4
Ramachandran plot of model and crystal structure of mouse TLR3 ectodomain. (A) Predicted model of mouse
TLR3 ectodomain. (B) Crystal structure of mouse TLR3 ectodomain. The different colored areas indicate 'disallowed' (white),
'generously allowed' (light yellow), 'additional allowed' (yellow), and 'most favored' (red) regions.
Figure 3
Comparison of model and crystal structure of mouse TLR3 ectodomain at the two ligand interaction regions. Blue:
structure obtained by homology modeling; orange: crystal structure (PDB code: 3CIG). (A) The modeled backbone structure of
mouse TLR3 ectodomain. (B) Model and crystal structure superimposed at the N-terminal interaction region. The root mean square
deviation is 1.96 Å. (C) Superimposition at the C-terminal interaction region. The root mean square deviation is 1.9 Å. The reported
interacting residues are presented with side chain and labelled with residue name and position in (B) and (C).
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For example, '_query' executes a specified XPath/XQuery;
the URL "http://zeus.krist.geo.uni-muenchen.de:8081/
exist/rest/db/lrrml?_query=//LRR [.//TAbbr='S']" returns
all the S type LRRs.
Application in homology modeling
LRRML was designed as a tool for template selection in
homology modeling of LRR proteins. Traditionally, the
template used in homology modeling is one or more full
length protein structures obtained via similarity search.
Nevertheless, due to the different repeat numbers and
arrangements of LRRs, the sequence identity between the
target and the full length template is usually not high
enough for homology modeling. With LRRML the most
similar structure-known LRR can be found for each LRR
in the target sequence as a local template. The combina-
tion of all local templates through multiple alignments
helps to achieve a high sequence identity to the target.
As test case we modeled the structure of mouse Toll-like
receptor 3 (TLR3) ectodomain. We assumed that the
structure of mouse TLR3 ectodomain were unknown and
excluded the LRRs of mouse/human TLR3 ectodomain
from LRRML. Through similarity search the optimal
template for each of the 25 LRRs in mouse TLR3 was
found. The sequence identity between each LRR pair
(target/template LRR) is listed in Table 5. Then a 26-line
multiple alignment was generated by the 25 template
sequences and the target sequence as the input of
MODELLER 9v3 [24]. The resulting three-dimensional
model (Figure 3A) was evaluated by PROCHECK [25],
with 98.2% residues falling into the most favored or
allowed regions of the main chain torsion angles
distribution, whereas the result of the TLR3 crystal
structure (PDB code: 3CIG) was 98.6% (Figure 4). The
mouse TLR3 has been shown to bind double-stranded
RNA ligand with both N-terminal and C-terminal sites
on the lateral side of the convex surface of TLR3 [26]. The
N-terminal interaction site is composed of LRRNT and
LRR1-3, and the C-terminal site is composed of LRR19-
21. We superimposed the resulting model onto the
crystal structure of mouse TLR3 ectodomain at the two
interaction sites by using SuperPose v1.0 [27]. The root
mean square deviations of the structures are 1.96 Å and
1.9 Å respectively (Figure 3B/C), indicating that the
predicted model sufficiently well matched the crystal
structure and was useful for prediction of ligand
interaction sites. These results demonstrate that homol-
ogy modeling using combined multiple templates
obtained from LRRML can create valuable information
to trigger further biochemical research. Interpretation of
structural details, however, should be done exercising
due care.
Conclusion
A specialised conformational leucine-rich repeats data-
base called LRRML has been developed. It is supported
by an XML database management system and can be
searched and browsed with either an easy-to-use web
interface or REST like interface. The interface is suitable
for most graphical web browsers and has been tested on
the Windows, Mac and Linux operating systems. LRRML
contains individual three-dimensional LRR structures
with manual structural annotations. It presents useful
sources for homology modeling and structural analysis
of LRR proteins. Since the amount of structure-deter-
mined LRR proteins constantly increases, we plan to
update LRRML every 2 to 3 months.
Availability and requirements
This database is freely available at http://zeus.krist.geo.
uni-muenchen.de/~lrrml.
Authors' contributions
TW and JG drafted the manuscript, extracted the data,
compiled the database, wrote the code for the web
interface and performed the statistical analysis. FJ, WMH,
RWS and SCR conceived of the study, built the database
server, participated in the database design and coordina-
tion and helped to draft the manuscript. TW and JG
should be regarded as joint first authors. All authors read
and approved the final manuscript.
Additional material
Additional file 1
The document type definition (DTD) file of LRRML.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1472-
6807-8-47-S1.dtd]
Additional file 2
The XML Stylesheet (XSLT) of LRRML.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1472-
6807-8-47-S2.xsl]
Acknowledgements
This work was supported by Graduiertenkolleg 1202 of the Deutsche
Forschungsgemeinschaft.
References
1. Matsushima N, Tanaka T, Enkhbayar P, Mikami T, Taga M, Yamada K
and Kuroki Y: Comparative sequence analysis of leucine-rich
repeats (LRRs) within vertebrate toll-like receptors. BMC
Genomics 2007, 8:124–143.
2. Dolan J, Walshe K, Alsbury S, Hokamp K, O'Keeffe S, Okafuji T,
Miller SFC, Guy Tear G and Mitchell KJ: The extracellular
Leucine-Rich Repeat superfamily; a comparative survey and
analysis of evolutionary relationships and expression pat-
terns. BMC Genomics 2007, 8:320–343.
BMC Structural Biology 2008, 8:47 http://www.biomedcentral.com/1472-6807/8/47
Page 8 of 9
(page number not for citation purposes)
3. Kobe B and Deisenhofer J: Crystal structure of porcine
ribonuclease inhibitor, a protein with leucine-rich repeats.
Nature 1993, 366:751–756.
4. Kobe B and Kajava AV: The leucine-rich repeat as a protein
recognition motif. Curr Opin Struct Biol 2001, 11:725–732.
5. Bell JK, Mullen GE, Leifer CA, Mazzoni A, Davies DR and Segal DM:
Leucine-rich repeats and pathogen recognition in Toll-like
receptors. Trends Immunol 2003, 24:528–533.
6. Kajava AV: Structural Diversity of Leucine-rich Repeat
Proteins. J Mol Biol 1998, 277:519–527.
7. Stumpp MT, Forrer P, Binz HK and Plckthun A: Designing Repeat
Proteins: Modular Leucine-richRepeat Protein Libraries
Based on the Mammalian Ribonuclease Inhibitor Family. J
Mol Biol 2003, 332:471–487.
8. Kubarenko A, Frank M and Weber AN: Structure-function
relationships of Toll-like receptor domains through homol-
ogy modelling and molecular dynamics. Biochem Soc Trans
2007, 35:1515–1518.
9. Rössle SC, Bisch PM, Lone YC, Abastado JP, Kourilsky P and Bellio M:
Mutational analysis and molecular modeling of the binding
of Staphylococcus aureus enterotoxin C2 to a murine T cell
receptor Vbeta10 chain. Eur J Immunol 2002, 32:2172–2178.
10. Hazai E and Bikádi Z: Homology modeling of breast cancer
resistance protein (ABCG2). J Struct Biol 2008, 162:63–74.
11. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H,
Shindyalov IN and Bourne PE: The Protein Data Bank. Nucleic
Acids Res 2000, 28:235–242.
12. Matsushima N, Kamiya M, Suzuki N and Tanaka T: Super-Motifs of
Leucine-Rich Repeats (LRRs) Proteins. Genome Inform 2000,
11:343–345.
13. Finn RD, Tate J, Mistry J, Coggill PC, Sammut JS, Hotz HR, Ceric G,
Forslund K, Eddy SR, Sonnhammer EL and Bateman A: The Pfam
protein families database. Nucleic Acids Res 2008, 36:D281–288.
14. Mulder NJ and Apweiler R: InterPro and InterProScan: tools for
protein sequence classification and comparison. Methods Mol
Biol 2007, 396:59–70.
15. Schultz J, Copley RR, Doerks T, Ponting CP and Bork P: SMART: a
web-based tool for the study of genetically mobile domains.
Nucleic Acids Res 2000, 28:231–234.
16. Wu CH, Apweiler R, Bairoch A, Natale DA, Barker WC,
Boeckmann B, Ferro S, Gasteiger E, Huang H, Lopez R,
Magrane M, Martin MJ, Mazumder R, O'Donovan C, Redaschi N
and Suzek B: The Universal Protein Resource (UniProt): an
expanding universe of protein information. Nucleic Acids Res
2006, 34:D187–191.
17. Heida N, Hasegawa Y, Mochizuki Y, Hirosawa K, Konagaya A and
Toyoda T: TraitMap: an XML-based genetic-map database
combining multigenic loci and biomolecular networks.
Bioinformatics 2004, 20 Suppl 1:i152–i160.
18. Kunz H, Derz C, Tolxdorff T and Bernarding J: XML knowledge
database of MRI-derived eye models. Comput Methods Programs
Biomed 2004, 73:203–208.
19. Jiang K and Nash C: Application of XML database technology
to biological pathway datasets. Conf Proc IEEE Eng Med Biol Soc
2006, 1:4217–4220.
20. eXist-db: an open source database management system. http://
exist-db.org.
21. The World Wide Web Consortium. http://www.w3.org.
22. Kabsch W and Sander C: Dictionary of protein secondary
structure: pattern recognition of hydrogen-bonded and
geometrical features. Biopolymers 1983, 22:2577–2637.
23. Jmol: an open-source Java viewer for chemical structures in
3D. http://www.jmol.org.
24. Fiser A, Do RK and Sali A: Modeling of loops in protein
structures. Protein Sci 2000, 9:1753–1773.
25. Laskowski RA, MacArthur MW, Moss DS and Thornton JM:
PROCHECK: a program to check the stereochemical
quality of protein structures. J Appl Cryst 1993, 26:283–291.
26. Liu L, Botos I, Wang Y, Leonard JN, Shiloach J, Segal DM and
Davies DR: Structral basis of Toll-like receptor 3 signaling
with double-stranded RNA. Science 2008, 320:379–381.
27. Maiti R, Van Domselaar GH, Zhang H and Wishart DS: SuperPose:
a simple server for sophisticated structural superposition.
Nucleic Acids Res 2004, 32:W590–594.
Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Structural Biology 2008, 8:47 http://www.biomedcentral.com/1472-6807/8/47
Page 9 of 9
(page number not for citation purposes)
Appendix 
55 
Paper 2 
 
 
 
 
 
 
 
 
 
 
TollML: a database of toll-like receptor structural motifs 
J. Mol. Model., 2010, 16:1283-1289 
Jing Gong, Tiandi Wei, Ferdinand Jamitzky, Wolfgang M. Heckl, Shaila C. Rössle and 
Robert W. Stark 
 
ORIGINAL PAPER
TollML: a database of toll-like receptor structural motifs
Jing Gong & Tiandi Wei & Ning Zhang &
Ferdinand Jamitzky & Wolfgang M. Heckl &
Shaila C. Rössle & Robert W. Stark
Received: 18 October 2009 /Accepted: 19 November 2009 /Published online: 19 January 2010
# Springer-Verlag 2010
Abstract Toll-like receptors (TLRs) play a key role in the
innate immune system. TLRs recognize pathogen-
associated molecular patterns and initiate an intracellular
kinase cascade to induce an immediate defensive response.
During recent years TLRs have become the focus of
tremendous research interest. A central repository for the
growing amount of relevant TLR sequence information has
been created. Nevertheless, structural motifs of most
sequenced TLR proteins, such as leucine-rich repeats
(LRRs), are poorly annotated in the established databases.
A database that organizes the structural motifs of TLRs
could be useful for developing pattern recognition pro-
grams, structural modeling and understanding functional
mechanisms of TLRs. We describe TollML, a database that
integrates all of the TLR sequencing data from the NCBI
protein database. Entries were first divided into TLR
families (TLR1-23) and then semi-automatically subdivided
into three levels of structural motif categories: (1) signal
peptide (SP), ectodomain (ECD), transmembrane domain
(TD) and Toll/IL-1 receptor (TIR) domain of each TLR; (2)
LRRs of each ECD; (3) highly conserved segment (HCS),
variable segment (VS) and insertions of each LRR. These
categories can be searched quickly using an easy-to-use
web interface and dynamically displayed by graphics.
Additionally, all entries have hyperlinks to various sources
including NCBI, Swiss-Prot, PDB, LRRML and PubMed in
order to provide broad external information for users. The
TollML database is available at http://tollml.lrz.de.
Keywords TollML . Toll-like receptor .
Leucine-rich repeats . XML database . Homology modeling
Introduction
Since the Drosophila Toll gene was discovered in the mid-
1980s [1], genome projects have led to the identification of
13 receptors in mammalian and more than 20 receptors in
non-mammalian genomes that are homologs of Drosophila
Toll. These receptors have been termed collectively Toll-
like receptors (TLRs). TLRs play a key role in innate
immunity. They recognize invading microbial pathogens
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and rapidly initiate intracellular signal transduction path-
ways to trigger expression of genes, whose products can
control innate immune responses [2]. All TLRs have a
common domain organization, with an extracellular ecto-
domain (ECD), a helical transmembrane domain (TD), and
an intracellular Toll/IL-1 receptor homology (TIR) domain
[3]. The ectodomain is a horseshoe-shaped solenoid
structure and is directly involved in the recognition of a
variety of pathogens including lipopolysaccharide, lipopep-
tide, cytosine-phosphate-guanine (CpG) DNA, flagellin,
imidazoquinoline and dsRNA [4]. The transmembrane
domain determines the subcellular localization of TLRs
[5]. The TIR domain is conserved across all TLRs and IL-1
receptors, and is also shared by downstream signaling
adaptor molecules. Upon receptor ligation, a TIR signaling
complex is formed between the receptor and the adaptor
TIR domains [6].
The TLR ectodomain contains varying numbers of
leucine-rich repeat (LRR) motifs, which are arrays of 20
to 30 amino acid-long protein sequences that are enriched
with the hydrophobic amino acid leucine. All LRR
sequences can be divided into a highly conserved segment
(HCS) and a variable segment (VS). The HCS consists of
an 11 or 12 residue stretch with the consensus sequence
LxxLxLxxN(Cx)xL. In this notation, the letter L represents
the amino acids leucine, isoleucine, valine or phenylala-
nine, which form a hydrophobic core, N represents
asparagine, threonine, serine or cysteine, and x is any
amino acid. The variable segment can vary in both length
and consensus sequence. Accordingly, several types of
LRRs have been proposed [7, 8]. Of these, typical (T) type
(xxLxxxxLxxLxx) and bacterial (S) type (xxLPx(x)LPxx)
LRRs have been observed in TLRs [9]. All LRRs in TLRs
are capped by N- and C-terminal LRRs that are usually
irregular and do not match any type of LRR consensus
sequences.
The atomic-detail crystal structure of the human TLR1
and TLR2 TIR domain was published in 2000 and gave the
first insight into the molecular basis of TIR signaling [10].
The crystal structures of the ectodomains of human TLR1-4
and mouse TLR2-4 have also been resolved [11–16]. These
structures demonstrate how the LRR-based platform is
adapted to ligand recognition. Nevertheless, more than
2,000 TLR proteins have been sequenced by high-
throughput genome sequencing projects. It is clear that the
discrepancy between the rate at which novel protein
sequences are discovered and the rate at which detailed
structural information on proteins can be obtained from
X-ray diffraction or nuclear magnetic resonance spectros-
copy will persist for the foreseeable future. Thus, a
comparative analysis at the sequence level is a useful
approach to identify and characterize structural motifs of
TLRs [9, 17] and to gain insight into how receptors and
ligands interact. Due to the variability of LRR motifs in
TLRs, however, the indicated repeat number and positions
(beginning/end of a repeating unit) for individual TLRs are
quite different or missing in established databases. Currently,
there is no collection of structural information for features that
are contained within LRRs, such as HCS, VS and sequence
insertions.
In this paper, we describe a database of TLR structural
motifs called TollML. The current release (3.1) includes all
known TLR sequences from the NCBI protein database
[18]. Structural motifs were identified and annotated by a
semi-automatic procedure that included comparison of
sequences with the sequences of TLRs that have a known
structure, consensus sequence matching, secondary struc-
ture prediction and multiple sequence alignments. Three
levels of motif elements were generated: (1) signal peptide
(SP), ectodomain (ECD), transmembrane domain (TD) and
TIR domain of each TLR; (2) LRRs of each ECD; and (3)
HCS, VS and insertions of each LRR. Some program
application examples are presented in the last section of the
paper.
Construction and content
Data extraction and pre-processing
Initial TLR sequences were extracted from the NCBI
protein database. Two groups of search results were
obtained using the search keys toll* and tlr*, where the
asterisk stands for any suffix, to ensure that all TLRs were
included. A manual data pre-processing step was performed
before the motif identification of these sequences. We
inspected the NCBI annotations of entries one-by-one to
exclude TLR related molecules such as adaptors, protein
kinases and transcription factors. After we performed these
filtering steps, 2,572 TLR entries remained (NCBI release:
1 September 2009). We then categorized the TLRs into
different families (TLR1-23) based on their original
annotations. In the instances in which entries were not
associated with explicit comments, we compared the
sequences with well classified TLR sequences using
sequence BLAST.
Motif identification
Three levels of structural motif categories were generated
adapting to the structural organization of TLRs. First,
each full length TLR sequence was divided into ECD,
TD and TIR domain. If a sequence started with a SP,
which directs the subcellular transport of a protein, the
presence of a SP was also indicated. Second, the ECD of
each TLR was partitioned into individual LRRs including
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canonical LRRs and N/C-terminal LRRs. Third, each
LRR was further divided into a highly conserved
segment (HCS) and a variable segment (VS). Insertions
within the VS that are longer than three residues were
identified and annotated.
The procedure mentioned above was semi-automated.
We first sorted the TLR sequences from each family into
subgroups, so that an arbitrary pair of sequences from the
same subgroup had a local sequence similarity greater than
90%. Then, the three-level structural motifs were identified
manually for a selected template sequence from each
subgroup. This selected template sequence was a full length
sequence that had the most detailed original annotations so
that the most accurate motif identifications could be
performed. Finally, the other members of the subgroup
received their motif partition assignments through multiple
alignments with the template. More than 300 subgroups
were generated for the 2,572 entries. Thus more than 300
templates were processed manually.
The manual motif identification of a template sequence
combined three approaches: consensus sequence matching,
secondary structure prediction and reference to original
annotations or literatures. The four domains on the first
level of the motif categorization (SP, ECD, TD and TIR)
have characteristic sequence features, so are usually
accurately divided in the original annotation of a selected
template. If a template did not have clear annotations, then
its sequence was compared to similar sequences with
known domains to determine its domain partitions. For
the second level of motif categorization, if a selected
template was associated with a reliable reference such as a
known crystal structure, its LRR partition was then
assigned accordingly. Otherwise, we matched the LRR
consensus sequence LxxLxLxxN(Cx)xL to the template
sequence amino-acid-by-amino-acid and detected LRR
motifs manually. In addition, protein secondary structure
predictions (PredictProtein [19], NNPREDICT [20],
PSIPRED [21] and SSPro [22]) helped to improve the
accuracy of LRR detection because all known crystal
structures of TLRs show that there is always a short
β-strand (3–5 residues) beginning at approximately the
third position of an LRR motif [11–15]. After an LRR was
identified, consensus sequence matching was used to
identify its HCS and VS motifs, as well as any insertions
that were longer than three residues for the third level.
Simultaneously, each LRR motif was classified into
different types (detailed in Database content) according to
the VS consensus sequences.
Database content
The TollML release 3.1 contains 2,572 TLR entries divided
into 23 families (entry distribution shown in Table 1).
Among these, 2,350 of the sequences contain an ectodo-
main and thus received motif annotations that correspond to
the second and third levels of motif categorization. The
other entries contain only a TIR domain with or without a
transmembrane domain. A total of 46,720 LRR motifs were
recognized from the ectodomain containing TLRs. These
LRR motifs were classified into five types: typical (T),
bacterial (S), N-terminal (NT), C-terminal (CT) and
irregular (I). A histogram of LRR length statistics (Fig. 1)
shows the characteristic length distribution of each LRR
type. The standard length of the T type LRR is 24 amino
acids. A large number of T type LRRs have insertions
and only some have deletions. These statistics suggest
that the evolution of T type LRRs may prefer insertion
over deletion. By contrast, the S type LRRs are more
highly conserved. Their lengths are concentrated on 20
and 21. N-terminal LRRs vary in length and do not form
a peak value in length distribution. Most C-terminal
LRRs contain four cysteines that are distantly separated
at the sequence level and form disulfide bonds with each
other. C-terminal LRRs are generally greater than 35
amino acids in length.
Annotations for each TLR entry include:
(1) Data management information: TollML ID and access/
modification date;
(2) Primary information extracted from the NCBI and
related literature: FASTA sequence, biological defini-
tion, cell information, glycosylation sites and ligands;
(3) Protein family classification;
(4) Database cross links: NCBI, Swiss-Prot [23], PDB
[24], LRRML [8] and PubMed [25];
(5) Three-level motif information.
Database comparison
Currently, several protein databases, such as Pfam [26],
InterPro [27], SMART [28] and Swiss-Prot, contain
information about TLRs. These databases predict the LRR
numbers and positions for their TLR entries by various
computational methods, thus resulting in a high frequency
of false negative predictions. Table 2 illustrates the LRR
numbers for human TLR1–10 as reported by these data-
bases. The manual motif identification procedure discussed
here provides TollML with the most complete database of
LRR motifs. Although Swiss-Prot presents more accurate
results than the other three databases that we investigated
(Table 2), TollML has four prominent characteristics that
distinguish it from Swiss-Prot:
(1) Comprehensive entry coverage. TollML covers 2,572
TLR sequences from 121 species and all sequences are
provided with detailed motif annotations. Swiss-Prot
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covers 636 TLR sequences from 17 species and only
59 sequences have LRR annotations (results obtained
on 24 February 2009).
(2) Structural motifs within an LRR. TollML annotates
the HCS, VS and insertion for each LRR. This
information is not present in any other published
protein databases.
(3) Uniform LRR definition. The beginning/end positions
of LRRs have been defined inconsistently across
researchers due to the periodicity of LRR motifs. This
variation leads to non-uniform LRR assignments in
Swiss-Prot. All LRR motifs in TollML start at the
beginning of the HCS and end at the end of the VS,
just before the HCS of the next LRR.
(4) Accessibility of motif sequences. The amino acid
sequence of any available motif is directly accessible
in TollML, whereas only the full length sequence is
directly accessible in Swiss-Prot.
Utility
Web application
The extensible markup language (XML) was standardized
in the 1990s and is well established as a format for
hierarchical biological data. TollML was designed by using
eXist [29], an XML database management system, and
XPath/XQuery [30] for processing queries and web forms.
The document type definition (DTD) file of TollML is
provided in the electronic supplementary material (ESM;
Supplementary file 1).
The entire database is browsable. When browsing,
entries appear in a summary table containing ID, definition,
family, species and links of motif partitions. Clicking on an
entry opens an XML Stylesheet (XSLT) [30] converted
HTML web page that describes the entry in detail. The
original XML file can also be downloaded. The XSLT file
that the program uses is provided in the ESM (Supplemen-
tary file 2). Aside from the textual view, the structural
motifs of TLRs can be exhibited by three-level dynamic
graphics. Figure 2 demonstrates the motif assignment for an
example entry (ID: TLR_561).
On the advanced search page of TollML, users can
search entries flexibly by inputting keywords, specifying
search fields, and defining annotation contents of the
output. After selected entries are returned, a search within
result button allows for further term filtering. The resulting
entries, or an arbitrarily selected subset thereof, can be sent
to generate multiple sequence alignments supplied by the
T-Coffee package [31]. In addition, a Wu-BLAST search
tool [32] is available. A query sequence can be BLASTed
against the entire database, against a certain TLR family, or
against a collection of sequences marked by a user-defined
label (available for registered users).
Fig. 1 Leucine-rich repeat (LRR) length distribution
Table 1 Entry distribution over Toll-like receptor (TLR) families for mammalian/non-mammalian groups
TLR 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 18 19 20–23 Total
Mammalian 85 146 108 443 132 106 109 101 124 72 10 11 9 0 0 0 0 0 0 1,456
Non-mammalian 356 276 84 77 58 3 102 11 30 0 0 1 4 6 42 2 7 5 52 1,116
Total 441 422 192 520 190 109 211 112 154 72 10 12 13 6 42 2 7 5 52 2,572
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Application in LRR prediction
The automatic identification of motifs in a protein sequence
is essentially a statistical pattern recognition problem.
Therefore, the performance of a prediction method is thus
strongly dependent on the quality and scale of the training
data set. A recent program, LRRscan [17], demonstrated the
feasibility of a statistics-based consensus matching algo-
rithm applied to LRR detection. TollML supplies a large
and reliable source to train LRR prediction methods of
different algorithms. As an example, we developed a 20×
12 position-specific weight matrix of LRR motifs based on
the LRR partitions from TollML (matrix available on the
TollML webpage). A matrix element denotes the frequency
probability of a certain amino acid occurring at a certain
position in the LRR HCS. We have already obtained
confident results through this sort of matrix scan with an
appropriate cut-off score. A five-fold cross validation
against all TollML entries indicates that the sensitivity and
specificity are both greater than 93%. This program was
implemented on the TollML webpage and has been named
LRRFinder. This method can be extended to predict LRR
motifs in other LRR containing proteins besides TLRs,
since all LRR types possess the same HCS pattern.
TLR1 TLR2 TLR3 TLR4 TLR5 TLR6 TLR7 TLR8 TLR9 TLR10
InterPro 4 4 8 7 7 3 9 10 6 4
Pfam 4 4 7 7 8 3 8 9 6 4
SMART 6 9 19 12 10 7 16 17 19 7
Swiss-Prot 8 14 22 21 15 13 27 24 26 15
TollML 21 21 25 23 23 21 28 28 28 21
Table 2 Comparison of leucine-
rich repeat (LRR) numbers of
human TLR1–10 in different
databases (results obtained on
24 February 2009)
Fig. 2 Online graphic display
of three-level structural motifs
of a database entry
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Application in homology modeling
Homology modeling is currently the most accurate compu-
tational method to predict protein structure. This system
constructs a structural model for a target protein sequence
from a template structure of a homologous protein. For this
method to work, the target and template structures must
have a sequence identity over 30%. The known crystal
structures of human TLR1–4 and mouse TLR2–4 ectodo-
mains supply valuable templates for the homology modeling
of other TLR ectodomains. However, given the variability in
repeat numbers and type arrangements of LRRs contained
within TLRs, a full length template with a sufficient sequence
identity is typically not available. This limitation can be
overcome by assembling multiple LRR templates. First, all
LRRs in the target sequence are identified. Then, the most
similar structure-known LRR based on sequence is found for
each LRR in the target sequence as a local template. Finally,
all local templates are assembled to generate a multiple
sequence alignment for the complete target sequence. TollML
enables the direct accessibility of accurate LRR sequence
partitions for the first step. The LRRML database [8] can
further provide suitable LRR structural templates. This LRR
template assembling approach was proven to be both feasible
and significant by recent structure modeling research into
human TLR7–9 [33].
Conclusions
We have developed a specialized database of TLR
structural motifs called TollML. It is supported by an
XML database management system and can be searched
and browsed with an easy-to-use web interface. This
interface is suitable for use with most graphical web
browsers and has been tested on the Windows, Mac and
Linux operating systems. TollML includes all TLR sequences
that are published in the NCBI protein database and semi-
automatically creates three levels of motif annotations. This
database can help to develop motif prediction programs, to
model three-dimensional structures of TLRs and to design
new mutation experiments to better understand receptor–
ligand or receptor–receptor interactions. We plan to update
TollML every 2–3 months since the number of sequenced
TLR proteins increases constantly.
Availability and requirements
This database is freely available at http://tollml.lrz.de. Any
internet user can search and download data from the
database, but only registered users can define and save
labels for arbitrary entries.
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Abstract 
So far, 13 groups of mammalian Toll-like receptors (TLRs) have been identified. Most TLRs have been 
shown to recognize pathogen-associated molecular patterns from a wide range of invading agents and 
initiate both innate and adaptive immune responses. The TLR ectodomains are composed of varying 
numbers and types of leucine-rich repeats (LRRs). As the crystal structures are currently missing for most 
TLR ligand-binding ectodomains, homology modeling enables first predictions of their three-dimensional 
structures on the basis of the determined crystal structures of TLR ectodomains. However, the quality of 
the predicted models that are generated from full-length templates can be limited due to low sequence 
identity between the target and templates. To obtain better templates for modeling, we have developed an 
LRR template assembly approach. Individual LRR templates that are locally optimal for the target 
sequence are assembled into multiple templates. This method was validated through the comparison of a 
predicted model with the crystal structure of mouse TLR3. With this method we also constructed 
ectodomain models of human TLR5, TLR6, TLR7, TLR8, TLR9, and TLR10 and mouse TLR11, TLR12, 
and TLR13 that can be used as first passes for a computational simulation of ligand docking or to design 
mutation experiments. This template assembly approach can be extended to other repetitive proteins. 
Key words 
Toll-like receptor; leucine-rich repeats; homology modeling; template assembly; 
TollML; LRRML 
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1. Introduction 
Cells of the innate immune system, such as macrophages and dendritic cells, express a 
limited number of germline-encoded pattern-recognition receptors (PRR) that 
specifically recognize pathogen-associated molecular patterns (PAMPs) within 
microbes. These molecular patterns are unique to these microbes and are absent in the 
host [1]. Toll-like receptors (TLRs) are currently the best-characterized members of the 
PRRs [2]. The progress of genome sequencing projects has led so far to the 
identification of 13 groups of TLRs in mammalian genomes, ten in humans and 13 in 
mice [3], and more than 20 in non-mammalian genomes [4]. All TLRs have a common 
domain organization, with an extracellular ectodomain, a helical transmembrane domain, 
and an intracellular Toll/IL-1 receptor homology (TIR) domain [5]. The extracellular 
domain (ectodomain) is responsible for the recognition of common structural patterns in 
various microbial molecules. For example, lipoproteins or lipopeptides are recognized 
by TLR2 complexed with TLR1 or TLR6, viral double-stranded RNAs by TLR3, 
lipopolysaccharides by TLR4, bacterial flagellins by TLR5, single-stranded RNAs by 
TLR7 or TLR8, and microbial CpG DNAs by TLR9 [6, 7]. The TIR domains of TLRs 
are associated with the intracellular signaling cascade leading to the nuclear 
translocation of the transcription factor NF-κB [8]. 
A TLR ectodomain contains 19 to 27 consecutive leucine-rich repeat (LRR) motifs 
sandwiched between two terminal LRR modules (LRRNT and LRRCT) [4]. LRRs exist 
in more than 6000 proteins and more than 100 crystal structures of these proteins have 
been deposited in the Protein Data Bank (PDB) [9, 10]. In every case, the protein adopts 
an arc or horseshoe shape. An individual LRR motif is defined as an array of 20 to 30 
amino acids that is rich in the hydrophobic amino acid leucine. All LRR sequences can 
be divided into a conserved segment and a variable segment. The conserved segments, 
LxxLxLxxNxL, generate the concave surface of the LRR arc or horseshoe by forming 
parallel β-strands, while the variable parts form its convex surface consisting of helices 
or loops. The terminal LRRNT and LRRCT modules stabilize the protein structure by 
shielding its hydrophobic core from exposure to solvent. 
To date, only the crystal structures of the ectodomains of human TLR1 through 4 and 
mouse TLR2 through 4 have been determined [11-15]. High-throughput genome 
sequencing projects, however, have led to the identification of more than 2000 TLR 
sequences. Thus, the structures of most TLRs are still unknown because structure 
determination by X-ray diffraction or nuclear magnetic resonance spectroscopy 
experiments remains time-consuming. Protein structure prediction methods are 
powerful tools to bridge the gap between sequence determination and structure 
determination. 
Homology modeling, also referred to as comparative modeling, is currently the most 
accurate computational method for protein structure prediction. This approach 
constructs a three-dimensional model for a target protein sequence from a three-
dimensional template structure of a homologous protein. Thus, the quality of the 
homology model strongly depends on the sequence identity between the target and 
template. Below 30% identity, serious errors may occur [16]. Due to different repeat 
numbers and distinct arrangements of LRRs in the TLR ectodomains, a proper full-
length template with a sufficiently high sequence identity to the target is often missing. 
This limitation can be overcome by assembling multiple LRR templates. In this 
approach the most similar (on the sequence level) LRR with a known structure is 
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searched as a local template for each LRR in the target sequence. Such an LRR template 
may be derived from TLRs or from other proteins. Thereby, a suitable template may be 
found even for an insertion-containing irregular LRR. All local template sequences are 
then combined to generate a multiple sequence alignment for the complete target 
sequence. Thus, a high-quality model can be created, even if no adequate single 
template is available. To facilitate a multiple template assembly of LRR proteins, we 
have developed the LRRML database [9], which archives individual LRR structures 
manually identified from all known LRR protein structures. In addition, we have 
developed TollML [4], a database of sequence motifs of TLRs. In TollML, all known 
sequences of TLR ectodomains were semi-automatically partitioned into LRR segments 
and are made available for query. For newly sequenced TLRs that are not yet archived 
in TollML, we have implemented an LRR prediction program named LRRFinder on the 
TollML webpage. It requires as input an LRR-containing amino acid sequence and 
returns the number and positions of LRRs in the input sequence. LRRFinder recognizes 
LRR motifs based on a position-specific weight matrix scan, with the sensitivity and 
specificity both higher than 93%. With the help of these two databases, LRR partitions 
of a TLR ectodomain can be directly obtained, and an optimal structure template for 
each LRR segment can be quickly found. A schematic flowchart of the modeling 
procedure is shown in Figure 1. 
In this study, we apply the multiple template assembly approach to TLRs. To 
demonstrate the potential of the method we constructed two models of the mouse TLR3 
ectodomain as a test case using our LRR template assembly method and a standard 
profile-profile alignment-aided full-length template recognition method. Both models 
were then compared with the crystal structure of mouse TLR3. The overall and ligand-
binding site conformation of the template assembly-based model is closer to that of the 
crystal structure than that based on the standard method. We also modeled the human 
TLR5 through 10 and mouse TLR11 through 13 ectodomains, which represent 
mammalian TLR ectodomains with unknown structures. A comparison of the model for 
human TLR6 with the very recently reported crystal structure of mouse TLR6 shows a 
very good structural agreement. 
2. Methods 
2.1 Template selection and sequence alignment 
Amino acid sequences of mouse TLR3, human TLR5 through 10, and mouse TLR11 
through 13 ectodomains were extracted from TollML release 3.0 (IDs 627, 531, 571, 
992, 575, 1022, 851, 703, 705, and 704). Their LRR partitions were annotated by 
TollML. For each LRR sequence contained in each target TLR, the three-dimensional 
LRR structure with the highest sequence identity was selected as a template from 
LRRML through a sequence similarity search. Then, a multiple sequence alignment of a 
target with all its local LRR templates was generated with each template comprising one 
alignment line. For instance, the mouse TLR3 has a total of 25 LRRs and accordingly 
required 25 templates. The associated multiple sequence alignment then has 26 lines 
(Figure 1). Because of the characteristic consensus sequences of LRRs, these 
alignments were made more accurately manually than automatically. To generate an 
alternate model with standard methods, the widely acknowledged template recognition 
program pGenTHREADER [17] was executed to find templates for mouse TLR3. This 
method calculates sequence profiles from an input sequence and combines profile-
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profile alignments with secondary structure specific gap-penalties, pair potentials, and 
solvation potentials using a linear combination. The output is the complete PDB 
structures that serve as candidate templates ranked by P-values. Each candidate 
sequence is aligned with the target sequence. 
2.2 Model construction and validation 
The initial three-dimensional coordinates of all models were calculated by MODELLER 
9v7 [18]. The above-described alignment file and the corresponding template structures 
of a target model were inputted into the default ‘model’ routine of MODELLER. A 
given number of three-dimensional models were calculated. The ectodomains of TLRs 
contain a number of insertion regions. Some of them corresponded to four to 15 amino 
acid-long gaps in the alignments because their templates do not contain a corresponding 
insertion. During modeling, these gaps produced loop structures in the model, thus 
deteriorating the model accuracy. ModLoop [19] was used to rebuild the coordinates of 
these loop regions. Finally, we used the model quality assessment programs ProQ [20] 
and MetaMQAP [21] to evaluate the output candidate models and select the one with 
the best scores as the final model. The structure superimpositions and molecular 
electrostatics involved in the structural analysis were carried out using SuperPose v1.0 
[22] and VMD [23], respectively. The docking studies of TLR11 and its ligand profilin 
were performed with GRAMM-X [24]. 
3. Results 
3.1 LRR templates 
The number of LRRs in the full-length ectodomains of mouse TLR3, human TLR5 
through 10, and mouse TLR11 through 13 is 25, 23, 21, 28, 28, 28, 21, 26, 25, and 27, 
respectively. Consequently, a total of 252 individual LRR templates sourced from 41 
different PDB structures were selected from LRRML. Their sequence identities with the 
targets vary from 26.0% to 95.7% (43.8% on average), and similarities from 39.0% to 
100% (58.2% on average). Remarkably, all cases of relatively low sequence identity (< 
35%) were caused by highly irregular target LRRs. These highly irregular sequences 
include LRRNT/CTs, the highly mutated LRR15 of TLR7/8/9, and the insertion-
containing LRRs whose templates do not include a similar insertion. The sources 
(LRRML IDs) and sequence identities of all LRR templates are listed in Table 1. 
As the modeling of mouse TLR3 was carried out to verify our approach, we assumed 
that the crystal structure of the mouse TLR3 ectodomain was unknown and excluded the 
corresponding LRR entries of mouse and human TLR3 ectodomains from LRRML 
before the template search. The selected individual LRR templates for mouse TLR3 
were associated with 18 PDB structures, 14 of which were from non-TLR proteins. The 
target-template sequence identities range from 33.3% to 50.0% (44.1% on average). By 
contrast, pGenTHREADER provided only complete PDB structures of LRR proteins as 
candidate templates, with each candidate possessing a pairwise sequence alignment with 
the target. Because no single template covered the entire sequence of mouse TLR3, we 
selected the first seven candidates by rank (except mouse and human TLR3) and 
combined them into a multiple alignment to avoid template gaps. These templates 
included PDB structures 2Z64, 2Z81, 1O6V, 3FXI, 2Z7X, 1JL5, and 3BZ5, which 
covered the closest homologues (mouse TLR2/4 and human TLR1/4) to mouse TLR3 
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among all proteins with known structures. Nevertheless, the sequence identities of the 
seven templates to mouse TLR3 range from 16.1% to 21.2% (18.7% on average), which 
fell much below the cut-off value 30% for homology modeling [16]. 
3.2 Structural models 
3.2.1 Model of mouse TLR3 
Recently, we constructed a model of mouse TLR3 with the LRR template assembly 
method as a test case of the LRRML database [9]. It revealed a horseshoe-shaped 
assembly adopting a regular solenoid structure without disordered regions. The model 
was superimposed with the crystal structure of mouse TLR3 ectodomain (PDB code: 
3CIG) [14] at its both ligand-binding regions, LRRNT through LRR3 and LRR19 
through LRR21. The backbone root mean square deviation (RMSD) is 1.96 Å and 1.90 
Å, respectively [9]. To verify the improvements of the database and the modelling 
process, we reconstructed the mouse TLR3 model (Figure 2b) with up-to-date LRR 
templates. Compared with the old model, four of the 25 LRRs of TLR3 in the new 
model were assigned new templates with higher sequence identities (Table 1). Because 
these four LRRs are not involved in the TLR3 ligand-binding sites, the corresponding 
RMSD values of the new model were the same as for the previous model. These values 
indicate that the model predicted with our method well matches the crystal structure and 
can be used to predict potential ligand-binding sites [25]. 
For comparison purposes, the mouse TLR3 ectodomain was also modeled with a 
standard profile-profile alignment-aided full-length template recognition method. All of 
the ten output models obtained from MODELLER for the full-length templates-based 
standard alignment showed a serious structural disorder spanning from LRR6 through 
LRR10 (Figure 2a). The LRR6 through LRR10 on the crystal structure form a regular 
solenoid structure with an α-helix in the variable segment of LRR8 (Figure 2c). By 
contrast, the corresponding LRRs on the model completely lost the proper LRR shape 
and interwove with one another. The disorder was caused by mismatches or target gaps 
in the alignment, where only two to four template LRRs were assigned to five target 
LRRs (Figure 2d). The standard alignment could not create a one-to-one 
correspondence between the target and template LRR units due to the irregularity of the 
LRRs. ProQ and MetaMQAP were used to evaluate the quality of the different models 
of mouse TLR3 (Table 2). Both programs make an integrative assessment of the 
structure quality considering geometry, stereochemistry, and energy distribution of the 
structures. Both template assembly-based models received better scores than the model 
based on standard method. 
3.2.2 Models of human TLR5 through 10 and mouse TLR11 through 13 
With the LRR template assembly method we modeled the human TLR5 through 10 and 
mouse TLR11 through 13 ectodomains. All of the resulting models are provided in 
Supplementary File 1. Ramachandran plots of these models were created with 
PROCHECK [26] and are provided in Supplementary File 2. Model evaluation data by 
ProQ and MetaMQAP are listed in Table 2. The models reveal a horseshoe shape 
(Figure 3), where a longer or shorter sequence (more or less LRR units) implies a 
smaller or larger horseshoe opening, e.g., TLR7/8 (smaller opening) and TLR6/10 
(larger opening). Their overall structural similarity reflects the phylogenetic 
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relationships among these TLRs. For example, TLR6 is similar to TLR10 while TLR7 
is similar to TLR8, consistent with the molecular tree proposed by Roach and co-
workers [27]. Mammalian TLRs are distinct from other LRR proteins in that they 
contain two to seven insertion-containing irregular LRRs, which may be necessary for 
ligand-binding and receptor dimerization. Our models show that all insertions are 
located on that face of the horseshoe, to which the convex site β-strands point, whereas 
the other face is completely insertion-free. 
To highlight the availability of these models for an analysis of receptor-ligand 
interaction mechanisms, we performed molecular electrostatics calculations of the 
mouse TLR11 model with a ligand. TLR11 can recognize profilin of some 
apicomplexan protozoa parasites. This protein is involved in parasite motility and 
invasion [28]. Expression of TLR11 is suppressed in humans [29]. The electrostatic 
analysis (Figure 4a) shows that the entire surface of the profilin of P. falciparum (PDB 
code: 2JKF) is predominantly negatively charged, whereas TLR11 exhibits several 
positively charged patches (Figure 4b). Protein docking studies using GRAMM-X 
showed that profilin and the positive patches on TLR11 possess compatible sizes and 
electrostatic complementarity (Supplementary File 3). 
Very recently, the crystal structure of the TLR6 ectodomain complexed with TLR2 and 
a Pam2CSK4 ligand was released in PDB (PDB code: 3A79). The TLR6 structure is a 
hybrid structure of mouse and inshore hagfish, where 18 mouse LRRs (LRRNT through 
LRR17) were hybridized with two hagfish LRRs (LRR18 and LRRCT) [30]. This 
crystal structure served as an additional benchmark for our template assembly approach. 
The superimposition of the mouse part of the crystal structure with our human TLR6 
model yielded a backbone RMSD of 1.94 Å, which indicates that the model is very 
similar to the crystal structure (Figure 5). A second model of human TLR6 was 
generated with pGenTHREADER in a similar procedure as described for the mouse 
TLR3 (Supplementary File 1). The backbone RMSD between the crystal structure and 
this model is 1.89 Å. The only full-length template used for this model was the structure 
of human TLR1 (PDB code: 2Z7X). Because TLR6 and TLR1 possess the same 
number of LRRs and have a very high sequence identity (63.3%), the structure of TLR1 
serves as an excellent full-length template. Under these very good conditions, both, the 
standard and the template assembly approaches, provided high-quality models. 
4. Discussion 
In template-based protein modeling, the overall sequence identity between the target 
and template is an important criterion for the selection of suitable templates [31]. For 
repetitive LRR proteins, however, there is often no appropriate full-length template 
available due to different repeat numbers and distinct arrangements. This problem can 
be solved by combining individual repeating units that are locally optimal for the target 
sequence. In the method validation with mouse TLR3, the average target-template 
sequence identity achieved by our method was 44.8%, which was significantly higher 
than that (18.7%) achieved by a standard profile-profile alignment-aided template 
recognition method. However, both the standard and the template assembly methods 
produced models of human TLR6 very well matched the crystal structure of mouse 
TLR6. The comparison between the models obtained with both methods highlights the 
potential of the template assembly approach. It can produce models with a similar 
quality as the standard profile-profile alignment method. The template assembly method, 
however, reveals its particular strength in situations where no adequate full-length 
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templates are available. In the case of TLR3, the standard profile-profile alignment 
method failed to predict a reliable model due to significant gaps in the template. Here, 
the template assembly method overcomes the difficulties and generates a realistic model. 
In a previous work, we constructed models of human TLR7/8/9 ligand-binding domains 
by combining LRR segments that were extracted from all known crystal structures of 
TLRs [32]. The average target-sequence similarities for TLR7/8/9 were 47.7%, 47.2%, 
and 46.8%, respectively. The resulting models supported experimentally determined 
ligand-binding residues [33, 34] and provided a reliable basis to identify potential 
ligand-binding residues and potential receptor dimerization mechanisms. Here, we went 
a step further and extended the scope of the approach by searching LRR segments from 
all LRR-containing proteins with known structures with the LRRML database because 
the same type of LRRs can exist in different proteins [9]. Consequently, 33 of the 41 
source PDB structures are non-TLR proteins (numbers derived from Table 1). The 
average target-sequence similarities for TLR7/8/9 increased to 55.9%, 58.2%, and 
59.2%. 
Another key issue in LRR protein modeling is the sequence-level LRR partition of the 
target TLR sequence. The indicated number and beginning/end positions of LRRs in 
TLRs vary largely across different databases or research reports due to the irregularity 
and periodicity of LRRs. TollML reports the most complete and accurate LRR motifs 
for TLRs as compared with a number of databases [4]. In addition, TollML provides a 
statistics-based LRR prediction program LRRFinder for new TLR entries that are not 
yet collected in TollML. It can recognize LRRs from an input amino acid sequence with 
high confidence. 
In conclusion, this work depicts an LRR template assembly approach for protein 
homology modeling. The comparison of a mouse TLR3 model with its crystal structure 
underlined feasibility and reliability of the method. With this method, a series of 
mammalian TLR ectodomains were modeled. These models can be used to perform 
ligand docking studies or to design mutagenesis experiments and hence to investigate 
TLR ligand-binding mechanisms. Our modeling approach can be extended to other 
repetitive proteins. 
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Table 1: Source and sequence identity (%) of the LRR templates. 
 mTLR3 hTLR5 hTLR6 hTLR10 mTLR12 
LRR LRRML ID Iden LRRML ID Iden LRRML ID Iden LRRML ID Iden LRRML ID Iden
NT 406 47.6 125 34.6 333 72.7 150 40.9 125 28.6
1 65 45.8 284 45.8 334 54.2 334 45.8 90 37.5
2 212 45.8 264 42.3 335 70.8 335 62.5 178 58.3
3 465 41.7 259 54.2 336 81.0 578 42.9 465 40.7
4 151 50.0 464 46.2 337 80.0 337 68.0 578 40.9
5 177 50.0 259 48.0 338 60.9 338 47.8 21 35.5
6 110 46.2 252 34.6 339 36.0 111 33.3 497 56.0
7 275 45.8 494 29.0 340 33.3 340 41.7 202 40.9
8 8 41.4 135 37.0 341 33.3 28 34.6 39 34.6
9 203 42.3 359 26.6 342 48.1 342 44.4 356 45.8
10 484 54.2 357 41.7 343 34.6 343 46.4 179 45.8
11 293 50.0 140 50.0 344 48.3 365 29.0 177 42.3
12 270 33.3 316 50.0 345 45.5 345 40.9 566 54.2
13 357 41.7 151 45.8 346 41.7 346 41.7 66 50.0
14 65 42.9 216 45.0 347 61.5 358 48.0 468 45.8
15 152 50.0 153 38.1 348 40.0 369 41.7 501 44.0
16 259 40.0 253 36.0 349 68.2 349 45.5 581 34.8
17 316 37.5 356 40.0 350 95.7 350 43.5 372 30.8
18 152 38.5 566 41.4 351 52.0 372 45.5 283 37.0
19 239 50.0 72 58.3 128 37.5 513 36.0 396 38.7
20 239 45.8 579 45.5 - - - - 260 37.5
21 92 50.0 484 40.9 - - - - 496 41.4
22 80 41.7 - - - - - - 315 45.8
23 628 46.2 - - - - - - 110 35.7
CT 575 42.9 149 31.7 149 31.7 514 29.9 149 20.0
 hTLR7 hTLR8 hTLR9 mTLR11 mTLR13 
LRR LRRML ID Iden LRRML ID Iden LRRML ID Iden LRRML ID Iden LRRML ID Iden
NT 257 40.6 250 30.0 125 29.0 125 36.7 125 26.5
1 293 45.8 509 45.8 314 41.7 76 38.5 491 54.2
2 107 36.0 573 48.0 101 41.7 191 37.5 107 50.0
3 106 52.4 581 47.6 219 55.0 288 44.0 254 54.2
4 261 45.8 509 45.8 310 41.7 559 36.4 152 50.0
5 140 44.0 564 44.0 157 41.7 557 40.0 4 53.8
6 583 47.6 106 52.4 106 47.6 238 30.4 419 52.0
7 105 45.8 509 45.8 501 41.7 463 44.0 285 44.0
8 573 45.8 573 50.0 259 37.5 271 45.8 135 41.7
9 79 45.8 494 41.7 357 50.0 157 45.8 488 52.0
10 500 46.2 573 42.3 367 37.0 506 44.0 498 36.7
11 500 52.0 316 54.2 337 40.0 237 45.8 128 33.3
12 488 40.7 261 37.0 274 31.0 509 46.2 288 48.0
13 129 44.0 92 37.5 92 33.3 500 54.2 505 45.8
14 386 37.9 259 44.0 357 34.6 7 50.0 573 54.2
15 36 33.3 300 29.6 139 15.6 111 45.8 260 50.0
16 316 41.7 494 41.7 170 37.5 38 42.3 148 36.0
17 358 46.2 158 40.0 316 40.0 484 43.5 262 45.8
18 316 41.7 314 41.7 135 45.8 360 29.2 293 50.0
19 494 50.0 296 37.5 316 44.0 73 37.5 105 45.8
20 503 41.7 128 45.8 493 40.0 403 28.6 260 48.0
21 92 41.7 77 45.8 252 41.7 102 30.4 466 46.2
22 78 48.0 573 60.0 288 44.0 121 34.5 565 41.7
23 552 45.8 169 36.0 111 37.5 316 50.0 93 50.0
24 210 50.0 283 53.8 289 41.7 35 36.0 79 50.0
25 133 40.7 271 45.8 259 45.8 - - 573 41.7
26 274 48.3 144 42.3 357 52.0 - - - - 
CT 149 36.7 149 33.9 149 28.8 469 26.2 149 36.5
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Table 2: Evaluation of the crystal structure and models of the TLRs. Higher ProQ_LG/MS and 
MetaMQAP_GDT values indicate higher model qualities; higher MetaMQAP_RMSD values indicate 
lower model qualities. a Model of Wei et al. (2008). 
Structure/Model 
ProQ_ 
LG/MS 
MetaMQAP_ 
GDT/RMSD 
mTLR3 crystal 7.215/0.469 69.840/1.962 
mTLR3 
pGenTHREADER 4.013/0.357 41.943/4.691 
mTLR3 a 5.136/0.423 54.068/3.080 
mTLR3 new 5.349/0.405 54.542/3.030 
hTLR5 4.707/0.358 54.803/3.126 
hTLR6 5.807/0.439 73.230/1.907 
hTLR7 4.980/0.381 52.816/3.224 
hTLR8 5.053/0.408 53.490/3.113 
hTLR9 5.025/0.386 53.774/3.181 
hTLR10 4.835/0.362 59.918/2.883 
mTLR11 4.371/0.351 49.178/3.433 
mTLR12 4.546/0.337 46.131/3.493 
mTLR13 4.827/0.407 55.709/2.982 
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Figure 1: Flowchart of the LRR template assembly method. 
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Figure 2: Homology models and crystal structure of the mouse TLR3 ectodomain. (a) The homology 
model based on the standard method. The framed region exhibits serious disorder. (b) The homology 
model based on template assembly method. (c) The crystal structure (PDB code: 3CIG). The dotted 
region is an insertion on LRR20 that is missing in the crystal structure. (d) The target-template sequence 
alignment of the disordered region of the standard method based model. The mismatches and target gaps 
resulted in the disorder in (a), where two to four template LRRs were wrongly assigned to five target 
LRRs. 
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Figure 3: Models of human TLR5 through 10 and mouse TLR11 through 13 ectodomains. The N-linked 
glycan sites of these TLRs were obtained from the NCBI protein database and are labelled with black 
balls. 
 
16 
Figure 4: Surface charge analysis (APBS electrostatics) of (a) the crystal structures of profilin (PDB code: 
2JKF) and (b) the model of mouse TLR11 ectodomain. Blue: positive charge; red: negative charge. 
 
17 
Figure 5: Superimposition of the homology model and the crystal structure of the TLR6 ectodomain. 
Green: homology model of human TLR6 (LRRNT through LRR17); orange: crystal structure of mouse 
TLR6 (LRRNT through LRR17). The Pam2CSK4 ligand-bind site is located on the variable parts of 
LRR10 through LRR12. The overall backbone RMSD is 1.94 Å and the backbone RMSD of the ligand-
binding region is 1.18 Å. 
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Supplementary file 1: Three-dimensional models of human TLR5-10 and mouse TLR10-13 ectodomains. 
Supplementary file 2: Ramachandran plots of the models. 
Supplementary file 3: Docking models of TLR11 and profiling ligand. 
 
Appendix 
82 
Paper 4 
 
 
 
 
 
 
 
 
 
 
Homology modeling of human Toll-like receptors TLR7, 8 and 9 ligand-binding 
domains 
Protein Sci., 2009, 18:1684-1691 
Tiandi Wei, Jing Gong, Ferdinand Jamitzky, Wolfgang M. Heckl, Robert W. Stark and 
Shaila C. Rössle 
 
Homology modeling of human
Toll-like receptors TLR7, 8, and 9
ligand-binding domains
Tiandi Wei,1 Jing Gong,1* Ferdinand Jamitzky,1,2 Wolfgang M. Heckl,1,3
Robert W. Stark,1 and Shaila C. Ro¨ssle1
1Department of Earth and Environmental Sciences, Center for Nanoscience, Ludwig-Maximilians-Universita¨t Mu¨nchen,
80333 Munich, Germany
2Leibniz Supercomputing Centre, 85748 Garching, Germany
3Deutsches Museum, 80538 Munich, Germany
Received 17 February 2009; Revised 14 May 2009; Accepted 1 June 2009
DOI: 10.1002/pro.186
Published online 11 June 2009 proteinscience.org
Abstract: Toll-like receptors (TLRs) play a key role in the innate immune system. The TLR7, 8, and
9 compose a family of intracellularly localized TLRs that signal in response to pathogen-derived
nucleic acids. So far, there are no crystallographic structures for TLR7, 8, and 9. For this reason,
their ligand-binding mechanisms are poorly understood. To enable first predictions of the
receptor–ligand interaction sites, we developed three-dimensional structures for the leucine-rich
repeat ectodomains of human TLR7, 8, and 9 based on homology modeling. To achieve a high
sequence similarity between targets and templates, structural segments from all known TLR
ectodomain structures (human TLR1/2/3/4 and mouse TLR3/4) were used as candidate templates
for the modeling. The resulting models support previously reported essential ligand-binding
residues. They also provide a basis to identify three potential receptor dimerization mechanisms.
Additionally, potential ligand-binding residues are identified using combined procedures. We
suggest further investigations of these residues through mutation experiments. Our modeling
approach can be extended to other members of the TLR family or other repetitive proteins.
Keywords: Toll-like receptor; leucine-rich repeats; protein-nucleic acid interaction; homology
modeling
Introduction
Toll-like receptors (TLRs) play an essential role in the
innate immunity, recognizing invasion of microbial
pathogens and initiating intracellular signal transduc-
tion pathways to trigger expression of genes, the prod-
ucts of which can control innate immune responses.1
To understand how these receptors work, it is crucial
to investigate them from a structural perspective. To
date, only the crystal structures of the ectodomains of
human TLR1/2/3/4 and mouse TLR3/4 have been
determined.2–6 The progress of genome projects, how-
ever, already led to the identification of 13 TLRs in
mammalian and more than 20 TLRs in nonmamma-
lian. A total of more than 2000 TLR proteins has been
sequenced.7 Thus, the structures of most TLRs are still
unknown because structure determination by X-ray
diffraction or nuclear magnetic resonance spectroscopy
experiments remains time-consuming. Here, computa-
tional methods can help to bridge the gap between
sequence determination and structure determination.
To this end, homology modeling is a powerful tool to
predict the three-dimensional structure of proteins.
Homology modeling is based on the assumption
that similar sequences among evolutionarily related
proteins share an overall structural similarity. The
modeling procedure can be divided into a number of
Additional Supporting Information may be found in the online
version of this article.
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steps.8,9 First, selection of suitable template(s) related
to the target sequence. A template segment assembly
can usually improve the model quality.10 Second,
alignment of the target sequence to the template(s).
Third, building coordinates of the three-dimensional
model based on the alignment. Fourth, evaluation of
the model and its refinement. The resulting model can
then be used to infer biological functionalities or to
generate hypotheses for new experiments. A recent
study on TLR411 highlighted the reliability and the sig-
nificance of homology modeling applied to TLRs.
The structure of a TLR consists of a leucine-rich
repeat (LRR) ectodomain, a helical transmembrane
domain, and an intracellular Toll/IL-1 receptor homol-
ogy (TIR) signaling domain.12 The ectodomain contains
varying numbers of LRRs and resembles a solenoid bent
into a horseshoe shape. At both ends there is a terminal
LRR that shields the hydrophobic core of the horseshoe.
These ectodomains are highly variable. They are directly
involved in the recognition of a variety of pathogen-
associated motifs including lipopolysaccharide, lipopep-
tide, cytosine–phosphate–guanine (CpG) DNA, flagellin,
imidazoquinoline, and ds/ssRNA.13 Upon receptor acti-
vation, a TIR signaling complex is formed between the
receptor and adaptor TIR domains.14
The receptors TLR7, 8, and 9 compose a family15
with a longer amino acid sequence than other TLRs.
They are localized intracellularly and signal in
response to nonself nucleic acids. They also contain an
irregular segment between their LRR14 and 15. A
recent study showed that the ectodomains of TLR9
and 7 are cleaved in the endolysosome to recognize
ligands.16 Only the cleaved forms can recruit MyD88
on activation. In the absence of the crystallographic
structures, we developed structural models of cleaved
ligand-binding domains of TLR7/8/9 by homology
modeling. From the structural model we predict
potential ligand-binding sites and infer possible con-
figurations of the receptor–ligand complex.
Results
Template identification
Our target structures are the cleaved functional ectodo-
mains of the human TLR7/8/9 comprising LRR15–25
and N/C-terminal LRRs. All the six structure-known
TLR homologues were employed as template sources:
human TLR1/2/3/4 and mouse TLR3/4. The TLR ecto-
domain is composed of strictly organized LRRs. Never-
theless, the LRR number of cleaved ligand-binding
domain of human TLR7/8/9 is 13 (LRR15–25 and N/C-
terminal LRR),16 whereas the LRR number of the struc-
ture-known TLRs varies from 20 to 25. Therefore, none
of the structure-known TLRs is suitable to serve as a full
length template. To overcome this limitation, LRR seg-
ments with higher sequence similarity to the individual
LRRs in the target were selected from the six complete
homologous structures. The segments were then com-
bined into the multiple templates. Figure 1 shows the
multiple alignment models for the three proteins TLR
7/8/9, presenting the relationship between target and
template segments. The sequence similarity between
each LRR pair (target/template LRR) is listed in Table
I. The average target–template similarities of TLR7/8/9
are 47.70, 47.20, and 46.78%, respectively.
Remarkably, the group of TLR7/8/9 has a unique
structural character that is absent in other TLRs. A
specific segment (26–32 residue long) is located
Figure 1. Models of multiple alignments between targets
and templates. The numbers 01–25 denote the canonical
LRRs; NT and CT denote N-/C-terminal LRRs. (A) Five
segments selected from four structures (2Z80 chain A:
human TLR2; 3CIG chain A: mouse TLR3; 2Z64 chain A:
mouse TLR4; 2A0Z chain A: human TLR3) were used as
templates for the human TLR7 ectodomain. (B) Six segments
selected from three structures (2Z66 chain A: human TLR4;
2A0Z chain A: human TLR3; 2Z7X chain A: human TLR2)
were used as templates for the human TLR8 ectodomain. (C)
Four segments selected from two structures (2A0Z chain A:
human TLR3; 2Z63 chain A: human TLR4) were used as
templates for the human TLR9 ectodomain.
Table I. Sequence Similarities (%) of Target–Template LRR Pairs
NT 15 16 17 18 19 20 21 22 23 24 25 CT Avg
TRL7 28.60 58.30 60.00 41.70 47.10 58.30 46.20 52.00 50.00 33.30 46.20 48.30 50.00 47.70
TRL8 29.40 41.70 52.00 50.00 57.70 60.00 40.60 44.00 52.00 36.00 60.00 42.30 53.30 47.20
TRL9 32.30 58.30 48.00 50.00 44.40 41.70 46.90 51.90 36.00 54.20 50.00 52.00 42.40 46.78
In the header line, 15–25 denote canonical LRRs. NT and CT denote N-/C-terminal LRRs. Avg denotes the average values.
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before LRR15, which was described as an undefined
region.17–19 The sequence similarity search against Pro-
tein Data Bank (PDB) provided no significant results.
Thus, we carried out secondary structure predictions for
this region with four different methods. As example, the
results for TLR9 are shown in Figure 2. All methods
indicated a short b-sheet at position 3–5 of the segment,
which is a prominent characteristic of LRRs. In addi-
tion, we compared its amino acid sequence with the
consensus sequence of LRRs. The most significant posi-
tions of the LRR consensus sequence, LxxLxLxxNxL,
are the four L residues which form the hydrophobic
core of a LRR structure. Here, the letter L not only
stands for leucine but also for other highly hydrophobic
residues. As illustrated in Figure 2, the specific segment
of TLR9 contains three of the four highly hydrophobic
residues. Also, the corresponding segment of TLR7/8
has the same features. Thus we regard this segment as
an irregular LRR. Because the N-terminal LRR together
with LRR1–14 of the receptor ectodomain are deleted
upon arriving in endolysosome, this irregular LRR may
become a new N-terminal LRR of the truncated struc-
ture. Moreover, multiple alignments of all known
mammalian sequences showed that this region is very
variable within each of the TLR7/8/9 groups. The struc-
ture of this LRR may be relatively relaxed, because it
lacks the first L residue that participates in forming the
hydrophobic core of a LRR structure and the N residue
that forms hydrogen bonds between neighboring LRRs.
These features also support the hypothesis that this
irregular LRR is an N-terminal LRR. For this reason, a
N-terminal LRR with known structure was selected as
corresponding template (Fig. 1).
Structure modeling and evaluation
The three-dimensional coordinates of the models were
created by MODELLER24 and modified by ModLoop.25
The final structures of the ectodomains of TLR7/8/9
reveal a large, arc-shaped assembly consisting of 11
canonical LRRs and two terminal LRRs, which
adopted a right-handed solenoid structure (Fig. 3).
The TLRs are distinct from other LRR proteins in that
their LRR consensus motifs are often interrupted by
extended insertions.26 Two 4–7-residue-long insertions
protuberate from the structure surface at LRR18 and
LRR20, respectively. These insertions are well con-
served in length and position on the sequence level in
the three TLRs. The models show that the insertions
are all located on one face of the arc, whereas the
other face is insertion-free (Fig. 3). The convex site
b-sheets are directed toward the insertion face. This
feature is consistent with the known structures of
TLR1/2/3/4. Because all the known ligand-binding
sites of TLR1/2/3/4 are on the insertion face of the
structure, the insertions suggest some functional sig-
nificance. In addition, the human TLR7/8/9 are glyco-
sylated as it is the case for other TLRs. The glycans
were shown to be nonfunctional for ligand binding.2–6
The NCBI protein database provides seven predicted
N-linked glycosylation sites for TLR7/8 cleaved form
and six for TLR9. All sites are located on the inser-
tion-free faces. The PDB format files of the three final
models are provided as Supporting Information Files
1–3. Evaluation of the models involved analysis of
geometry, stereochemistry, and energy distributions in
the models. The evaluation results (Table II) are indic-
ative of a good quality of all three models.
Figure 2. Irregular region analysis of TLR9. Four methods (PredictProtein,20 NNPREDICT,21 SSPro,22 and GOR IV23) were
used to predict the secondary structures of the irregular region of TLR9. The results (italic letters) indicate a short b-sheet at
position 3–5 of this region. Besides, this region matches the LRR pattern at three important positions (bold letters). These
features support the presumption that this irregular region is a beginning N-terminal LRR after the ectodomain cleavage.
Table II. Model Evaluation
TLR7 TLR8 TLR9 TLR3
ProQ_LG/MS 5.340/0.461 4.613/0.402 4.355/0.339 7.923/0.526
PROCHECK 97.4% 96.2% 97.5% 99.6%
ModFOLD_Q/P 0.7588/0.01 0.7100/0.0126 0.7166/0.0121 0.7116/0.0124
MetaMQAP_GDT/RMSD 57.534/3.049 A˚ 53.908/3.121 A˚ 54.645/3.244 A˚ 79.322/1.566 A˚
All these displayed scores indicate the models to be reliable in terms of overall packing. For comparison purpose, the values of
TLR3 crystal structure (PDB code: 2A0Z) were also listed. ProQ_LG: >1.5 fairly good; >2.5 very good; >4 extremely good.
ProQ_MS: >0.l, fairly good; >0.5, very good; >0.8, extremely good. PROCHECK: percentage of residues in most favored
regions and additional allowed regions. ModFOLD_Q: >0.5, medium confidence; >0.75, high confidence. ModFOLD_P: <0.05,
medium confidence; <0.01, high confidence. MetaMQAP_GDT/RMSD: an ideal model has a GDT score over 59 and a RMSD
around 2.0 A˚.
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Figure 3. Structural models and ligand-binding regions of TLR7/8/9. Insertions are located on one face of the horseshoe,
whereas the other face is insertion-free. The reported essential residues are located on the insertion face (labeled in blue).
The orange regions are potential ligand-binding regions on the insertion face. [Color figure can be viewed in the online issue,
which is available at www.interscience.wiley.com.]
Figure 4. Partial multiple sequence alignments of different mammalian TLR7/8/9. The multiple sequence alignments represent
the conservation of each residue in the potential ligand-binding regions (corresponding to the orange regions in Fig. 3). In the
first line below the alignments, plus signs designate important residues as reported in the literature and the asterisks
designate highly conserved positions. In the second line, the number of positive docking predictions of each position is
indicated. In the third line, blue squares designate important residues as reported in the literature and green squares indicate
the suggested ligand-binding residues. [Color figure can be viewed in the online issue, which is available at
www.interscience.wiley.com.]
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Potential ligand-binding residues
Several residues are essential for the ligand recogni-
tion: Asp543 in TLR8; Asp535 and Tyr537 in
TLR9.18,27 Our models can help to understand the bio-
logical function of these residues (Fig. 3). According to
these reported residues and the sequence comparison
of TLR7/8/9, we inferred a ligand-binding region for
TLR7/8/9, respectively (detailed in the Discussion sec-
tion). It is located at the insertion face of the ectodo-
main around LRR17 (Fig. 3). Because of the consider-
able size of the nucleic acids, the ligand-binding
region should contain more interacting residues. We
identified potential ligand-binding residues in the
ligand-binding region aside from the experimentally
determined ones. To accomplish this goal we inte-
grated results from manual analyses and automatic
docking programs.
TLR3 is closely related to the TLR7/8/9 family
because of its intracellular localization and nucleic
acid ligand. Therefore, we used the recently published
crystal structure of the mTLR3-dsRNA 2:1 complex6 as
a guide to predict the essential interacting residues in
TLR7/8/9. From all interacting residues of mTLR3, we
identified three principles for the essential residues:
1. The essential residues are located on the protein
surface and spatially close to each other.
2. They are highly conserved among species.
3. They create a nonnegatively charged environment.
On basis of these principles, we searched for addi-
tional residues that might be essential for ligand rec-
ognition. At first, surface residues that were spatially
close (within two LRRs) to the experimentally deter-
mined essential residues were marked on the predicted
models (orange regions in Fig. 3). These residues can
be far from each other on the sequence level. Then,
multiple alignments of all known mammalian TLR7/8/
9 sequences were generated to select the highly con-
served residues (columns with an asterisk in Fig. 4)
from the marked ones. Notably, the L (or I, V) and N
residues of the LRR consensus sequence LxxLxLxxNxL
are conserved, but they cannot interact with ligands,
because they are buried to form the hydrophobic core
of an LRR. These residues are not labeled with aster-
isks in Figure 4.
Four protein-RNA docking programs and five
protein-DNA docking programs (listed in the Materials
and Methods section) were used to predict ligand-bind-
ing residues in TLR7/8 and TLR9. A residue from the
prefiltered regions was marked as a ligand-binding resi-
due, if it was positively predicted by at least two pro-
grams. In Figure 4, the number of positive predictions
is listed for each target residue. The surface charge dis-
tributions of the regions of interest were calculated to
verify the charge pattern in the predicted ligand-bind-
ing regions [Fig. 5(A)]. The resulting residues corre-
spond to positively charged or neutral environments.
Figure 5(B) illustrates the protein surface residues
from the different steps of our investigation for TLR7/
8/9, respectively. All final predicted ligand-binding
residues are summarized in Table III. These residues
are indicated in green in both Figures 4 and 5(B).
Discussion
All three resulting models revealed similar conforma-
tions. This supports the assumption that TLR7/8/9 share
Figure 5. Surface analysis of ligand-binding regions
of TLR7/8/9. (A) Surface charge distribution (APBS
electrostatics) of ligand-binding regions of TLR7/8/9.
Blue: positive charge; white: neutral; red: negative
charge. (B) Important residues in ligand-binding regions
of TLR7/8/9. Blue: important residues as reported in
the literature; pink: residues close the blue ones but excluded
from the potential ligand-binding residues
through investigating processes; green: suggested
potential ligand-binding residues (residue name and
number are labeled). [Color figure can be viewed in the online
issue, which is available at www.interscience.wiley.com.]
Table III. Potential Ligand-Binding Residues
of TLR7/8/9
TLR7 K502 S504 G526 Q531 N551 R553 L556 S575 H578
TLR8 S492 Q519 N539 R541 F544 H566
TLR9 R481 N483 T486 H505 Q510 H530 K532 Y554 S556
Q557
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a common ligand-binding and signaling mechanism.18
We compared and analyzed the predicted structures to
suggest the receptor–ligand 2:1 complex models.
Ligand-binding region
The mouse TLR9 contains a short fragment in its
LRR17 that is homologous to the methyl CpG DNA
binding domain protein.27 The mutant of Asp535 and
Tyr537 in this fragment abolished the TLR9 func-
tion.27 In the human TLR8, the Asp543 that corre-
sponds to TLR9’s Asp535 was determined to be
required for the TLR8 function.18 Through sequence
comparison, the Asp residue was found to be highly
conserved in the TLR7/8/9 family but not in other
TLRs. We considered this Asp to be significant for
TLR7, because the TLR7/8/9 are highly homologous
and their ligands are all pathogen-derived nucleic
acids. In particular, the TLR7 and 8 are present as
tandem duplication in many studied genomes dis-
cussed by Roach et al.15 In this regard, TLR7/8/9 have
a ligand-binding region located spatially around the
Asp residue.
We can further exclude the necessity of other
ligand-binding regions on the ectodomains, because
the minimum size of stimulatory oligonucleotides is
six bases.28 These oligonucleotides are not large
enough to reach another ligand-binding region on the
receptor.
Receptor dimerization
The signaling mechanism of all TLRs is likely to
involve dimerization of the ectodomains.18 However,
this can be achieved in various ways by using different
receptors and stimuli. TLR9 is a preformed dimer. The
distance between both monomers is reduced upon
contact with CpG DNA.29 TLR1/2 are activated and
connected into a heterodimer by triacylated lipopep-
tide.4 TLR4 recognizes lipopolysaccharide indirectly
through the coreceptor protein MD-2 and is induced
to form a TLR4-MD-2 homodimer.5 In the TLR3
homodimer the dsRNA interacts with two regions of
each receptor ectodomain. Direct protein–protein
interactions between both receptors occur at their
C-terminal LRRs, whereas the other regions are sepa-
rated by the dsRNA.6
The structures obtained by the homology model-
ing together with the identification of possible ligand-
binding sites can be used to derive a working hypothe-
sis for the structure of the receptor–ligand complex.
We propose three possible receptor–ligand 2:1 com-
plex models for the TLR7/8/9 family (Fig. 6). In all
three models, the ssRNA or CpG DNA ligand interacts
with the binding region on the insertion surface of
both receptor ectodomains. The ectodomains are on
opposite sides of the ligand. Simultaneously, the intra-
cellular TIR domains are also in a dimer configuration.
Thus the C-terminal LRRs of each monomer, which
are connected to the TIR through a 20-amino-acid-
long transmembrane stretch, are spatially close to each
other. The main difference between the three models
is the relative position of the ectodomains. In the first
model [Fig. 6(A)], both C-terminal LRRs are brought
into proximity, forming a protein–protein contact.
Both binding regions sandwich the ligand. In the sec-
ond model [Fig. 6(B)], both receptors are shifted apart
along the ligand extending directions back to back. In
the third model [Fig. 6(C)], both receptors are shifted
in opposite directions face to face. Obviously, the min-
imum ligand size required by the first model is the
smallest. Therefore, a CpG DNA of six bases is already
long enough to stimulate TLR9.28 The minimum size
required by the second and third models is larger.
These two models, however, cannot be excluded,
because there is so far no evidence that TLRs have
only one dimer form. Without the crystal structure of
their ligands, it is difficult to determine a more precise
Figure 6. Proposed models of receptor–ligand 2:1 complex.
Wei et al. PROTEIN SCIENCE VOL 18:1684—1691 1689
model for the receptor dimerization. Hence, it remains
interesting to study the atomic structure of the stimu-
latory ssRNA/CpG DNA and to further determine the
detailed interactions between ligands and receptors.
Materials and Methods
Template identification and
sequence alignments
Amino acid sequences with LRR motif partitions of
human TLR7/8/9 ectodomain were extracted from
TollML.7 TollML is a specialized database of TLR
sequence motifs, derived from the NCBI protein data-
base.30 Multiple sequence alignments of all individual
LRRs of TLR7/8/9 to the LRR consensus sequence are
provided as Supporting Information File 4. Because
the TLR ectodomain is a repetitive protein (LRRs), we
selected and combined segments from all the six
known TLR ectodomain structures into multiple tem-
plates to optimize the sequence similarity between tar-
gets and templates. The six candidate templates were
human TLR1/2/3/4 and mouse TLR3/4 and were
obtained from the PDB.31 The PDB codes are 2Z7X,
2Z80, 2A0Z, 2Z63, 2Z66, 3CIG and 2Z64, respectively.
Three steps led to the identification of structural tem-
plates. First, we partitioned the known structures into
a total of 136 individual LRRs. Because of the irregu-
larity of the LRR sequences, the partition according to
the LRR consensus sequences was performed man-
ually. Second, the LRRs were collected into the
LRRML database,32 which can return the most similar
LRR for an input LRR sequence through similartiy
search. Third, optimal template pieces for each target
were found and combined to generate multiple
alignments. Because the TLR LRRs follow common
characteristic consensus sequences, target–template
alignments were generated more accurately by hand
than through software.
Structure construction and analysis
The initial three-dimensional coordinates of the mod-
els were generated by the fully automated program
MODELLER 9v3.24 The input files were the multiple
alignment file and the coordinate files of the tem-
plates. The ligand-binding domains of TLR7/8/9 con-
tain two 4–7-residue-long insertion regions, which
correspond to gaps in the multiple alignment. During
the modeling these regions became loop structures,
which limited the model accuracy. ModLoop25 was
used to modify these loop regions. The resulting
models were evaluated by PROCHECK,33 ProQ,34
ModFOLD,35 and MetaMQAP.36
The detection of potential ligand-binding sites was
achieved through residue conservation analysis, sur-
face charge analysis, and several automatic docking
programs. BindN,37 DP-Bind,38 DBS-PRED,39 DBS-
PSSM,40 and PreDs41 were used for protein-DNA
docking of TLR9. BindN, Pprint,42 RNAbindR,43 and
RISP44 were used for protein-RNA docking of TLR7/8.
Conclusions
We predicted three-dimensional structures of the
closely related TLR7/8/9 ligand-binding domains by
homology modeling. LRR segments were selected from
known TLR structures, which are locally optimal for
the target sequences. These segments were then com-
bined into multiple templates.
To predict essential residues in the ligand-binding
region, sequence conservation and charge distributions
were examined. Only highly conserved nonnegative
residues that are positively predicted by at least two
docking programs can be considered as potential
ligand-binding residues. Based on these models we
also suggest three possible receptor dimerization
schemes which require different minimum ligand
sizes.
In summary, our models provide a structural
framework that can act as a guide to develop a func-
tional hypothesis to interpret experimental data of
TLR7/8/9. They may also facilitate efforts to design
further site-directed mutagenesis to learn the ligand
recognition and the downstream signaling mecha-
nisms. The presented modeling approach can be
extended to other repetitive protein domains.
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a b s t r a c t
Toll-like receptors (TLRs) belong to the Toll-like receptor/interleukin-1 receptor (TLR/IL-1R) superfamily
which is deﬁned by a common cytoplasmic Toll/interleukin-1 receptor (TIR) domain. TLRs recognize
pathogen-associated molecular patterns and initiate an intracellular kinase cascade to trigger an imme-
diate defensive response. SIGIRR (single immunoglobulin interleukin-1 receptor-related molecule),
another member of the TLR/IL-1R superfamily, acts as a negative regulator of MyD88-dependent TLR sig-
naling. It attenuates the recruitment of MyD88 adaptors to the receptors with its intracellular TIR
domain. Thus, SIGIRR is a highly important molecule for the therapy of autoimmune diseases caused
by TLRs. So far, the structural mechanism of interactions between SIGIRR, TLRs and adaptor molecules
is unclear. To develop a working hypothesis for this interaction, we constructed three-dimensional mod-
els for the TIR domains of TLR4, TLR7, MyD88 and SIGIRR based on computational modeling. Through pro-
tein–protein docking analysis, we developed models of essential complexes involved in the TLR4 and 7
signaling and the SIGIRR inhibiting processes. We suggest that SIGIRR may exert its inhibitory effect
through blocking the molecular interface of TLR4, TLR7 and the MyD88 adaptor mainly via its BB-loop
region.
 2009 Elsevier Inc. All rights reserved.
1. Introduction
Toll-like receptors (TLRs) are essential for the innate immune
system because they recognize molecules, such as single-stranded
RNA or CpG DNA that are associated with pathogens. Such nuclear
antigen-recognizing receptors are also important in the autoim-
mune disease systemic lupus erythematosus. The disease pro-
gresses as a consequence of the recognition of self nucleic acids
by TLRs (Rahman and Eisenberg, 2006). For the future development
of therapeutic approaches it is important to understand possible
TLR inhibition mechanisms from a structural point of view.
TLRs belong to the Toll-like receptor/interleukin-1 receptor
(TLR/IL-1R) superfamily, which is deﬁned by the presence of a
conserved cytoplasmic Toll/interleukin-1 receptor (TIR) domain
(Bowie and O’Neill, 2000) connected to an ectodomain through a
single transmembrane stretch. To date, 13 TLRs have been identi-
ﬁed in mammals. Their ectodomains consist of 16–28 leucine-rich
repeats (LRRs). These LRRs provide a variety of structural frame-
works for the binding of protein and non-protein ligands including
lipopolysaccharide (LPS), lipopeptide, CpG DNA, ﬂagellin, imidazo-
quinoline and double-/single-stranded RNA (Gay and Gangloff,
2007). TLRs are capable of recognizing ligands in a dimer form
(Latz et al., 2007; Liu et al., 2008; Park et al., 2009; Peter et al.,
2009; Wei et al., 2009). Upon receptor activation, an intracellular
TIR signaling complex is formed between the receptor and down-
stream adaptor TIR domains (O’Neill and Bowie, 2007). MyD88
(Myeloid differentiation primary response protein 88) was the ﬁrst
intracellular adaptor molecule characterized among all known
adaptors in the TLR signaling (Takeda and Akira, 2004). It consists
of an N-terminal death domain (DD) separated from its C-terminal
TIR domain by a linker sequence. MyD88 also forms a dimer
through DD-DD and TIR-TIR domain interactions when recruited
to the receptor complex (Burns et al., 1998). MyD88 can recruit
IRAK (IL-1RI-associated protein kinases) through its DD to continue
signaling and, ﬁnally, to induce the nuclear factor-jB (NF-jB) lead-
ing to the expression of type I interferons. Although the MyD88-
1047-8477/$ - see front matter  2009 Elsevier Inc. All rights reserved.
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dependent pathway is common to most TLRs, TLR3 exclusively
uses TRIF (TIR domain-containing adapter inducing interferon-b)
for signaling (MyD88-independent) while the TLR4 can signal via
both pathways (Takeda and Akira, 2004).
SIGIRR (Single immunoglobulin interleukin-1 receptor-related
molecule), also known as TIR8, was initially identiﬁed as an Ig do-
main-containing receptor of the TLR/IL-1R superfamily (Thomas-
sen et al., 1999). Both the extracellular and intracellular domains
of SIGIRR differ from those of other Ig domain-containing recep-
tors, as its single extracellular Ig domain does not support li-
gand-binding. Its intracellular TIR domain cannot activate NF-jB
because it lacks two crucial amino acids, Ser447 and Tyr536. More-
over, the TIR domain of SIGIRR extends that of the typical TLR/IL-1R
superfamily member by more than 73 amino acids at the C-termi-
nal (C-tail) (Thomassen et al., 1999). Instead, SIGIRR acts as an
endogenous inhibitor for MyD88-dependent TLR and IL-1R signal-
ing. This behavior was shown by over expression of SIGIRR in Jur-
kat or HepG2 cells which showed substantially reduced LPS, CpG
DNA or IL-1-induced activation of NF-jB (Polentarutti et al.,
2003; Qin et al., 2005;Wald et al., 2003). Thus, SIGIRR has attracted
tremendous research interest because of its regulating function in
cancer-related inﬂammation and autoimmunity (Lech et al., in
press). For example, systemic lupus erythematosus is caused by
TLR7-mediated induction of type I interferons. Compared with
wild type mice Sigirr-deﬁcient mice develop excessive lymphopro-
liferation when introduced into the context of a lupus susceptibil-
ity gene (Lech et al., 2008). Although the signiﬁcance of SIGIRR has
been widely acknowledged, its inhibition mechanism remains un-
clear owing to a lack of structural information.
Mutagenesis studies investigated three deletion mutants of SI-
GIRR (Qin et al., 2005): DN (lacking the extracellular Ig domain),
DTIR (lacking the intracellular TIR domain) and DC (lacking the
C-tail of the TIR domain with deletion of residues 313–410). The
results showed that only the TIR domain (excluding the C-tail part)
is necessary for SIGIRR to inhibit TLR4 signaling (Qin et al., 2005).
Nevertheless, detailed structural interaction mechanisms of SI-
GIRR’s TIR domain are still missing.
So far, the structures of the TIR domains of human TLR1, 2, 10
and IL-1RAPL have been determined by X-ray crystallography
(Khan et al., 2004; Nyman et al., 2008; Xu et al., 2000). The TLR1
and 2 modules occur as monomers in solution and the packing of
the molecules in the crystal lattice does not suggest a likely
arrangement for a functional dimer. In contrast, the TLR10 and
IL-1RAPL TIR domains were present as homodimers. Although they
demonstrate different dimer conformations, a highly conserved
BB-loop region plays a crucial role in both dimer interfaces. Using
this information, we have constructed three-dimensional models
for TIR domains of TLR4, TLR7, MyD88 and SIGIRR by homology
modeling and protein threading. Models of essential molecular
complexes involved in the TLR4 and 7 signaling pathways and
the SIGIRR inhibiting process are proposed and compared based
on results of protein–protein docking studies. We chose TLR4 as
an additional example to elucidate the mechanisms involved in
the negative regulation of the MyD88-dependent TLR signals by SI-
GIRR, because different mechanisms of TLR4 recognizing LPS and
TLR7 recognizing single-stranded RNA may lead to different struc-
tural interactions of receptor with SIGIRR, which enables further
insight into the molecular interaction.
2. Methods
2.1. Templates identiﬁcation and sequence alignments
Amino acid sequences of the target proteins, human TLR4
(GenBank Accession No. O00206), TLR7 (Q9NYK1), MyD88
(AAC50954) and SIGIRR (CAG33619) were extracted from the NCBI
protein database (Wheeler et al., 2008). Three-dimensional models
of TLR4 (Asn672-Ala814), TLR7 (Cys889-Asp1036), MyD88
(Glu159-Pro296) and SIGIRR (Tyr165-Pro308, without the C-tail
Arg309-Ser392) were constructed by homology modeling. Due to
the homology of the target proteins, four common templates were
obtained via BLAST search against the Protein Data Bank (PDB)
(Berman et al., 2000). They were TLR1 (PDB code: 1FYV), TLR2
(1FYW), TLR10 (2J67) and IL-1RAPL (1T3G). Multiple sequence
alignment of each target with the templates was generated with
MUSCLE (Edgar, 2004) and analyzed with Jalview (Clamp et al.,
2004). Because the secondary structure of the TIR domain is com-
posed of well-organized alternating b-strands and a-helixes, we
adjusted the alignments manually according to the secondary
structure information to improve the alignment quality. The sec-
ondary structure of each target was predicted by PSIPRED (Bryson
et al., 2005). In addition, the C-terminal tail of the TIR domain,
which is unique to SIGIRR, has no homologue of known structure
to serve as a template. In this case we employed the protein
threading method THREADER 3.5 (Jones et al., 1995) to determine
a template structure. The selected template was NSF-N (N-terminal
domain of N-ethylmaleimide sensitive factor, PDB code: 1QCS).
2.2. Model construction and validation
The initial three-dimensional coordinates of the models were
generated by the fully automated program MODELLER 9v3 (Fiser
et al., 2000). The input ﬁles for each model were a 5-line multiple
alignment ﬁle (one target and four templates) and coordinate ﬁles
of the templates. During modeling, gap regions in the alignment
produced 3–8 residue-long loop structures in the model, which
deteriorated the model’s accuracy. ModLoop (Fiser and Sali,
2003) was used to rebuild the coordinates of these loop regions.
ModLoop optimizes the positions of non-hydrogen atoms of a loop
(shorter than 20 residues) relying on a protocol consisting of a con-
jugate gradient minimization and a molecular dynamics simula-
tion. Finally, we used the model quality assessment programs
ProQ (Wallner and Elofsson, 2003), ModFOLD (McGufﬁn, 2008)
and MetaMQAP (Pawlowski et al., 2008) to evaluate the output
candidate models and select the most reliable one.
2.3. Model docking
Unrestrained pairwise model docking included eight com-
plexes of TIR domains: TLR4-TLR4, TLR7-TLR7, MyD88-MyD88,
TLR4 dimer-MyD88 dimer (tetramer), TLR7 dimer-MyD88 dimer
(tetramer), TLR4-SIGIRR, TLR7-SIGIRR and MyD88-SIGIRR. We
used GRAMM-X (Tovchigrechko and Vakser, 2006) and ZDOCK
(Chen et al., 2003), which are widely accepted rigid-body pro-
tein–protein docking programs, to predict and assess the interac-
tions between these complexes. Both programs rank the 10 most
probable predictions out of thousands of candidates based on
geometry, hydrophobicity and electrostatic complementarity of
the molecular surface. We then selected the most reasonable
solution from these top 10 lists in consideration of further qual-
iﬁcations. Brieﬂy, these qualiﬁcations included residue conserva-
tion of the interaction sites, steric compatibility of the amino
acid linker to the transmembrane helix, and knowledge from
published articles (Bell et al., 2006; Loiarro et al., 2007; Nunez
Miguel et al., 2007; Nyman et al., 2008; Park et al., 2009; Polto-
rak et al., 1998). The buried surface interaction area of dimer
models were calculated with the protein interfaces, surfaces
and assemblies service (PISA) at the European Bioinformatics
Institute (Krissinel and Henrick, 2007).
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3. Results
3.1. Molecular modeling of TIR domains
In the secondary structure-aided alignments for the homology
modeling, the average target-template sequence similarity of
TLR4, TLR7, MyD88 and SIGIRR was 51.7%, 50.4%, 44.5% and
42.7%, respectively (detailed in Table 1). The resulting structures
exhibit a typical TIR domain conformation in which a central
ﬁve-stranded parallel b-sheet (bA-bE) is surrounded by a total of
ﬁve a-helixes (aA–aE) on both sides (Fig. 1A). The loops are named
by the letters of the secondary structure elements that they con-
nect. For example, the BB-loop connects b-strand B and a-helix
B. The structure of NSF-N was identiﬁed as a template for SIGIRR’s
C-tail through protein threading. This template was ﬁrst-ranked by
THREADER according to the energy Z-score (Z = 2.7: borderline sig-
niﬁcant (Jones et al., 1995)). The C-tail contains a four-stranded
parallel b-sheet with an a-helix and several loop structures on
one side, while the other side points to SIGIRR’s TIR (Fig. 1A). These
results suggest that the TIR domain and the C-tail of SIGIRR are not
an integrative structure, but two interconnected individual mod-
ules. There is a 3 residue-long short linker (Leu307-Arg309) be-
tween the last secondary structure aE of SIGIRR’s TIR and the
ﬁrst secondary structure bA of SIGIRR’s C-tail. Therefore, the C-tail
can only be situated next to the aE of the TIR domain. Further eval-
uation of the models involved analysis of geometry, stereochemis-
try and energy distributions of the molecules. The evaluation
results (Table 2) indicate high quality for all models in terms of
overall packing.
Multiple sequence alignment of TIR domains from different
molecules detected seven conserved boxes in the TIR domain
(Fig. 1B). Our models show that they correspond to b-strand A
(bA), b-strand B (bB), BB-loop, b-strand C (bC), b-strand D (bD), b-
strand E (bE) and a-helix E (aE). Functional signiﬁcance can usually
be observed in conserved regions. Nevertheless, the ﬁve b-strands
(boxes 1, 2, 4–6) are embedded structures that form a hydrophobic
core of the TIR domain and hence are not likely to interact with
other molecules. Also, the aE (box 7) of SIGIRR is blocked because
it is linked to the C-tail. In this vein, the BB-loop (box 3) and aE of
TLR4, TLR7 and MyD88, along with the BB-loop of SIGIRR, may be
Table 1
Protein sequence similarities (%) between targets and templates.
TLR1 TLR2 TLR10 IL-1RAPL Avg
TLR4 53.4 57.8 51.4 44.2 51.7
TLR7 51.0 55.8 49.3 45.6 50.4
MyD88 44.5 45.3 40.6 47.4 44.5
SIGIRR 41.8 42.3 37.7 49.0 42.7
Fig. 1. Three-dimensional structures and conserved regions of TIR domains of TLR4, TLR7, MyD88 and SIGIRR. (A) The BB-loop and aE regions are highlighted in orange and
green respectively. As there is a three residue-long linker between the two modules of SIGIRR’s TIR, the orientation of the C-tail as shown here is speculative. (B) Multiple
sequence alignment of different TIRs indicates seven conserved boxes. (C) Surface charge distribution (APBS electrostatics) of BB-loop and aE with red indicating areas of
negative charge and blue indicating positive charge. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this
article.)
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important to ensure binding speciﬁcity achieved by different com-
binations of TIRs during signaling (Fig. 1A). Fig. 1C illustrates the
electrostatic surface potential of these BB-loops and aEs. Accord-
ingly, all BB-loops can be divided into two self-complementary
parts. The N-terminal (upper region of BB-loops in Fig. 1C) is neg-
atively charged, whereas the C-terminal (lower region of BB-loops
in Fig. 1C) is positively charged. The aEs, by contrast, are predom-
inantly positive.
3.2. Pairwise docking of TIR domains
Theprocedureof protein–protein docking is highly computation-
ally oriented. The reliability of docking results strongly depends on
the quality of dockingmethods. In order to verify the prediction con-
ﬁdence of TIR-TIR interaction of both methods GRAMM-X and
ZDOCK, we unrestrainedly inputted as test case the TIR domains of
human TLR10 as test case, for which the dimeric crystal structure
is known. The native dimerization geometry of TLR10 was present
in the top 10 solutions of both GRAMM-X and ZDOCK and was
ﬁrst-ranked by GRAMM-X and sixth-ranked by ZDOCK. The incom-
pleteness of TLR10’s crystal structure led to the ﬁrst ﬁve incorrect
predictions of ZDOCK, in which large structural gaps were involved
in the dimer interfaces. It was therefore straightforward to exclude
these ﬁve solutions. This test highlights the feasibility and reliability
of GRAMM-X and ZDOCK applied in TIR-TIR docking.
As noted above, TIR domains are able to interact heterotypically
with each other. To elucidate how SIGIRR disturbs the MyD88-
dependent TLR4 and 7 signals, an understanding of the interaction
mode of the TLR4 and 7 signaling complexes without the presence
of SIGIRR is indispensable. We thus performed unrestrained rigid-
body docking for eight TIR complexes. Each docking method re-
turned the 10 most probable models for an input. Thus each com-
plex received a total of 20 candidate models separated into two
sets. Some models from the same set had similar conformations
whereas most differed considerably from one another. There were
some shared models (intersection) across both sets for each com-
plex. These shared models were considered as more conﬁdent
solutions than others. The optimal docking solution was selected
for each complex from the 20 candidates based on three criteria,
as follows:
1. Exclude models that do not exist in the intersection of both
resulting sets.
2. Exclude models that contain a steric incompatibility of the
amino acid liker to the transmembrane helix.
3. Include only those models in which the dimerization geometry
is supported by reported experimental data or the dimerization
interface is associated with highly conserved boxes as described
in Fig. 1B.
For most complexes this three-step ﬁltering led to a unique
solution. In the case of the TLR4-TLR4 and the TLR7 dimer-
MyD88 dimer, where these three rules did not yield a unique solu-
tion, a further qualiﬁcation had to be considered. The highest-
ranked model by ZDOCK/GRAMM-X ranking was then accepted
as the optimal model. The ZDOCK/GRAMM-X ranking and the bur-
ied surface interaction area of all optimal models are detailed in
Table 3. All resulting docking models are provided in Supplemen-
tary ﬁle 1.
3.2.1. TLR4–TLR4
The signaling mechanism of TLR4 involves receptor dimeriza-
tion (Park et al., 2009). After the three-step ﬁltering two candidate
models remained. Their ZDOCK/GRAMM-X rankings were 1/6 and
9/2. The ﬁrst model was accepted because it was best ranked on
average and ZDOCK provided a clear-cut ranking. TLR4’s TIR re-
veals an axially symmetric dimer (Fig. 2A) with the BB-loop (in-
volved residues: Pro714-Ala717) of one monomer protruding
into a groove formed by the aC (Cys747-Ile748) and DD-loop
(Gln782) of the other. The aB (Ala719) of each monomer interacts
tightly with each other in the middle of both BB-loop connections.
In this model, the Pro714 of one monomer and the Gln782 of the
other are connected by a hydrogen bond, which supports Poltorak’s
(1998) conclusion that the corresponding residue Pro712 is essen-
tial to mouse TLR4’s function.
3.2.2. TLR7–TLR7
TLR7’s TIR forms a face-to-tail conformation. The BB-loop (face,
Glu930–Pro938) of one monomer is preceded by the aE (tail,
Tyr1024–Ala1032) of the other (Fig. 2B). The BB-loop also interacts
with some other regions close to the aE, including: CD-loop
(Lys982–Val983), bD (Ile986–Leu988), aD (Gly1009), DE-loop
(Ser1010–Ser1011), bE (Val1012–Pro1016) and EE-loop (Thr1017
and Ala1021). Aside from this connection, the EE-loop (Thr1017–
Ala1021) of the frontal monomer approximates the aA (Thr905–
Glu917) of the posterior. Since the BB-loop and aE are located on
opposite sides of a TIR domain, such a face-to-tail dimer can be ex-
tended by additional TIRs. This dimer model may be relevant for a
possible oligomerization of nucleic acid-recognizing TLRs. As dis-
cussed by Bell et al. (2006), oligomers might be formed if a nucleic
acid ligand is sufﬁciently long to aggregate several receptors.
3.2.3. MyD88–MyD88
MyD88 forms a dimer when it is incorporated into a receptor
complex (Burns et al., 1998). In this model, the BB-loops
(Asp195–Cys203) from both monomers were docked together in
an antiparallel self-complementary packing (Fig. 2A). Additionally,
both aCs (Cys233–Lys238) were brought into contact next to the
BB-loop connection. The model is axially symmetric similar to
the dimeric crystal structure of human TLR10 (Nyman et al.,
2008). Our model is consistent with Loiarro’s (2007) conclusion
that a heptapeptide, which mimics the BB-loop of MyD88’s TIR do-
main, strongly interferes with dimerization of MyD88.
Table 2
Model evaluation. ProQ_LG: >1.5 fairly good; >2.5 very good; >4 extremely good.
ProQ_MS: >0.l fairly good; >0.5 very good; >0.8 extremely good. ModFOLD_Q: >0.5
medium conﬁdence; >0.75 high conﬁdence. ModFOLD_P: <0.05 medium conﬁdence;
<0.01 high conﬁdence. MetaMQAP_GDT/RMSD: an ideal model has a GDT score over
59 and a RMSD around 2.0 Å.
ProQ_LG/MS ModFOLD_Q/P MetaMQAP_GDT/RMSD
TLR4 4.764/0.705 0.6177/0.022 76.923/2.123 Å
TLR7 4.374/0.579 0.6199/0.022 71.791/2.138 Å
MyD88 3.966/0.628 0.5749/0.027 73.188/2.202 Å
SIGIRR 3.783/0.438 0.7589/0.010 65.068/2.737 Å
C-tail 2.018/0.300 0.7731/0.009 52.083/3.023 Å
Table 3
Ranking and interaction area of the selected docking models.
ZDOCK GRAMM-X Interaction area (Å2)
TLR4–TLR4 1 6 639.0
TLR7–TLR7 1 3 965.3
MyD88–MyD88 1 7 737.2
TLR4  2-MyD88  2 4 1 1395.1
TLR7  2-MyD88  2 1 5 1249.3
TLR4–SIGIRR 1 6 1092.4
TLR7–SIGIRR 4 1 1055.2
MyD88–SIGIRR 2 9 818.1
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3.2.4. TLR4 dimer–MyD88 dimer
The receptor dimers and MyD88 dimer described above were
assembled into tetramers. The TLR4 dimer provides a negatively
charged binding pocket adjacent to its interface (Fig. 3). This pock-
et is constituted by the aC (Gln755) of one TLR4 monomer as well
as the aB (Ala719–His724) and aC (Tyr751–Thr756) of the other
monomer (TLR4*). The highly conserved, positively charged aE
(Cys280–Arg288) of a MyD88 monomer just ﬁlls the pocket and
makes interactions with the above described residues of TLR4
(Fig. 2A). This connection is further stabilized by three surrounding
links: MyD88’s DE-loop (Ile271) to TLR4’s CD-loop (Arg763–
Ala764); MyD88’s EE-loop (Asp275–Thr277) to TLR4’s CD-loop
(Thr756–Gln758); and MyD88’s aA (Gln181–Asn186) to TLR4*’s
CD-loop (Trp757–Leu760).
3.2.5. TLR7 dimer–MyD88 dimer
After the three-step ﬁltering, two candidate models remained
for this dimer. Their ZDOCK/GRAMM-X rankings were 1/5 and 4/
6, respectively. The ﬁrst model obtained the higher ranking in both
programs and was thus accepted as optimal. Although TLR7 dimer-
izes in a different manner as compared to TLR4, it also generates a
negatively charged aE-binding pocket for MyD88 at the corre-
sponding location (Figs. 2B and 3). The pocket is composed of aA
(Glu906–Glu911) and EE-loop (Trp1015–Pro1019) of one TLR7
monomer, and AA-loop (Thr899–Val904) and aA (Thr905–
Glu906) of the other monomer (TLR7*). This pocket connection is
further stabilized by three surrounding links: TLR7’s aA (Glu906)
and AA-loop (Thr899–Pro902) to MyD88’s CD-loop (His248–
Arg251); TLR7’s EE-loop (Pro1019–Ala1021) to MyD88’s AB-loop
(Asn186–Arg188) and bB (Leu189); and TLR7*’s aA (Glu906–
Ala914) to MyD88’s AB-loop (Thr185–Asn186) and aA (Gln181–
Gln184). Both TLR4–MyD88 and TLR7–MyD88 tetramers show a
T-shaped conformation, where the highly conserved aE of
MyD88 plays a central role (Fig. 2).
3.2.6. TLR4-sigirr
SIGIRR heterodimerizes with TLR4 and acts as an inhibitor of
TLR signaling (Qin et al., 2005). Our docking model exhibits an
extensive interface that is composed of three patches, which indi-
cates a strong molecular afﬁnity (Fig. 2A). First, a consecutive
stretch containing SIGIRR’s BB-loop (Asp200–Glu209) and aB
(Pro210–Ser211) interacts with TLR4’s CD-loop (Trp757–Leu760).
Second, SIGIRR’s aC (Arg235–Arg243) protrudes into the groove
formed by TLR4’s aB (Ala719–His728) and aC (Tyr751–Gln755).
Third, SIGIRR’s aD (Pro268–Ala269) interacts with TLR4’s BB-loop
(Val716–Ala717). Fig. 3 shows that the proper MyD88’s aE-binding
Fig. 2. Models of SIGIRR inhibiting the MyD88-dependent TLR4 and 7 signaling. Interacting regions of BB-loop and aE are labeled in orange and green respectively. Other
interacting regions are labeled in yellow. All interacting residues (orange/green/yellow) are represented using CPK (Corey, Pauling & Kultun) convention. (A) Models of SIGIRR
inhibiting the TLR4 signaling. (B) Models of SIGIRR inhibiting the TLR7 signaling.
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pocket presented by the TLR4–TLR4 dimer does not persist in the
TLR4-SIGIRR dimer. Notably, the C-tail of SIGIRR is located on the
opposite side of SIGIRR’s interacting surface. Therefore, it may
not participate in the dimer interface (Qin et al., 2005).
3.2.7. TLR7–SIGIRR
Similar to TLR7–TLR7, the TLR7–SIGIRRmodel is face-to-tail, with
SIGIRR replacing the rear TLR7 monomer as shown in Fig. 2B. The
molecular interface between TLR7 and SIGIRR is larger than that be-
tween TLR7 and TLR7. SIGIRR’s BB-loop (Asp200–Ala208) together
with the beginning of the adjacent aB (Pro210–Ser211) interacts
with TLR7’s aE (Tyr1024–Thr1035), CD-loop (Lys982–Asp984), bD
(Val985–Leu988), DE-loop (Ser1010–Ser1011) and bE (Val1012–
Glu1014). Simultaneously, TLR7’s DD-loop (Lys993–Phe995) inter-
acts with SIGIRR’s AA-loop (Asp173) and aA (Asn182). Likewise,
there is no MyD88 aE-binding pocket on this dimer (Fig. 3) and SI-
GIRR’s C-tail does not seem to play any role (Qin et al., 2005).
3.2.8. MyD88–SIGIRR
SIGIRR interferes with the functional dimer conformation of
MyD88 by heterodimerization with MyD88 (Qin et al., 2005). The
molecular interface between MyD88 and SIGIRR is also quite large
(Fig. 2A). SIGIRR’s BB-loop (Asp201–Ala208) complements
MyD88’s BB-loop (Asp195–Val204) by substituting the other BB-
loop in the customary MyD88 homodimer. Furthermore, SIGIRR’s
AA-loop (Ser172–Cys174) and aC (Arg235–Ala236) interacts with
MyD88’s aC (Gln229–Thr237) under the BB-loops. This model is
similar to the dimeric crystal structure of human TLR10 (Nyman
et al., 2008), where the BB-loop was identiﬁed as a main compo-
nent of interactions. Likewise, SIGIRR’s C-tail does not seem to af-
fect the dimer (Qin et al., 2005).
4. Discussion
So far, the only crystallized dimer structure of TLR’s TIR do-
main is the TLR10 dimer (Nyman et al., 2008), where the BB-loop
and aC of each monomer constitute the major part of the sym-
metric dimer interface. Nunez Miguel et al. (2007) assumed that
TLR4 dimerizes in a manner identical to that of TLR10 despite
having no direct evidence. However, we do not consider them
to be necessarily identical, because the TIR domain has various
inherent dimer conformations (Khan et al., 2004; Nyman et al.,
2008; Tao et al., 2002) and TLR4 has different ligand-binding
and signaling mechanisms than TLR10. Poltorak et al. (1998) re-
ported that a single point mutation (Pro712His) of the TIR domain
of murine TLR4 abolished the TLR4 response to LPS. Our human
TLR4 dimer model supports their results. The corresponding res-
idue Pro714 is located at the very tip of the BB-loop and interacts
tightly with Gln782 of the other monomer. In contrast to the
intensively studied TLR4, structural information about the TIR do-
main of TLR7 is missing. We thus propose a dimer model of the
TLR7 TIR domain. The dimer interaction is maintained mainly
by the BB-loop and aE, which are highly conserved among TIRs
of different molecules (Fig. 1B).
Triggering of the TLR causes the adaptor protein MyD88 to be
recruited to the receptor complex, which in turn promotes associ-
ation with kinases IRAK4/1. Mal (MyD88-adaptor-like) is another
TIR domain-containing adapter protein speciﬁcally required by
the TLR2 and 4 signaling (Gray et al., 2006). A previous study indi-
cated that Mal promotes the recruitment of MyD88 to TLR4 as a
bridging factor and there is no direct interaction between MyD88
and TLR4 (Brown et al., 2006). However, Mal has been shown to
be dispensable for TLR4 signaling when MyD88 is fused to a PIP2
targeting domain (Kagan and Medzhitov, 2006). Therefore, direct
interactions between TIR domains of MyD88 and TLR4 may medi-
ate signal transduction. This alternate Mal-independent pathway
could contribute to signaling as discussed recently (Monie et al.,
2009; Ohnishi et al., 2009). Dunne et al. (2003) modeled the
TLR4-MyD88 heterodimer using TLR4 and MyD88 monomers. This
monomer to monomer model, however, may not fully reﬂect the
molecular interactions. Our model of the receptor dimer docking
to the MyD88 dimer provides additional information for a struc-
tural interpretation. In particular, both tetramers (TLR4 dimer-
MyD88 dimer and TLR7 dimer-MyD88 dimer) exposed in our study
demonstrate that the stimulus-induced dimerization of TIR do-
mains creates a new negatively charged molecular pocket for the
binding of the positively charged aE of the MyD88 adaptor
(Fig. 3). In the presence of SIGIRR, the proper shape and electric
Fig. 3. Surface charge distribution of TIR dimers.Both TLR4-TLR4 and TLR7-TLR7 dimers generate a negatively charged (red) pocket adjacent to their dimer interface to hold
the positively charged (blue) aE of MyD88 (charge of aE shown in Fig. 1C). The incorporation of SIGIRR completely disturbed the proper shape and electric environment of the
pocket. The aE is represented by a green tube and the other part of MyD88 is omitted for better view. (For interpretation of the references to colour in this ﬁgure legend, the
reader is referred to the web version of this article.)
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environment of the MyD88-binding pocket are completely dis-
turbed (Fig. 3).
The results from the pairwise docking studies presented here
could be assembled to derive a working hypothesis for the TLR4
and 7 signaling transductions and the SIGIRR inhibition mode
(Fig. 2). Receptor activation would trigger the formation of TLR4
and 7 TIR dimers recruiting MyD88 TIR dimers resulting in a
signaling tetramer. Model predictions including SIGIRR reveal that
SIGIRR binds to TLR4 and 7 by occupying their self-interacting
sites. On the other hand, the MyD88-SIGIRR dimer shows a resem-
blance to the MyD88 homodimer. That is, SIGIRR replaces a MyD88
monomer, interrupting the MyD88 homodimer formation. In all
cases the BB-loop of SIGIRR plays a key role in binding. The relative
positions of all these TIR complexes to the cell/endosome mem-
brane are difﬁcult to expatiate because MyD88 is dissociated from
the membrane, and TIR domains of TLR4, TLR7 and SIGIRR are con-
nected to their transmembrane helix by a 20–30 amino acid-long
loop stretch which endows the TIR domain with ﬂexible depth
and orientation in a cell. Remarkably, TLR4, TLR7 and MyD88 pos-
sess a more extensive molecular interface with SIGIRR (heterodi-
mer) than with themselves (homodimer) (Table 3). Fig. 3 also
shows that the spatial approximation of receptor-SIGIRR is closer
than that of receptor-receptor. These observations highlight the
strong molecular afﬁnity of SIGIRR as an inhibitor. In addition,
according to our model, SIGIRR’s unique C-tail is distant from the
active BB-loop consistent with the observation that this tail is
not required for SIGIRR’s inhibitory effect on TLR signaling (Qin
et al., 2005).
In summary, we propose a residue-detailed structural frame-
work of SIGIRR inhibiting the TLR4 and 7 signaling pathways.
These results were obtained by computer modeling and are ex-
pected to facilitate efforts to design further site-directed mutagen-
esis experiments to clarity the regulatory role of SIGIRR in
inﬂammatory and innate immune responses.
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Abstract
Multiple genetic factors contribute to the clinical variability of spontaneous systemic lupus
erythematosus (SLE) but their role in drug-induced SLE remain largely unknown. Hydro-
carbon oil-induced SLE depends on mesothelial cell apoptosis and Toll-like receptor (TLR)-
7-mediated induction of type I interferons. Hence, we hypothesized that TIR8/SIGIRR,
an endogenous TLR inhibitor, prevents oil-induced SLE. Sigirr-deficient dendritic cells
expressed higher TLR7 mRNA levels and TLR7 activation resulted in increased IL-12
production in vitro. In vivo, lack of SIGIRR increased surface CD40 expression on spleen
CD11c+ dendritic cells and MX-1, TNF, IL-12, BAFF and BCL-2 mRNA expression
6 months after pristane injection. Spleen cell counts of CD4−/CD8− ‘autoreactive’ T cells
and B220+ B cells were also increased in Sigirr−/− mice. Serum autoantibody analysis
revealed that Sigirr deficiency specifically enhanced the production of rheumatoid factor
(from 4 months of age) and anti-snRNP IgG (from 5 months of age), while anti-Smith IgG
or anti-dsDNA IgG were independent of the Sigirr genotype. This effect was sufficient to
significantly aggravate lupus nephritis in Sigirr-deficient mice. Structure model prediction
identified the BB loop of SIGIRR’s intracellular TIR domain to interact with TLR7 and
MyD88. BB loop deletion was sufficient to completely abrogate SIGIRR’s inhibitory effect
on TLR7 signalling. Thus, TIR8/SIGIRR protects from hydrocarbon oil-induced lupus by
suppressing the TLR7-mediated activation of dendritic cells, via its intracellular BB loop.
Copyright  2009 Pathological Society of Great Britain and Ireland. Published by John
Wiley & Sons, Ltd.
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Introduction
Genetic and environmental factors drive both the
onset and the progression of autoimmune diseases
[1]. As such, a number of variants in immunoreg-
ulatory genes increase the risk for systemic lupus
erythematosus (SLE) [2–4]. In mice, lack of single
genes, such as TGFβ1, DNAse1, Lyn, Fas or C1q,
is sufficient to cause late-onset lupus-like autoim-
munity [5–9]. Mutant Sle1 or TLR9 can trig-
ger lupus in C57BL/6 mice only in the presence
of a second genetic factor, eg the lpr mutation
[10,11]. Weaker modifier genes, such as IL-10 or
IL-27R, enhance lupus only in a genetic context
of multiple susceptibility genes, eg being provided
by the specific genetic background of MRL mice
[12,13].
The TIR8 gene encodes for single immunoglobu-
lin IL-1-related receptor (SIGIRR), a member of the
Toll-like receptor (TLR)/IL-1 receptor family [14,15].
Over-expression of SIGIRR in Jurkat or HepG2
cells suppresses LPS or IL-1-induced activation of
NF-κB, hence SIGIRR is an endogenous inhibitor of
TLR and IL-1 signalling [14,16,17]. Sigirr-deficient
mice develop severe immunity-mediated tissue dam-
age upon pathogen challenge or dextran-induced dam-
age of the intestinal epithelium [16,18–21]. Lack
of SIGIRR also enhances spontaneous autoimmu-
nity in C57BL/6lpr/lpr mice [22]. These mice suf-
fer from defective Fas-induced apoptosis of autore-
active lymphocytes, which massively increases the
exposure of nuclear autoantigens to the immune
system [23]. Hence, the aggravated phenotype of
Sigirr-deficient C57BL/6lpr/lpr mice could best be
explained by a suppressive effect of Sigirr on self-
RNA and -DNA-mediated activation of dendritic cells
and B cells, a process known to involve TLR7 and
TLR9 [10,24–27]. For example, plasmacytoid den-
dritic cells are the major source of type I inter-
ferons upon recognition of RNA via TLR7 [25],
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whereas conventional dendritic cells produce inter-
feron mainly upon cytosolic RNA recognition recep-
tors [28].
Whether SIGIRR also suppresses environmentally-
induced autoimmunity is unknown. To address this
question would require SLE-like disease to be induced
in genetically unaltered mice without a predisposing
autoimmune genetic background. We therefore used
the hydrocarbon oil 2,6,10,14-tetramethyl-pentadecane
(pristane) to induce SLE in Sigirr−/− and Sigirr+/+
mice of an identical C57BL/6 background. Intraperi-
toneal injection of pristane induces apoptosis of
mesothelial cells, followed by granulomatous peri-
tonitis with the formation of ectopic lymphoid tis-
sue [29]. In this model, the persistent abundance of
apoptotic peritoneal cells in the context of chronic
inflammation triggers TLR7 signalling, type I inter-
feron expression and the subsequent evolution of
antinuclear antibodies, immune complex disease and
lupus nephritis [30,31]. We hypothesized a role for
Tir8/Sigirr in limiting pristane-induced SLE by sup-
pressing intraperitoneal inflammation and/or autoanti-
body generation.
Methods
Animal studies
Sigirr-deficient mice on a F6 C57BL/6 genetic back-
ground were generated as previously described [19].
The genotype was assured by PCR in each mouse at
5 weeks of age before mice of both genotypes were
intraperitoneally injected with 0.5 ml pristane (Sigma-
Aldrich, Steinheim, Germany). Blood samples were
taken at monthly intervals after pristane injection (at
age 6 weeks) until sacrifice at 6 months after pristane
injection. In a subgroup of mice, peritoneal lavage
fluid was obtained at 2 and 28 days after pristane
injection. All experiments were performed in accor-
dance with the German animal care and ethics legisla-
tion and had been approved by the local government
authorities.
Phenotype analysis
Flow cytometry, real-time quantitative (TaqMan) RT–
PCR, and autoantibody analysis were performed as
previously described [22,32]. PCR primers are listed
in Table 1. Formalin-fixed tissue sections (2 µm) for
periodic acid–Schiff (PAS) stains were prepared fol-
lowing routine protocols. The severity of kidney
disease was graded by an observer blinded to the
genotype of the mice, using a glomerulonephritis
activity score (0–24) normally used for the assess-
ment of human lupus nephritis [31]. Immunostain-
ing was performed on either paraffin-embedded or
frozen sections as described [26], using the fol-
lowing primary antibodies: anti-mouse C3c (com-
plement, GAM/C3c/FITC, 1 : 200; Nordic Immuno-
logical Laboratories, Tilburg, The Netherlands) or
anti-mouse B220 (BD Pharmingen, Heidelberg, Ger-
many). Negative controls included incubation with a
respective isotype antibody. Semi-quantitative scor-
ing of glomerular C3c deposits from 0 to 3+ was
performed on 15 cortical glomerular sections, as
described [33].
Structure and interaction model predictions
Amino acid sequences of human TLR7, MyD88 and
SIGIRR (targets) were extracted from the NCBI pro-
tein database [34]. TIR domains of TLR7, MyD88 and
SIGIRR (TYR165-PRO308, without the C-terminal
extension) were modelled by homology modelling.
Four template structures were obtained via BLAST
search against the Protein Data Bank (PDB) [35]:
TLR1 (PDB code 1FYV), TLR2 (1FYW), TLR10
(2J67) and IL-1RAPL (1T3G). Multiple alignments of
target-template sequences and structural coordinates of
templates were submitted to MODELLER 9v3 [36]
to generate the three-dimensional (3D) target struc-
tures. Since the C-terminal extension of SIGIRR has
no structure-known homologue, we built its struc-
ture using protein threading (THREADER 3.5 [37]).
The resulting models were then evaluated by ProQ
[38] and MetaMQAP [39]. The protein docking pro-
grams GRAMM-X [40] and ZDOCK [41] were used
to predict the pairwise interactions between these TIR
domains. Both programs can return 10 models ranked
as the most probable predictions, selected from thou-
sands of candidates, based on geometry, hydropho-
bicity and electrostatics complementarity of molecule
surfaces.
In vitro studies
HEK 293 cells (2 × 105), stably transfected with
hTLR7, were cultured overnight in 1 ml DMEM com-
plete medium before being transiently transfected with
lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA)
and pUNO, full-length hSIGIRR or SIGIRR mutants,
all in pUNO expressing vector (Invivogen, San Diego,
CA, USA) and the NF-κB luciferase reporter con-
struct (Clontech, Mountain View, CA, USA) with a
final amount of 2 µg. After 24 h the cells were stimu-
lated with 1 µg imiquimod (Invitrogen) and luciferase
activity was determined after 6 h using Promega’s
Dual-Glo luciferase kit. The primers were designed
to anneal to the template sequences flanking the target
sites, which were sequences to be deleted (BB loop-
SIGIRR, forward, 5′-GACTGCCCCGACCTCTTGG
TGAACCTGAG-3′, reverse, 5′-CAAGAGGTCGGGG
CAGTCGCTGTAGGAG-3′;TIR-SIGIRR, forward,
5′-GTGGAGATACGGAAGGTGCAGTACAGGC-3′,
reverse, 5′-CACCTTCCGTATCTCCACCTCCCCAT
AC-3′). The pUNO-hSIGIRR plasmid was used as
the template for mutagenesis. A 25 µl PCR reaction
was composed of 1 µl template (200 ng), 1 µl each
primer (20 pM each), 2 µl dNTP mixture, 2.5 ml 10×
buffer, 0.5 µl Pfu Turbo DNA polymerase (2.5 U)
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and dH2O. The reaction was started with 2 min at
95 ◦C to pre-denature the template. This was followed
by 18 cycles of 1 min at 95 ◦C, 1 min at 58 ◦C and
1 min/kbp at 68 ◦C. Following the PCR reaction, 1 µl
DpnI (20 U; NEB, Ipswich, MA, USA) was added
and the mixture was incubated at 37 ◦C for 1 h to
degrade the original unmodified plasmid templates.
After DpnI digestion, 2 µl of the mixture was used
to transfect DHα-competent cells by heat shock. After
a 1 h recovery in 300 µl LB medium without antibi-
otics, the transformed Escherichia coli was spread on
Blas-Agar Blasticidin plates (Invivogen, San Diego,
CA, USA) and incubated at 37 ◦C overnight. Colonies
were selected and grown overnight in 3 ml LB with
blasticidin.
Statistical analysis
Statistical significance was evaluated by ANOVA or
by two-tailed Student’s t-test (two group comparisons)
at p < 0.05. Data were expressed as mean ± SEM.
Results
Sigirr modulates peritoneal cytokine production
after pristane exposure
Intraperitoneal injection of pristane induces massive
apoptosis of mesothelial cells and infiltrating neu-
trophils [29], lipogranuloma formation and interferon
signalling by peritoneal macrophages [30]. Macro-
scopically we did not detect any difference in the
peritoneal cavities of Sigirr+/+ and Sigirr−/− mice
2 and 28 days after pristane injection (Figure 1A,
left). Lavage fluids from these time points revealed
large numbers of dead mesothelial cells and mono-
cyte/macrophages often ingesting apoptotic neutrophils
(Figure 1A, right), but cell counts were identical in
Sigirr+/+ and Sigirr−/− mice (not shown). Lavage
fluid flow cytometry for propidium iodine and annexin
V revealed comparable levels of early apoptotic
(annexin V+) cells and late apoptotic (annexin V/
propidium iodine+) cells in Sigirr+/+ and Sigirr−/−
mice at all time points (not shown). Real-time
RT–PCR from peritoneal lavage fluid cell mRNA
showed significantly higher levels for IL-12 and TNFα
at 2 days and IFNγ and the IFNα/β-dependent gene
Mx1 28 days after pristane injection (Figure 1B).
Lavage fluid ELISA revealed significantly higher lev-
els of TNFα but not of IL-12p40 2 days after pris-
tane injection, while IFNα, -β and -γ were not
detectable by ELISA (Figure 1C). At 28 days, TNFα
and IL-12p40 levels had increased but were genotype-
independent (Figure 1C).
Sigirr suppresses the activation of dendritic cells
6 months after pristane exposure
We used flow cytometry to quantify the numbers
of splenic CD11c dendritic cells that stain positive
for the activation marker CD40 at 6 months of age.
Lack of Sigirr significantly increased the numbers of
CD40+ dendritic cells (Figure 2A). Lack of Sigirr was
also associated with increased mRNA levels of Mx1,
TNFα, IL-4 and IL-12 in these cells (Figure 2B).
Sigirr-deficient spleen dendritic cells also expressed
higher levels of Baff and Bcl2 (Figure 2C), which
support the survival of B and/or T cells [42]. Con-
sistent with the stronger activation of dendritic cells,
Sigirr-deficient mice had higher IL-12p40 serum levels
as compared to wild-type mice injected with pristane
at 6 months of age (5.9 ± 1.6 versus 1.1 ± 0.8 ng/ml,
p < 0.0001). Thus, Sigirr suppresses dendritic cell
activation and serum IL-12p40 levels 6 months after
pristane exposure.
Sigirr suppresses pristane-induced
lymphoproliferation
Pristane induced mild splenomegaly at 6 months
in wild-type mice. Lack of Sigirr caused a trend
towards higher spleen weights, but with consider-
able interindividual variability (Figure 2D), but flow
cytometry revealed sigificantly higher numbers of
spleen cells in Sigirr-deficient mice treated with pris-
tane (Figure 2E). This was due to lymph follicle
hyperplasia with massive enlargement of B220+ B
cell areas (Figure 2F). We also observed higher num-
bers of CD4/CD8 double-negative ‘autoreactive’ T
cells and CD4+CD25+ ‘regulatory’ T cells in Sigirr-
deficient mice treated with pristane (Figure 3C, D).
The latter was consistent with a significant induction
of Foxp3 mRNA levels in CD3+CD4+CD25+ cells
of Sigirr-deficient mice (Figure 3E). The numbers of
CD3+CD4+ and CD3+CD8+ cell were not affected
by the Tir8 genotype (Figure 3A, B). However, in
CD4+CD25−T cells, lack of Sigirr was associated
with higher mRNA expression levels of the Th1 mark-
ers T-bet and IFNγ (Figure 3F) and the Th2 markers
Gata and IL-4 (Figure 3G). The Th17 marker Ror-
γ was significantly down-regulated, although IL-17
mRNA levels were markedly induced in pristane-
treated Sigirr-deficient mice (Figure 3H). Together,
Sigirr suppresses the expansion of spleen B cells as
well as of autoreactive and regulatory T cells after
pristane injection.
Sigirr suppresses pristane-induced autoantibodies
to nuclear autoantigens
We obtained serum samples at monthly intervals
from pristane-treated mice of both genotypes and
antibody levels were determined by ELISA. Total
serum IgG levels were comparable at all time points
in Sigirr-deficient and wild-type mice (Figure 4).
Small amounts of antibodies directed against dsDNA
IgG of the IgG1 isotype and against nucleosomes
were detectable by ELISA but the levels did not
differ between Sigirr-deficient and wild-type mice
(Figure 4). The specificity of dsDNA autoantibodies
was confirmed by Critidiae luciliae assay (not shown).
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Figure 1. Tir8/Sigirr genotype and pristane-induced peritonitis. Pristane injection into Sigirr+/+ and Sigirr−/− mice caused
lipogranuloma formation in the peritoneal cavity, as indicated by white arrows in the left image of (A). The right image of (A) shows
microscopic analysis of peritoneal fluids, which revealed large amounts of apoptotic cells (black arrows) inside and outside of
phagocytes (white arrows and insert), independent of the Sigirr−/− genotype. (B) Real-time RT–PCR of peritoneal fluid samples
taken 2 and 28 days after pristane injection was used to quantify intraperitoneal mRNA expression. Data are expressed as a ratio
to respective 18s rRNA as a reference gene. (C) Peritoneal fluid levels of TNFα and IL-12p40 were determined by ELISA. Data in
(B, C) are expressed as means ± SEM of 14 mice in each group of Sigirr+/+ (black bars) and Sigirr−/− mice (white bars). ∗p < 0.05
versus wild-type; #p < 0.05 versus 2 days
Anti-dsDNA of the IgG2a/c, IgG2b and IgG3 isotypes
remained undetectable at all time points (not shown).
By contrast, lack of Sigirr significantly induced the
production of rheumatoid factor and anti-SnRNP IgG
from 4 and 5 months after pristane exposure, respec-
tively (Figure 4). Antibodies against the Smith anti-
gen were produced from month 4, but the levels
did not differ between the two genotypes (Figure 4).
Thus, Sigirr specifically suppresses the production of
rheumatoid factor and anti-SnRNP IgG but does not
affect DNA autoantibody production after pristane
exposure in mice.
Sigirr prevents pristane-induced lupus nephritis
Pristane does not cause major autoimmune tissue
lesions in C57BL/6 mice, although mild
glomerulonephritis may develop [30]. Lack of Sigirr
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Figure 2. Sigirr genotype, dendritic cell activation and spleen morphology. (A) The total number of spleen CD11c+ dendritic
cells positive for the activation marker CD40 was quantified 6 months after pristane injection by flow cytometry. Data represent
means ± SEM from 14 mice in each group. #p < 0.05 versus pristane-injected wild-type mice. (B, C) RNA was isolated from
spleen CD11c+ cells from Sigirr−/− (white bars) and Sigirr+/+ mice (black bars) 6 months after pristane injection for real-time
RT–PCR analysis. Data are expressed as means of the ratio of the specific mRNA to that of 18S rRNA ± SEM. ∗p < 0.05 versus
wild-type mice. (D, E) Spleen weight (D) was determined 6 months after pristane injection in untouched wild-type mice (grey bar),
pristane-injected wild-type mice (black bar) and Sigirr-deficient mice (white bar). Total spleen cell numbers (E) were determined by
flow cytometry, as described in Methods. ∗p < 0.05 versus untouched wild-type mice; #p < 0.05 versus pristane-injected wild-type
mice. (F) Representative images of spleen PAS stains and B220 immunostaining from mice at 6 months. Original magnification, ×100
was associated with diffuse mesangio-proliferative
glomerulonephritis, as indicated by glomerular hyper-
cellularity, PAS-positive matrix expansion and
glomerular leukocyte infiltrates (Figure 5A). Glomeru-
lar C3c deposits were scored 1.2 ± 0.2 in Sigirr−/−
mice and 0.3 ± 0.1 in wild-type mice (p = 0.003;
Figure 5A). The composite activity score for lupus
nephritis was 6.8 ± 0.6 in Sigirr−/− mice and 3.5 ±
0.3 in wild-type mice (p = 0.0002; Figure 5B). Albu-
minuria constantly increased in Sigirr-deficient mice
and started to be significantly higher at 5 months as
compared to wild-type mice (Figure 5C). The differ-
ence was highest at 6 months. Together, Sigirr protects
mice from diffuse proliferative lupus nephritis after
pristane exposure.
In silico structure analysis predicts the BB loop
of Sigirr’s TIR domain as the interaction site
with TLR7 and Myd88
Because lupus autoantigens drive SLE by ligat-
ing TLR7, we speculated that Sigirr is induced by
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Figure 3. Sigirr genotype and T cell subsets. Six months after pristane injection, spleen T cell subsets were assessed by flow
cytometry (A–D), as described in Methods. The histograms presents mean ± SEM of at least 14 mice in each group. (E–H)
Real-time RT–PCR from CD4+CD25+ cells or CD4+CD25− cells was used to quantify additional T cell markers. Data ratios
to respective 18s rRNA as a reference gene and are expressed as means ± SEM of 10 mice in each group. #p < 0.05 versus
pristane-injected wild-type mice
inflammation and that it suppresses TLR7 signalling,
especially in antigen-presenting cells. Sigirr mRNA
was induced in spleen monocytes by LPS or TNFα/
IFNγ , with a maximum expression level at 18 h of
stimulation (Figure 6A, B). In addition, the TLR7 ago-
nist imiquimod activated bone marrow dendritic cells
to produce IL-12, a response that was five-fold higher
in Sigirr-deficient dendritic cells (Figure 6C), perhaps
also because the basal TLR7 mRNA expression was
significantly higher in Sigirr-deficient dendritic cells
(Figure 6D). But can Sigirr directly interfere with
TLR7 signalling at the structural level?
Because crystallographic structures of human TLR7,
MyD88 and SIGIRR TIR domains are not avail-
able, we developed 3D structural models based on
homology modelling and protein threading. The pre-
dicted structures of TLR7, MyD88 and SIGIRR TIR
domains were evaluated as extremely good or ideal
by several model quality assessment programs (data
not shown). The BB loop (face) and the α-helix
E region (neck) appeared to be conserved among
all the different TIR domains (Figure 7A) and are
localized on opposite regions of the SIGIRR TIR
domain (Figure 7B). Then, the protein-docking soft-
wares GRAMM-X and ZDOCK were used to pre-
dict pairwise molecular interaction sites of com-
plexes formed by TLR7–TLR7, MyD88–MyD88,
TLR7–SIGIRR and MyD88–SIGIRR. The top-ranked
dimer model was selected for each complex
(Figure 7C). According to these predictions, receptor
activation would trigger the formation of TLR7 TIR
dimers in a face-to-neck orientation, recruiting MyD88
TIR face-to-face dimers and forming a T-shaped
signalling tetramer (complex B in Figure 7C). The
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Figure 4. Sigirr genotype and serum immunoglobulin and
lupus autoantibody levels. Wild-type mice (open squares) and
Sigirr-deficient mice (black squares) were bled at monthly
intervals after pristane injection to determine serum levels
of IgG and a number of different autoantibodies, as indicated by
ELISA. Data represent means ± SEM from at least 14 mice in
each group. ∗p < 0.05 versus wild-type mice at the same time
point
stimulus-induced dimerization of TIR domains cre-
ates a molecular pocket for the binding of α-helix E
of the MyD88 adaptor. Model predictions, including
SIGIRR’s TIR, revealed that SIGIRR interacts with
TLR7 by occupying TLR7 TIR’s α-helix E region
with its BB loop, which should interrupt TLR7 homod-
imer formation (complex A in Figure 7C). In addi-
tion, SIGIRR’s BB loop was predicted to interact
with the BB loop of MyD88, which should inter-
rupt MyD88 homodimer formation (complex C in
Figure 7C). According to our model, SIGIRR TIR’s
unique C-terminal extension (ca. 100 amino acids;
Figure 7B) is located distant from the BB loop, con-
sistent with the observation that this extension is
not required for SIGIRR’s inhibitory effect on TLR
signalling (16).
Table 1. Primers used for RT–PCR
Gene name Primer sequence
Baff Forward 5′-CCTCCAAGGCATTTCCTCTT-3′
Reverse 5′-GACTGTCTGCAGCTGATTGC-3′
Bcl2 Forward 5′-GATCCAGGATAACGGAGGCT-3′
Reverse 5′-GGTCTTCAGAGACAGCCAGG-3′
FoxP3 Forward 5′-TTCATGCATCAGCTCTCCAC-3′
Reverse 5′-CTGGACACCCATTCCAGACT-3′
Gata3 Forward 5′-GCCTGCGGACTCTACCATAA-3′
Reverse 5′-AGGATGTCCCTGCTCTCCTT-3′
Ifn-γ Forward 5′-ACAGCAAGGCGAAAAAGGAT-3′
Reverse 5′-TGAGCTCATTGAATGCTTGG-3′
Il-4 Forward 5′-TGAACGAGGTCACAGGAGAA-3′
Reverse 5′-CGAGCTCACTCTCTGTGGTG-3′
Il-12 Forward 5′-CTAGACAAGGGCATGCTGGT-3′
Reverse 5′-GCTTCTCCCACAGGAGGTTT-3′
Il-17 Forward 5′-TCCAGAAGGCCCTCAGACTA-3′
Reverse 5′-TGAGCTTCCCAGATCACAGA-3′
Mx1 Forward 5′-TCTGAGGAGAGCCAGACGAT-3′
Reverse 5′-CTCAGGGTGTCGATGAGGTC-3′
Ror-γ Forward 5′-ACAGAGACACCACCGGACAT-3′
Reverse 5′-GGTGATAACCCCGTAGTGGA-3′
Tbet Forward 5′-TCAACCAGCACCAGACAGAG-3′
Reverse 5′-ATCCTGTAATGGCTTGTGGG-3′
Tnf-α Forward 5′-CCACCACGCTCTTCTGTCTAC-3′
Reverse 5′-AGGGTCTGGGCCATAGAACT-3′
18s RNA Forward 5′-GCAATTATTCCCCATGAACG-3′
Reverse 5′-AGGGCCTCACTAAACCATCC-3′
A Sigirr TIR mutant lacking the BB loop
can no longer block TLR7 signalling
To verify the functional role of the BB loop for
TLR7 signalling, we over-expressed full-length TLR7
in HEK293 cells, together with full-length Sigirr or
various Sigirr mutants. Full-length Sigirr potently sup-
pressed NF-κB reporter gene expression 6 h after stim-
ulation with the TLR7 agonist imiquimod (Figure 7D).
By contrast, lack of the TIR domain or the BB
loop only completely abrogated this inhibitory effect
on TLR7 signalling. Together, Sigirr TIR’s BB loop
mediates the inhibitory effect of Sigirr on TLR7
signalling.
Discussion
Lack of Sigirr clearly aggravated pristane-induced
autoimmune tissue injury. In the kidney, Sigirr-
deficiency was associated with diffuse proliferative
lupus nephritis and significant albuminuria as com-
pared to wild-type C57BL/6 mice, which revealed only
minor glomerular abnormalities. The role of Sigirr in
inhibiting pristane-induced autoimmunity was clearly
documented by increased dendritic cell activation,
increased numbers of CD4/CD8 double-negative T
cells and B cells in spleen as well as increased serum
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Figure 5. Sigirr genotype and lupus nephritis 6 months after pristane injection. (A) Renal sections were stained with PAS and
immunostaining was performed for complement factor C3c (DAPI stains cell nuclei blue), as indicated. Original magnification, ×200.
Images are representative for 10 mice in each group. (B) The lupus nephritis activity index (range 0–24) was assessed on renal
PAS-stained sections at 6 months after pristane injection, as described in Methods. (C) Urinary albumin : creatinine ratio was
determined from urine samples taken from at least 14 wild-type mice (open squares) and Sigirr-deficient mice (black squares) at
monthly intervals after pristane injection. #p < 0.05 versus pristane-injected wild-type mice
levels of IL-12 and selected autoantibodies in Sigirr-
deficient mice. In this regard, the data from pristane-
induced lupus matches our previous data obtained
from Sigirr-deficient C57BL/6lpr/lpr mice with sponta-
neous autoimmunity [22]. However, in C57BL/6lpr/lpr
mice Sigirr had a global suppressive effect on the
evolution of hypergammaglobulinaemia and autoanti-
bodies of multiple specificities as early as at 2 months
of age [22]. By contrast, in pristane-induced lupus,
lack of Sigirr massively increased the production of
rheumatic factor and RNA autoantibodies, but not
before 4–5 months after pristane exposure. This was
most obvious for anti-Sm IgG and anti-U1snRNP,
because the Sm (Smith) antigen is the protein com-
ponent and U1snRNP the RNA component of the
U1snRNP ribonucleoprotein complex [43,44].
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Figure 6. Sigirr suppresses TLR7 signalling in dendritic cells. (A) Sigirr mRNA expression was determined by real-time RT–PCR
on RNA samples from spleen monocytes 12 h after stimulation with various doses of LPS or TNFα/IFNγ . (B) Sigirr induction was
quantified in spleen monocytes at various time intervals after stimulation with a given dose of LPS or TNFα/IFNγ . Data represent
mean ratios of Sigirr/18s rRNA ± SEM from three independent experiments. (C) Bone marrow dendritic cells from wild-type
mice (black bars) and Sigirr-deficient mice (white bars) were stimulated with imiquimod, as described in Methods. IL-12p40 was
determined after 24 h in cell culture supernatants. (D) Basal TLR7 mRNA expression was determined in the same cells by real-time
RT–PCR and is illustrated as a ratio to the respective 18s rRNA expression. Data represent means ± SEM from three independent
experiments. ∗p < 0.05 versus medium; #p < 0.05 versus wild-type mice
Because Sigirr-deficient mice did not display a
broader spectrum of autoantibodies than wild-type
mice, Sigirr does not seem to directly promote loss-
of-tolerance or epitope spreading. Obviously, Sigirr
rather specifically fosters the expansion of IgG and
RNA autoreactive lymphocyte clones that produce the
necessary components for pathogenic RNA immune
complexes. In turn, such RNA immune complexes are
known trigger TLR7 activation and type I interferon
signalling, a positive amplification loop [24,45–46].
In fact, pristane-induced lupus is driven by TLR7
signalling [30,31] and, most interestingly, lack of
TLR7 selectively impaired the production of pristane-
induced snRNP antibodies [30,31]. We therefore
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Figure 7. Models of SIGIRR inhibiting the TLR7 signalling pathway. (A) Amino acid sequence homologies of the intracellular TIR
domains of human TLR7, MyD88 and SIGIRR. (B) The 3D structural model of SIGIRR’s intracellular TIR domain was predicted as
described in Methods. The BB loop is indicated in orange; the α-helix E region is indicated in green. Note that the SIGIRR-specific
C-terminal extension links at the α-helix E. (C) Complex B, TLR7 homodimers (dark blue), linked by BB loop (orange)–α-helix
E (green) interaction, bind MyD88 homodimers (light blue), forming a T-shaped conformation. MyD88 homodimers are formed
by BB loop interactions (orange). The TLR7–MyD88 complex may not form when SIGIRR recruits to this complex as follows:
the predicted TLR7–SIGIRR interaction (complex A) should affect TLR7 homodimer formation, and SIGIRR–MyD88 interaction
(complex C) may affect MyD88 homodimer formation (SIGIRR interfering sites indicated by open arrows). (D) HEK293 cells,
constitutively expressing TLR7, were seeded at a concentration of 2 × 105 cells/well in a 12-well plate, and cultured overnight
in 1 ml DMEM complete medium. The next day the cells were transfected with TIR8 or TIR8 mutants or pUNO control vector
and the NF-κB luciferase reporter construct, as described in Methods. Cells were stimulated with 1 µg imiquimod and luciferase
activity was determined after 6 h. The values are percentages of the imiquimod-stimulated cells expressing empty pUNO vector.
Data represent means ± SEM of at least two independent experiments. ∗p < 0.05 versus pUNO control
hypothesized that Sigirr may directly inhibit TLR7
signalling.
Previous studies suggested that Sigirr can inhibit
TLR4 (but not TLR3 or TLR5) signalling via inter-
action at the level of their respective intracellular TIR
domains, which inhibits the necessary recruitment of
its adaptor Myd88 [17]. Our structure-based prediction
model of putative TIR–TIR interaction sites identified
the BB loop of SIGIRR’s intracellular TIR domain
as the most likely interaction site with TLR7, as well
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as with MyD88. Deletion of the BB loop completely
abrogated SIGIRR’s inhibitory effect on TLR7 sig-
nalling, as did the deletion of the entire TIR domain.
These data are in line with the report of Qin et al [17]
and further prove that SIGIRR also inhibits TLR7 via
this mechanism. In addition, Sigirr suppresses TLR7
mRNA expression, which adds to its suppressive effect
on TLR7 signalling.
In pristane-induced lupus, the immunoregulatory
function of Sigirr clearly localizes to the central
lymphoid organs, as indicated by the impact of Sigirr
deficiency on lymphocyte numbers and activation
states and autoantibody production.
We conclude that genes that regulate autoantigen-
driven dendritic cell activation determine environmen-
tally triggered autoimmunity, and that Tir8/Sigirr loss-
of-function mutations represent a novel genetic risk
factor for hydrocarbon oil-induced autoimmunity in
mice.
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